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Clinical research in cystic fibrosis (CF) requires study endpoints that are 
sensitive to airways disease, repeatable and non-invasive. Despite significant 
advances in the treatment of CF, lung function assessments continue to rely on the 
forced expiratory volume in 1 second (FEV1). Although simple to perform, it lacks 
sensitivity, is difficult for younger subjects, and changes over time. An alternative 
method of assessing lung physiology is to derive measures of ventilation 
heterogeneity from inert gas washout tests. In early lung disease, measures of gas 
mixing appear to be more sensitive than spirometry. In addition, since only tidal 
breathing is required, they are more physiological and are more straightforward for 
younger subjects. Widespread use has been impaired by the lack of a robust and cost 
effective gas analyser technology. 
The work presented in this thesis concerns the adaptation, validation and then 
use of a novel gas analyser (Innocor) in a clinical system for the performance of 
multiple breath washouts. Lung clearance index (LCI), a simple measure of 
ventilation heterogeneity, has been calculated from washouts in 52 adults with CF 
and 50 healthy controls. LCI was more sensitive to disease than FEV1 in CF, being 
elevated in 11 of the 12 CF patients with normal spirometry. In healthy subjects, LCI 
has been shown to be repeatable and reproducible, with a narrow range of normal 
that is stable over a wide age range.  
In a separate study of 19 patients, LCI has also been shown to improve with 
treatment of an exacerbation in CF. Correlation with changes in other biochemical 
(serum CRP, peripheral blood white cell count, sputum IL-8, sputum neutrophil) 
clinical (symptom score) or structural (computed tomography) markers was poor. 
Short term change in LCI has also been demonstrated in CF patients in response to 
chest physiotherapy, although there was considerable heterogeneity of response in 
terms of both LCI and volume of lung ventilated by tidal breathing (as measured by 
washout functional residual capacity).  
In addition to LCI, multiple breath phase III slope analysis has been performed 
on washouts of CF patients and healthy controls, and this has been compared to other 
measures of lung physiology. Proposed measures of convective and diffusive gas 
mixing have been shown to be unreliable in CF. These studies have also been the 
first to demonstrate multi-centre use of washout tests as endpoints. 
The technology described here offers the possibility of a simple and reliable 
system for performing multiple breath washouts, though at present it is not available 
commercially. The studies have added to the understanding of the utility and 
reliability of washout tests, as well as some of their limitations. It is hoped that in 
future LCI will be an important clinical endpoint in therapeutic intervention studies 
in CF, and that it will also offer new ways to follow changes in lung physiology in 
other diseases. 
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DLCO The diffusing capacity of the lung for carbon monoxide, a measure of 
integrity of the alveolar membrane 
DLCO / VA Diffusing capacity corrected for alveolar volume, also known as KCO 
ENaC Epithelial sodium channel 
FEF Forced Expiratory Flow, usually suffixed by a number to indicate the 
percentage of FVC that flow was measured between 
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FVC Forced Vital Capacity 
GL67 Genzyme corporations Lipid 67 
GTA Gene Therapy Agent 
IL Interleukin 
KCO See  DLCO / VA 
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MBW Multiple Breath Washout 




MS Mass Spectrometer 
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RV/TLC Ratio of Residual Volume to Total Lung Capacity 
Sacin A measure of ventilation heterogeneity due to diffusion-convection 
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Scond A measure of convective ventilation heterogeneity in the lung 
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SD Standard Deviation 
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SnIII Normalised phase III (alveolar) slope 
TLC Total Lung Capacity 
TO Lung volume Turnover 
VD Dead space 
Vexp Volume expired 
V/Q Ventilation / Perfusion ratio 
VT Tidal Volume 
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Chapter 1- Introduction 
 
Overview 
This thesis concerns the technical validation, adaptation and use in a clinical 
setting of a novel gas analyser technology to measure multiple breath inert gas 
washouts in patients with airways disease. The research was initiated by the Cystic 
Fibrosis Gene Therapy Consortium as part of an ongoing programme into the 
development of minimally invasive biomarkers of cystic fibrosis (CF) disease 
activity. In this regard, multiple breath washouts are particularly attractive as 
potential study endpoints, since they are non-invasive and are believed, particularly 
in early airways disease, to be sensitive to processes occurring in the small airways. 
The majority of the work presented in this thesis was carried out in patients with 
cystic fibrosis or in healthy controls. However, the value of this technique is not 
limited to CF, and the final chapter describes results obtained from other patient 
populations. 
The first part of this introduction concerns the genetics and pathophysiology of 
CF lung disease, and the nature of the gene therapy programme whose requirements 
have driven this research. The final part of the introduction describes the nature of 
CF airways disease and considers the current literature on multiple breath washout 
tests.  
 




Cystic fibrosis is the most common lethal autosomal recessive disease of 
Caucasians. The condition has a carrier frequency of 1:25 and affects 1 in 2500 live 
births. The faulty gene was identified almost 20 years ago, and encodes an epithelial 
ion channel known as the cystic fibrosis transmembrane conductance regulator 
(CFTR) (Riordan, Rommens et al. 1989). CFTR is a member of a class of proteins 
termed the ATP-binding cassette (ABC) family (Gadsby, Vergani et al. 2006). 
Unlike other members of the family however, the CFTR functions as a chloride 
channel, and is regulated by protein kinase A in a c-AMP dependent fashion (see 
Figure 1.1). CFTR forms part of a multi-protein assembly in the apical plasma 
membrane, and is also responsible for the regulation of a number of cellular 
processes. In particular it acts to down-regulate the activity of the transepithelial 
sodium channel (ENaC) in the apical epithelial membrane. In addition to this, it also 
interacts with calcium-activated chloride channels and potassium channels 
(Kunzelmann, Schreiber et al. 2000). These other proteins are potential modifiers of 
the CF phenotype, and may help to explain the wide variability in clinical phenotype 
even amongst those with identical CFTR mutations. 
Over 1500 CFTR mutations have been described 
(http//www.genet.sickkids.on.ca/cftr), but the most common mutation in the CF gene 
is a deletion of phenylalanine at position 508, known as ∆F508. This is largely 
responsible for the high incidence of CF in the Caucasian population, where it 
accounts for over two thirds of CF mutations (Bobadilla, Macek et al. 2002). The 
mutations are grouped into six classes depending on their effect on gene expression 
(see Figure 1.2) (Rowe, Miller et al. 2005). These classifications are not merely 
academic since clinical severity is affected by the amount of residual CFTR activity. 
For instance, the presence of a class IV mutation (e.g. R117H) is associated with 
pancreatic sufficiency, and class V mutations may be associated with particularly 
mild phenotypes (e.g. congenital bilateral absence of vas deferens, with no other 
clinical manifestations of CF). Patients whose genotypes include class I or II 
mutations (i.e. the more severe mutations, where there is no or little CFTR expressed 
 






















Figure 1.1: Structure of the cystic fibrosis transmembrane regulator (CFTR) 
molecule. The protein is expressed in apical cell membranes where it functions as a 
chloride channel. The channel is made up of two membrane spanning domains (I and 
II), each consisting of 6 membrane spanning alpha helices. Two nucleotide binding 
domains (NBD1 and NBD2) mediate ATP hydrolysis, and it is on one of these 
(NBD1) that the most common CFTR mutation (∆F508)) occurs. Phosphorylation of 
the R domain permits a conformational change and opening of the channel. CFTR 
interacts through its C terminus with an array of different cellular proteins, including 
cytoskeleton, cell signaling mechanisms, and other ion channels - in particular the 
epithelial sodium channel ENaC (in purple). 


























Figure 1.2: Classes of CFTR mutation and their effect on gene expression. Class I 
mutation – transcription errors; Class II – defective protein maturation and 
trafficking; Class III – disordered regulation; Class IV defective channel gating; 
Class V – splicing abnormalities; Class VI – accelerated turnover. The first three of 
these are associated with particularly diminished or absent CFTR activity and more 
severe clinical phenotypes. Adapted from Rowe et al. (Rowe, Miller et al. 2005). 
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at the cell surface) on both alleles have, on average, more rapid deterioration in lung 
function, and lower survival rates, than patients who have class IV or V mutations 
(i.e. those possessing some residual CFTR activity) on at least one allele (de Gracia, 
Mata et al. 2005). Even amongst those with identical CFTR genotypes however, 
there is considerable phenotypic variability. The reasons for this are multi-factorial, 
and include not only the activity of modifier genes but also social and environmental 
factors, such as access to specialist healthcare and compliance with treatment 




Lung disease in cystic fibrosis  
Pulmonary manifestations of CF present as chronic bacterial bronchitis that 
progresses to chronic suppurative bronchiectasis and ultimately respiratory failure 
and death. In the lung, CFTR is detectable on the apical membrane of ciliated cells 
within the gland ducts and in the superficial epithelium of healthy individuals 
(Kreda, Mall et al. 2005). In CF, the submucosal glands and distal airways are 
obstructed by thick tenacious secretions. The clinical syndrome suggests a failure of 
the normal airway defence mechanisms against bacterial infection. There are two 
main hypotheses that have been proposed to link the clinical findings with the known 
actions of the CFTR chloride channel. 
The first of these hypotheses, known as the high salt hypothesis, was proposed 
by Smith et al. (Smith, Travis et al. 1996). They observed that cultures of CF airway 
epithelia in vitro lacked the innate anti-pseudomonal activity present in cultures of 
healthy cells. Furthermore, this activity was dependent on a low molecular weight 
soluble factor, human β-defensin-1, which could be inactivated by high 
concentrations of NaCl (Goldman, Anderson et al. 1997). Such high ASL salt 
concentrations had been demonstrated in vivo and in vitro (Joris, Dab et al. 1993; 
Smith, Travis et al. 1996). The theory proposed that loss of the CFTR Cl
-
 channels 





 from accompanying Na
+
 absorption, as in CF sweat ducts (Quinton 
1990), with consequent inhibition of defensin activity. There is impaired clearance of 
bacteria deposited on the airway surface during normal respiration, and neutrophils 
and macrophages are recruited, ultimately disrupting normal airway function and 
leading to the familiar picture of chronic infection and inflammation. 
However, this theory is not supported by in vivo observations on airway 
surface liquid (ASL) height, nor by the effects on ASL volume of ionic and non-ionic 
osmolytes (Tarran, Grubb et al. 2001). The alternative, and increasingly widely 
accepted, explanation for the clinical effects of CFTR deficiency is known as the low 
volume hypothesis (Matsui, Grubb et al. 1998). It is proposed that the absence of 
CFTR leads to over-activity of ENaC (since CFTR down-regulates ENaC in the wild 
type). Excessive sodium is absorbed, and chloride follows through non-CFTR 
chloride channels. In support of this, a mouse model with excessive ENaC activity 
has a lung phenotype similar to that of human CF (Mall, Grubb et al. 2004). There is 
a net absorption of ions and fluid, which leads to a shrinking of the ASL layer, 
dehydration of mucous secretions and collapse of epithelial cilia. The effects on the 
mucus layer and the cilia are felt to be crucial in the development of CF lung disease. 
In health, the mucus layer is a gel consisting of around 1% salt, 1% high molecular 
weight secreted mucins (MUC5AC and MUC5B), and 98% water (Verdugo, Tam et 
al. 1983). At its inner surface, between the mucus layer and the epithelial cell 
membrane, lies a thin pericilliary liquid layer (PCL). This layer provides a low 
viscosity solution in which the cilia can beat rapidly (8-15Hz). It also prevents 
adhesion of the mucus to the epithelial surface, thereby lubricating the movement of 
mucus during cough clearance (Zahm, Pierrot et al. 1989). 
The regulation of the PCL volume is complex, and is dependent on the integrity 
of both CFTR-dependent chloride secretion and CFTR regulation of ENaC. Blockage 
of chloride secretion with bumetanide, or addition of an artificial active Na
+
 channel 
in the form of nystatin, leads to excess ion and water absorption (Boucher 2007). 
Healthy airway epithelia in culture maintain an ASL depth of 7µm, but CF airway 
epithelia continue to absorb the ASL and the cilia collapse onto the cell surface 
(Tarran, Button et al. 2005). This reflects the failure of the mutant CFTR to act as a 





 channel or ENaC regulator, and occurs despite normal adenosine regulatory 
pathway in CF. 
Unregulated absorption of ions and water across the CF airway epithelium 
causes shrinkage of the PCL in CF and dehydration of the overlying mucus layer 
(Figure 1.3). Shrinkage of the PCL impairs the action of the cilia and brings an 
increasingly adhesive mucus layer into contact with the epithelium. The disruption of 
the mucociliary escalator leads to sequestration of mucus in the lungs and 
immobilized mucus forms plaques. These plaques cause airflow obstruction and 
permit chronic infection with pathogenic bacteria. The exact process by which the 
infection is initiated is unclear, but may comprise inhaled bacteria that are not 
cleared efficiently, or the initial infection may follow an insult to the lung, e.g. viral 
infection or aspiration (Abman, Ogle et al. 1988). Whatever the initiating event, 
lungs of CF patients become colonised early in the course of the disease with 
bacteria such as Staphylococci or H. influenza (Rosenfeld, Gibson et al. 2001). These 
infections become persistent in the first few years of life and the inflammatory 
response leads to neutrophil recruitment and activation. This in turn stimulates 
hypersecretion of mucin. Bacterial products and cellular debris accumulate, along 
with polymeric DNA which makes the mucus more viscous and even harder to expel 
(Zahm, Girod de Bentzmann et al. 1995). The CF airways fill up with purulent 
secretions and a vicious cycle of infection, inflammation and progressive 
endobronchial destruction is established.  
The clinical course is typically punctuated by periods of exacerbation, when 
bacterial infection gains the upper hand over host defence. At these times there is 
usually deterioration in lung function, and associated symptoms of infection. The 
involvement of different infecting organisms, particularly Pseudomonas aeruginosa 
and Burkholderia cepacia, further alters the delicate balance in favour of greater 
inflammation. The majority of bacteria in the CF airways are located within the 
mucus layer, and virtually none are intracellular or bound to the epithelium 
(Baltimore, Christie et al. 1989).  
The formation of Pseudomonas biofilms appears to be encouraged by the 
thickened mucus. The mucus limits bacterial motility and diffusion of excreted 
proteins (Dawson, Wirtz et al. 2003). The resulting high bacterial densities are 
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detected by the bacteria’s quorum-sensing mechanisms, which triggers a phenotypic 
change to biofilm forms (Davies, Parsek et al. 1998). In addition, the thick mucus 
layer and the increased oxygen consumption of the epithelial cells leads to an oxygen 
gradient across the mucus, with particularly hypoxic areas in mucus plugs 
(Worlitzsch, Tarran et al. 2002). This hypoxic environment favours the growth of 
Pseudomonas and the switching to biofilm formation. 
It is acknowledged however that this may not represent the entire story. For 
example, primary ciliary dyskinesia results in a complete failure of mucociliary 
transport, but the patients do not usually suffer such severe generalised 
bronchiectasis, and it is consistent with a normal life expectancy (Schidlow 1994). It 
may be that defective CFTR leads to dysregulation of the host defences in other more 
complex ways. In vitro studies using CF epithelial cells have demonstrated an 
increased secretion of pro-inflammatory cytokines in unstimulated cells that is 
unrelated to the nature of the CFTR mutation and independent of effects on chloride 
transport (Weber, Soong et al. 2001). Other studies have looked at the response of 
CF and non-CF epilthelial cell cultures to stimulation with inflammatory cytokines 
and bacterial products (Aldallal, McNaughton et al. 2002; Becker, Sauer et al. 2004). 
Both of these studies showed considerable variability in response to stimulation, 
making it hard to demonstrate a clearly pro-inflammatory phenotype in CF cells in 
vitro. To overcome the problem of confounding genetic variability between different 
cell lines, Perez et al. applied a specific inhibitor of CFTR chloride conductance to 
well differentiated human tracheal cells grown in an air-liquid interface (Perez, Issler 
et al. 2007). Inhibition of CFTR was sufficient to cause an increase in IL8 in both 
unstimulated cells and in response to Pseudomonas aeruginosa products.  
It is obviously much harder to investigate the development of inflammation in 
vivo since almost all patients with CF also have established chronic bacterial 
infection. A number of studies of infant bronchoalveolar lavage (BAL) fluid have 
found evidence of airway inflammation without concurrent lower airway infection 
(Balough, McCubbin et al. 1995; Khan, Wagener et al. 1995). Subsequent studies 
have since disputed this (Armstrong, Grimwood et al. 1997; Dakin, Numa et al. 
2002), but it remains clear that inflammation is an early event in CF. 
 

















Figure 1.3: Proposed mechanism for the development of chronic airway infection in 
CF, after Boucher (Boucher 2007). In normal airways (A), hydration is controlled by 
Na+ absorption & Cl- secretion. In CF (B), the absence of CFTR leads to 
unregulated Na+ absorption and associated dehydration of the pericilliary layer 
(PCL) and mucus. Mucus becomes adherent in plaques which allow bacterial 
colonisation (C), encouraged by a hypoxic gradient across the plaque. The resulting 
inflammatory response (D) leads to a vicious cycle of inflammation, mucus secretion 
and retention, and ultimately airway destruction. 
High 
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Effects in the airways 
The harmful effects of CFTR dysfunction are particularly manifest in the small 
airways. Only relatively low levels of CFTR expression are found in the bronchial 
epithelium, but CFTR is expressed throughout the distal airway and is greatest in the 
respiratory bronchioles (Engelhardt, Zepeda et al. 1994). The pathological hallmarks 
of CF are infection and inflammation, and small airways are particularly susceptible 
to the effects of airway wall inflammation and obstruction.  
High resolution computed tomography (HRCT) scans cannot image normal 
airways with a diameter of less than 2mm. However, abnormalities in the small 
airways can be visualised on CT, either indirectly in the case of mosaic attenuation 
due to gas trapping, or directly as mucus plugging or airway dilatation (Hansell 
2001). CT studies have shown that there is progressive airway wall thickening, most 
marked in the peripheral airways, and that progression of this correlates with changes 
in mid expiratory flows (de Jong, Nakano et al. 2005). Unless there is associated 
airway dilatation, airway wall thickening will have a disproportionate effect on the 
luminal resistance of the smaller airways. Pathological studies have shown that this 
airway wall thickening is due to epithelial enlargement, smooth muscle thickening 
and epithelial metaplasia with goblet cell extension into the small airways 
(Bedrossian, Greenberg et al. 1976; Tiddens, Koopman et al. 2000). 
Small airways are also particularly prone to mucus plugging, which has been 
described as affecting more than 50% of the total luminal volume in 64% of small 
airways in the severely affected lungs removed at lung transplantation (Burgel, 
Montani et al. 2007). Copious surface mucus has been shown in respiratory 
bronchioles at electron microscopy (Simel, Mastin et al. 1984). In addition to directly 
obstructing small airways, sequestration of mucus increases the surface tension, 
thereby further promoting airway closure and gas trapping.  
There is a paucity of pathological data in young or healthy subjects. This means 
that, although we know newborns have histologically normal lungs (Chow, Landau 
et al. 1982), there is little information on how this progresses to the advanced 
changes seen in lungs removed at transplantation or autopsy. Specimens taken from 
patients who have undergone lung transplantation show a variety of airway 
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abnormalities, including bronchiectasis, fibrosis, inflammation, mucus impaction, 
pulmonary vascular changes and reduced small airway density (Hamutcu, Rowland 
et al. 2002). It is not clear whether the reduction in small airway density is due to 
progressive destruction or dilatation. It is also unclear how the different pathological 
processes interact to produce such variability in lung damage and destruction, both 
within and between individuals. 
 
Other clinical features of CF 
Although the most striking pathological effects of CF are manifest in the lung, 
deficiency of CFTR also leads to disease in other organs where the receptor is 
expressed. These include the gastrointestinal tract, liver, pancreas, sinuses, 
reproductive tract and sweat glands. In the majority patients, these conditions can be 
managed medically and are not fatal, but they do contribute significantly to 
morbidity and to the burden of disease. 
Patients commonly present in the neonatal period with meconium ileus or in 
childhood with a failure to thrive. In addition to this, an increasing number of 
patients are now detected by neonatal screening, which presents opportunities for 
earlier identification and treatment of those with milder phenotypes. 
 
Clinical management of CF 
Over the last few decades there has been a striking and progressive 
improvement in life expectancy (Figure 1.4). A disease that was previously fatal in 
childhood now has a median life expectancy of mid to late 30’s (Dodge, Lewis et al. 
2007). This enormous improvement has been brought about by a better 
understanding of the pathology of CF, and more effective treatment. The treatment 
available however remains essentially symptomatic, and aimed at the consequences 
of the disease rather than correcting the underlying defect. Improved antibiotic 
therapy has been crucial to this improvement in life expectancy. Patients are now 
closely monitored for signs of infection and treated early and aggressively with at 
least two antibiotics. Other advances include the early eradication of Pseudomonas 
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(Wood and Smyth 2006), patient segregation to prevent cross-infection (Cheng, 
Smyth et al. 1996; Vonberg and Gastmeier 2005), nebulised DNase (Fuchs, Borowitz 
et al. 1994), and the use of nebulised and long term oral antibiotics to control 
infection (Ramsey, Pepe et al. 1999; Southern, Barker et al. 2004). The other major 
advance has been in the management of patients’ nutritional status. Pancreatic 
enzyme supplements, specialist dietician services and the use of artificial feeds 
where necessary are all standard practice (Dodge and Turck 2006). 
Recently, the use of nebulised hypertonic saline has been reported as showing a 
modest, but sustained, improvement in lung function and a more dramatic fall in the 
rate of pulmonary exacerbations and requirement for antibiotics (Elkins, Robinson et 
al. 2006). This is thought to occur as a result of improvements in mucociliary 
clearance caused by osmotically driven hydration of the mucus layer (Donaldson, 
Bennett et al. 2006). 
However, all of this is not without cost. Quite apart from the financial cost of 
treatments, there is a considerable burden in terms of patient time and effort. 
Nebulised antibiotics and physiotherapy can each take up to 30 minutes to complete, 
and are usually prescribed twice daily. In addition to this, patients have numerous 
oral treatments to remember at different times of day, and may be on artificial feeds, 
inhalers and insulin injections. 
In addition to the conventional therapies described above, there has been much 
interest in the possibility of designing therapies for specific genetic defects. 
Examples of such approaches include the use of drug screening programmes to look 
for compounds that will correct the abnormal ∆F508 processing or activate residual 
CFTR activity (Ma, Vetrivel et al. 2002; Verkman 2004). A number of compounds 
have been identified as being active in vitro against the G551D mutant (Pedemonte, 
Lukacs et al. 2005), but no such drugs have yet been used in large clinical trials. The 
use of aminoglycosides to rescue CFTR stop mutations has also failed to demonstrate 
consistent improvement in CFTR levels or function vivo (Clancy, Rowe et al. 2007). 




Figure  1.4: Median survival age for US patients with CF since first description of 
CF. Data from 1985 onwards are CF Foundation projections for median survival age 
for a patient born in that year with CF. From Davis (Davis 2006). 
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Gene therapy for CF 
When the CFTR gene was first identified there was tremendous optimism that 
we would soon have a “cure”. On the face of it, CF is an attractive target for gene 
therapy: it is a common single gene disorder with an abbreviated life expectancy; the 
site of major pathology (the lung) is easily accessible; and there is evidence to 
suggest that partial correction of the underlying defect would be able to achieve 
clinical benefit (Johnson, Olsen et al. 1992). The challenges however have been far 
greater than was first appreciated.  
 
Viral vectors 
The human immune system, with an evolutionary head start of several millions 
of years, has so far resisted attempts to circumvent its defences against the repeat 
administration of viral vectors. Typically adenovirus or adenovirus-associated viral 
(AAV) vectors have been used. Techniques that have been tried to enhance 
transfection efficiency include attenuation of the virus vector (Yeh and Perricaudet 
1997), alteration of cell surface receptors to target vectors to the apical membrane 
(Kreda, Pickles et al. 2000), and masking of surface antigens by polyethylene glycol 
(O'Riordan, Lachapelle et al. 1999). For both these vectors many subjects have pre-
existing neutralising antibodies, affecting even initial administration (Chirmule, 
Propert et al. 1999). Both the adenovirus and AAV are immunogenic and adenovirus 




The most basic form of non-viral gene therapy is naked DNA. However, this is 
inefficient at gene transfer and subject to endonuclease degradation (Lechardeur, 
Sohn et al. 1999). In order to improve transfection efficiency, the DNA can be 
complexed with lipids to form lipoplexes, or poly-cation molecular complexes to 
form polyplexes (Montier, Delepine et al. 2004). These lack the specificity of viral 
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vectors, and have reduced transfection efficiency, but are not immunogenic and 
hence are suitable for repeat administration (Hyde, Southern et al. 2000). 
Although there are a number of different formulations available for lipoplexes 
or polyplexes, one of the most promising so far has been Genzyme Corporation’s 
Lipid 67 (GL67). In a recent preclinical study comparing different vector 
formulations using the same plasmid, the preparation using GL67 had greatest 
efficacy (McLachlan, Davidson et al. 2005). In addition to this, there are already 
clinical data on gene therapy using a GL67 vector (Alton, Stern et al. 1999), and 
toxicity data in normal subjects (Chadwick, Kingston et al. 1997). 
The other key component of a gene therapy agent (GTA) is the plasmid. The 
first trial of nebulised gene therapy used a liposome consisting of GL67 and a 
synthetic plasmid with the CF gene and a cytomegalovirus promoter inserted. Seven 
of eight patients in the active arm reported flu-like symptoms within 6 hours of 
nebulisation. In addition, there was a statistically significant 7.5% reduction in gas 
transfer, and evidence of a systemic inflammatory response including raised C-
reactive protein (CRP) and IL-6 in the active group. These features were not seen in 
the control (lipid alone) group, nor in the healthy volunteers previously dosed with 
lipid alone as part of a toxicity study.  
It has since been appreciated that unmethylated CpG motifs in the bacterial 
DNA are recognised by the host innate immune system as foreign (Schwartz, Quinn 
et al. 1997; McLachlan, Stevenson et al. 2000). Removing these has been one of the 
major changes to the plasmid formulation since the earlier study. The other important 
improvements have been to source a promoter capable of early and prolonged gene 
expression.  
 
The CF Gene Therapy Consortium 
In the late 1990s, there were three groups in the UK working on non-viral gene 
transfer in CF, all of which published separate clinical trials of CFTR gene transfer to 
the nasal epithelium within a few years of each other (Caplen, Alton et al. 1995; Gill, 
Southern et al. 1997; Porteous, Dorin et al. 1997; Hyde, Southern et al. 2000). The 
only trial of nebulised gene therapy to the lung followed shortly after (Alton, Stern et 
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al. 1999). These three groups combined in 2001 to form the UK Cystic Fibrosis Gene 
Therapy Consortium, funded by a programme grant from the CF Trust. The 
advantages of amalgamation include the sharing of resources and experience, the 
removal of unnecessary project duplication, the formation of core facilities and 
improved access to patients (Alton 2004).  
There is a highly focussed approach, concentrating on the development and 
delivery of a gene therapy agent that as near as possible fulfils the following criteria 
(Alton 2004): 
1. Repeatedly administrable 
2. Manufactured stably and to clinical standards 
3. Deliverable by nebuliser  
4. Acceptable safety profile 
5. Able to reach clinical trial within 5 years 
 
In order to realize these aims, the consortium has concentrated on the 
development of a GTA based on GL67 and a CpG-free plasmid, as discussed above. 
This has been tested in pre-clinical studies using sheep as a large animal model, since 
the anatomy and physiology of the sheep lung are much closer to that of man than 
the mouse lung (Harris 1997). The consortium has now reached a point where, 
pending the results of a pilot trial, the wave 1 gene therapy agent will be ready for 
large scale production and multi-centre clinical testing by the end of 2009. 
 
Measuring response to gene therapy in CF 
An important challenge of the gene therapy programme has been how to 
measure the response to treatment. Early gene therapy studies were limited in scope, 
and were designed as proof of principle rather than to effect clinical benefit (Caplen, 
Alton et al. 1995; Gill, Southern et al. 1997; Porteous, Dorin et al. 1997; Zabner, 
Cheng et al. 1997; Alton, Stern et al. 1999; Hyde, Southern et al. 2000; Noone, 
Hohneker et al. 2000). The endpoints used in these studies reflect this, and are 
summarised in Table 1.1.  
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Rather than a single endpoint, all of these studies relied upon a combination of 
markers of successful gene therapy, and the sophistication and number of these 
increased in the later studies. The endpoints were chosen on the basis of their ability 
to reflect presence of vector gene transfer, or presence of functioning CFTR. There 
was no attempt to demonstrate any clinically beneficial effect of gene therapy. 
Although all of these studies incorporated clinical assessments - including lung 
function in all cases, as well as measures of serum inflammation and immunology, 
radiological assessments in the form of chest x-ray or chest CT, symptom score, and 
nasal biopsy histology - these were used to assess safety of the gene therapy agent. In 
other words, they were looking for absence of deterioration in clinical state, rather 
than presence of an improvement.  
Measures of biologic activity are acceptable for phase I or II studies, but 
ultimately it is necessary to demonstrate an improvement in clinical status (Ramsey 
and Boat 1994). The methods that can be used to demonstrate successful gene 
therapy are summarised in Table 1.2. 
The first two of these methods, demonstration of successful gene delivery or 
expression, require invasive sampling of the lower airway at bronchoscopy. This is 
not without its’ own risks, and is not suitable for frequent sampling. Even if samples 
can be obtained, the demonstration of mRNA or protein expression, particularly in 
the context of low levels of background expression, present their own challenges 
(Rowe, Accurso et al. 2007). 
Assessment of CFTR activity is traditionally performed by measuring trans-
epithelial nasal potential difference (Middleton and Alton 2006). This technology has 
been around for many years, and was instrumental in defining the function of the 
CFTR. However, the technique is operator-dependent and even in a single centre the 
reproducibility of repeat measurements on two separate occasions is poor (Yaakov, 
Kerem et al. 2007). Bioelectric measurements have also been performed in the 
bronchial tree (Knowles, Gatzy et al. 1981; Alton, Stern et al. 1999), but this requires 
the patient to have a bronchoscopy under a general anaesthetic and hence is not 
suitable for repeated measurements. In the trial by Alton et al., bronchial brushing 
samples were also taken to assess in-vitro cAMP-mediated chloride efflux (Alton, 
Stern et al. 1999).  




























































































Caplen NJ, 1995 9/6    
  
Gill DR, 1997 8/4    
  
Porteous DJ, 1997 8/8    
  
Zabner J, 1997 12   
   
Alton EW, 1999 8/8      
Noone PG, 2000 11   
   
Hyde SC, 2000 10/2      
Table 1.1: Endpoints used as measures of efficacy of gene transfer in previous 
(phase I) trials of non-viral gene therapy. In addition, all 7 trials included a number 
of measures of safety of gene therapy, including symptom scores, lung function 
assessments, chest X-ray or chest CT, serum biochemistry and immunology and 
histology of nasal biopsies. 
 
Endpoint Means of demonstrating endpoint 
Gene transfer • mRNA expression in target cells 
CFTR expression • Immunohistochemistry of airway epithelial cells 
CFTR activity 
• Trans-epithelial potential difference or chloride permeability 
• Mucociliary clearance 
• Airway surface liquid height 
Clinical effect 
• Improved lung function 
• Reduced lung inflammation 
• Structural improvement (e.g. as demonstrated on HRCT) 
• Improved quality of life 
• Improved longevity 
 Table 1.2: Methods of assessing response to gene therapy in clinical trials. Either 
gene transfer, expression or CFTR activity are essential endpoints in early, phase I, 
trials. In addition to these endpoints, phase III trials require evidence of clinical 
benefit. 
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Although assessment of CFTR expression and activity are important, 
ultimately, it is necessary to demonstrate clinical benefit. Ideally this would include 
improved survival or quality of life. These are difficult parameters to measure 
without large numbers of patients being treated and followed for a long period of 
time. Instead, there are a number of surrogate clinical endpoints that are used to 
measure improvement in lung function or clinical status. These were summarised in a 
consensus statement from the Cystic Fibrosis Foundation in 1994 (Ramsey and Boat 
1994). The potentially useful measures of treatment efficacy in patients over 6 yrs of 
age are listed in Table 1.3. For Phase I and II trials, measures of CFTR function (e.g. 
mucociliary clearance and PD measurements) are sufficient. For phase III trials 
however, all the endpoints listed reflect changes in clinical status, either as 
improvement in lung function, reduction in inflammatory burden, or improved 
quality of life.  
The development of more accurate and appropriate biomarkers of CF disease 
activity is not a problem limited to the development of CF gene therapy, and is an 
important challenge for all research into the effects of new therapies in CF.  
 




Phase I and II clinical trials Phase III clinical trials 
 
• CT scanning of chest 
• Bronchoscopy with BAL, 
brushings and/or biopsy 
• PD measurements (upper and 
lower airways) 
• Mucociliary clearance 
• Complete lung function testing 
• Exercise testing 
• Aerosol deposition 
• Bronchial reactivity 
• CXR score 
• Arterial blood gas or oximetry 
• Serum inflammatory markers 
• Bronchoscopy, BAL & brushings 
• Spirometry 
• Sputum for microbiology & DNA 
 
Measures of clinical efficacy 
• Anthropometry 
• Quality of life / illness severity 
scoring 




Table 1.3: Proposed endpoints for trials of new therapies in cystic fibrosis, from the 
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Assessment of lung function in CF 
Anatomy and physiology of the small airways 
The human bronchial tree is a dichotomous asymmetrically branching structure 
of approximately 23 divisions. The large airways contain cartilage to maintain 
patency. Small airways are arbitrarily defined as non-alveolated and non-
cartilaginous airways less than 2mm in diameter. With division, the airways become 
smaller and the histology gradually changes. In the proximal airway, there are 
abundant mucus-secreting goblet cells. These are absent from the distal airway in 
health, and the secretory cells of terminal bronchioles are the Clara cells. The 
epithelial cells are more cuboidal and ciliated cells are sparser, with fewer and 
shorter cilia. The airway walls are much thinner in the small airways and the 
proportion of smooth muscle increases towards the periphery. With successive 
divisions, the number of airways rises exponentially, together with the total airway 
cross sectional area. The contribution of each generation to total airway resistance 
therefore diminishes rapidly in more peripheral generations. The calibre of the small 
airways is maintained by a dynamic process that is dependent upon a variety of 
interacting factors and varies with the phase of respiration. Patency is maintained by 
the elastic pull of the surrounding connective tissue. The forces that act to collapse 
the small airways include smooth muscle tone and the surface tension of the airway 
surface liquid. During expiration, this is increased by the elastic recoil of airway 
tissue and the air pressure in the alveoli. 
Small airways narrow during expiration even in normal subjects – this accounts 
for the differences in the inspiratory and expiratory flow-volume loops. In CF 
patients, there are additional factors that act to upset this dynamic balance in favour 
of airway collapse. There is airway wall thickening due to inflammation, smooth 
muscle hyperplasia, and destruction of the surrounding connective tissue (Hamutcu, 
Rowland et al. 2002). In addition to this, mucus is retained in the small airways due 
to failure of the mucociliary escalator. This can obstruct the airways directly 
(Hamutcu, Rowland et al. 2002), but will also increase the surface tension of the 
fluid in the airway, and hence favour collapse. 
 




Whilst the forced expiratory volume in 1 second (FEV1) is the currently 
accepted gold standard to monitor trials of new treatments for CF (Ramsey and Boat 
1994), the rate of decline in this parameter has steadily reduced over the last decade 
(Que, Cullinan et al. 2006). Power calculations show that many hundreds of patients 
would need to be treated over a year, or more, to see any beneficial effect of a novel 
therapeutic agent aimed at the basic defect (Davis, Byard et al. 1997). However, the 
use of spirometry to measure FEV1 and forced vital capacity (FVC) is well 
established in both clinical and research settings. It has the advantage that it is widely 
used, equipment requirements have been standardized, and normal ranges have been 
defined.  FEV1 and FVC can usually be reproducibly obtained, but the measurement 
is non-physiological, is dependent on effort and technique, and in particular is 
difficult to measure accurately in young children. More importantly, FEV1 is 
insensitive to early disease. This is particularly true in children with CF, in whom 
spirometry now remains within the normal range for the majority until 18 yrs 
(Cystic-Fibrosis-Foundation 2005).  
Recently a number of studies have looked at the structure of the lung using CT 
scanning (Demirkazik, Ariyurek et al. 2001; Brody, Klein et al. 2004; de Jong, 
Nakano et al. 2004). High resolution CT (HRCT) is a sensitive indicator of early CF 
lung disease and HRCT scores have also shown greater progression with time than 
spirometry (Helbich, Heinz-Peer et al. 1999; de Jong, Nakano et al. 2004). Evidence 
of bronchiectasis, peribronchial thickening, gas trapping and mucus plugging have 
all been demonstrated in those with spirometry within the normal range, including 
quite advanced changes in some cases (Brody, Klein et al. 2004; de Jong, Nakano et 
al. 2004). In addition, therapeutic responses have been shown on HRCT in the 
absence of any change in spirometry (Robinson, Goris et al. 2005).  
Further evidence that spirometry is insensitive to early pulmonary disease has 
come from studies of gas mixing in the lung. In the presence of normal spirometry 
these have shown evidence of abnormal gas mixing on MRI ventilation scans of the 
lung (Mentore, Froh et al. 2005), or multiple breath washouts (Gustafsson, Aurora et 
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al. 2003; Aurora, Gustafsson et al. 2004). These will be discussed in more detail later 
in this chapter. 
Another problem with spirometry is that normal absolute values change over 
time. In normal children, FEV1 increases with age and in normal adults there is a 
gradual decline in FEV1 with older age (Quanjer, Tammeling et al. 1993; Rosenthal, 
Bain et al. 1993). In CF patients this background annual decline is exaggerated, and 
is of the order of 100 ml/yr in those with moderate to advanced lung disease 
(Rosenberg, Howatt et al. 1992). Evolving normal ranges are a particular problem in 
adolescent CF patients. The delayed pubertal growth spurts frequently seen in CF 
(Haeusler, Frisch et al. 1994) make it difficult to define appropriate normal values in 
this population, just when robust treatment end points are most relevant. This causes 
difficulties in long term follow up studies, since continuous adjustment must be made 
for the subject’s age and (in the case of children) height and developmental stage. 
For this reason FEV1 is usually quoted as a percentage of the predicted value. 
In the clinic, FEV1 is considered normal if it lies within the range 80-120% of the 
predicted value. Thus, a patient could theoretically have lost 30% of their spirometric 
lung function (if their baseline was 120% predicted), before the FEV1 was recognised 
as being outwith the normal range. This may help to explain the lack of sensitivity of 
FEV1 to early lung disease on CT in the cross-sectional studies described above. Use 
of different prediction equations for “normality” can also have profound effects on 
the measured rate of decline in “percent predicted” values for spirometry (Merkus, 
Tiddens et al. 2002), particularly in adolescence. 
The reasons for the insensitivity of FEV1 to early airways disease are intrinsic 
to the measurement itself. FEV1 is the volume of air expired within the first one 
second of a forced expiration, hence it measures the air flow over that period. 
Assuming that patient effort is unchanged with each attempt, in early lung disease it 
reflects a measure of total airways resistance. In more advanced lung disease the 
picture becomes more complicated by gas trapping and flow-dependent airway 
collapse due to reduced elasticity. 
There is an exponential increase in total airways cross-sectional surface area 
with each division of the bronchial tree, illustrated in Figure 1.5. The small airways, 
of less than 2mm, are pathways of low flow and individually high resistance. 
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Because of the increase in total cross sectional area however, collectively they 
contribute only around 10% of total airways resistance in healthy adults (Macklem 
and Mead 1967). Hence, there can be quite considerable disturbance of the small 
airways, with relatively little effect on FEV1. This was shown by Brown et al., who 
used beads of different sizes to obstruct small and large airways in explanted animal 
lungs and assessed the effect of this on pressure-volume curves (Brown, Woolcock et 
al. 1969). They demonstrated that in dogs, which have collateral channels like man, 
obstruction of 50% of the small airways caused only a 10% increase in total airway 
resistance, and had no measurable effect on vital capacity (VC) or pressure-volume 
curves.  
Thus FEV1 will be abnormal in conditions that cause obstruction of the larger 
airways or in conditions severely affecting the majority of peripheral airways. The 
insensitivity to mild disease in small airways has led to term the “silent zone”. This 
refers to the deterioration in lung function that occurs between the start of a disease 
process and the ability to detect it on spirometry. The initial stages of the disease 
process in CF occur in the small airways (Brownlee 2006). In addition, it is these 
airways that are the target for nebulised gene therapy. In order to measure the 
response to therapy, and to identify patients with early (and potentially reversible) 
lung disease, there is thus a need for an assay of lung function that has the potential 
to reflect changes in the small airways.  
As with any trial endpoint, the assay also has to fulfil the following criteria 
(Rosenfeld 2007): 
• Minimally invasive and simple for the patient to perform  
• Limited harmful or unpleasant side-effects 
• Practical, with standardized equipment and interpretation 
• Reproducible (with minimal error and variability) 
• Sensitive 
• Biologically relevant 
• Stable, or behaves predictably, over time 




Figure 1.5: Illustration (not to scale) of the cross sectional area of the airways. With 
successive dichotomic divisions of the airway tree the cross sectional area at each 
level increases exponentially. Arrows on the left hand represent the flow of expired 
air in the airways: low flow (thin arrows) in multiple narrow peripheral airways and 
high flow (thicker arrows) in a smaller number of central airways. 
 
 
Airway tree  Cross sectional area  
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Measurement of small airway function 
Standard lung function measurements 
Although FEV1 is relatively insensitive to mild small airways disease, there are 
a number of other lung function assays that appear to be more sensitive. One of the 
best described of these is the forced expiratory flow between 25 and 75% of FVC 
(denoted as FEF25-75). This is derived from the flow-volume loop generated during 
spirometry and calculated as the mean forced expiratory flow during the middle half 
of the FVC (that between 25% and 75% of the total FVC). A number of variations on 
this measurement also exist, but all have in common the measurement of the forced 
expiratory flow at low lung volumes, and are often referred to as measures of mid 
expiratory flow. Mid expiratory flow measurements are more sensitive to early 
airways dysfunction than FEV1 (Kraemer, Blum et al. 2005), and are more sensitive 
to abnormalities on CT (Gustafsson, de Jong et al. 2007). Pathology studies have also 
shown that these measurements can be related to histological changes in the small 
airways (Petty, Silvers et al. 1982). A major barrier to the wider use of these tests 
however is that they are very dependent on patient effort, are poorly reproducible, 
both within and between visits, and have poorly defined normal ranges in different 
age groups (Timonen, Randell et al. 1997). 
The forced oscillation technique (FOT) is an alternative method of assessing 
airway function that measures the impedance of the entire respiratory system. The 
forced oscillations are superimposed on the normal respiratory cycle, avoiding the 
need for any special respiratory manoeuvres (Oostveen, MacLeod et al. 2003). 
However, measurement can be affected by swallowing, integrity of mouthpiece or 
noseclip seal, irregular breathing or hyperventilation. In addition, the signal is 
attenuated by compliance of the upper airways, particularly at higher frequencies. A 
number of approaches have been developed to cope with this (Michaelson, Grassman 
et al. 1975; Peslin, Duvivier et al. 1985), but the standard practice is to minimise this 
upper airway shunt by compression of the cheeks (Oostveen, MacLeod et al. 2003). 
FOT is a promising technique that has been used in both adults and children, and 
reference data are available for both populations. However, the reference ranges are 
dependent on the exact measurement conditions, and frequency band assayed, for 
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which there is no universal standard. In addition, reproducibility is poor, with a day 
to day coefficient of variation of repeat measurements of around 10-11% in adults 
(Gimeno, van der Weele et al. 1993), and as high as 16% in children (Timonen, 
Randell et al. 1997). Finally, FOT is of uncertain value for measuring peripheral 
airway function, and cannot differentiate between intra and extra pulmonary 
disorders (Oostveen, MacLeod et al. 2003). 
 
Inert gas washout tests 
It has been appreciated for some time that there are regional differences in the 
distribution of ventilation even in normal lungs (Milic-Emili, Henderson et al. 1966). 
In early airways disease however, this heterogeneity of ventilation distribution is 
more pronounced (Mentore, Froh et al. 2005), possibly as a result of blockage or 
constriction of small airways by inflammation, remodelling or retained secretions. 
Even minimal heterogeneity in bronchoconstriction produces clusters of poorly 
ventilated airways through a positive feedback on surrounding smooth muscle, 
resulting in significant heterogeneity of ventilation distribution (Venegas, Winkler et 
al. 2005). This can be demonstrated on HRCT, where gas trapping is an early sign of 
small airways dysfunction (Hansell, Rubens et al. 1997). Ventilation heterogeneity 
can also be demonstrated on hyperpolarized helium MRI scanning, which permits 
direct visualisation of the distribution of a single inspiration, and which has been 
used to show changes in ventilation distribution in response to therapy (Samee, Altes 
et al. 2003; Mentore, Froh et al. 2005). Alterations in ventilation distribution impact 
upon the efficiency of gas mixing during breathing, and it is this that is measured by 
inert gas washout tests. These can either be performed on a single vital capacity 
breath, or during prolonged tidal breathing.  
It is important to appreciate that these tests are not specific measures of small 
airways disease, but rather measures of overall ventilation heterogeneity, and that 
this can itself be affected by a number of different processes. Disease of large and 
medium airways will also produce regional differences in ventilation distribution, as 
will differences in the time constants of lung regions due to parenchymal or chest 
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wall disease. In patients with advanced CF lung disease, there may be extensive 
airway obstruction, with mucus plugging, bronchiectasis, and destruction of 
supporting tissue (Helbich, Heinz-Peer et al. 1999), and it is unlikely that differences 
in small airways alone are responsible for the ventilation heterogeneity seen in these 
patients. In well patients however, with little or no spirometric impairment (including 
children), it is likely that small airways changes are at least partially responsible for 
changes in gas mixing. 
 Evidence for this is, to a certain extent, circumstantial and it is not possible to 
know exactly what the MBW indices represent at a histological level since data on 
airway pathology in subjects with mild disease is not available and is not likely to be 
forthcoming. However, our understanding of CF is that the disease affects primarily 
the small airways, at least initially (Brownlee 2006). This leads us to believe that 
MBW indices are particularly sensitive to small airways dysfunction, since LCI 
appears to be particularly sensitive to early airways disease in CF (see below). 
Further support for this came from a paper by Gustafsson  et al. looking at CT 
appearances, spirometry and LCI in 44 children (age 5-19 yrs) with CF (Gustafsson 
2007). As had been previously reported, sensitivity of spirometry to structural 
abnormalities on CT was poor. LCI was the most sensitive to structural lung 
abnormalities, particularly to air trapping, for which it had a sensitivity of 94%. 
Normal LCI in a patient with CF almost excluded the presence of structural 
abnormalities on HRCT.  In addition, LCI was also elevated in one third of those 
with a normal CT score, which may represent the presence of physiological 
abnormalities due to disease that is below the limit of resolution of the CT scanner. 
 
 
1. Single breath washout 
The classic single breath nitrogen washout test involves the administration of 
100% oxygen to the subject during a slow inspiration from FRC to total lung 
capacity (TLC), followed by a slow expiration. The resulting trace of expired 
nitrogen against volume is conventionally divided into four distinct phases (Figure 
1.6). The first phase represents the absolute dead space (e.g. of the apparatus, mouth 
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and upper airway). The second represents the rising nitrogen concentration as gas is 
expired from the bronchi. Together these two phases represent the anatomical dead 
space of the lungs. The third phase is the expiration of alveolar gas. In a “perfect” 
lung in which ventilation distribution was entirely even this would be a straight line. 
The final phase, a sharp increase in expired gas concentration seen in some subjects, 
represents expulsion of air beyond the point at which some airways have collapsed 
and is known as the closing volume (Forkert, Dhingra et al. 1979). 
 SBW tests can also be performed with exogenous tracer gas. In this case a gas 
mixture containing inert tracer, usually SF6 or helium, is inhaled instead of 100% 
oxygen. The expired gas concentration profile is the inverse of that for nitrogen, 
since the concentration of tracer falls as gas is expired from the alveolar 
compartment. 
It has been recognised since the 1940s that non-uniformity of gas mixing in the 
lung results in a sloping alveolar plateau (Fowler 1949), and ventilation 
heterogeneity can therefore be inferred from the steepness of this slope (also referred 
to as the phase III slope). Imperfect convective (bulk flow) gas mixing occurs 
between different regions of the lung as a result of differences in airway calibre and 
expansion of the lung. Sequencing between these regions contributes to the sloping 
alveolar phase, and this becomes steeper in disease. Interaction between convective 
and diffusive gas mixing in the periphery also contributes to variations in ventilation 
efficiency and a sloping alveolar plateau (Prisk, Lauzon et al. 1996; Dutrieue, 
Vanholsbeeck et al. 2000). Since diffusion is related to the molecular mass of the gas 
molecule, SBW tests can be refined by using helium and sulphur hexafluoride (SF6) 
together. This allows inferences to be made about the ventilation of the most 
peripheral air spaces (Gronkvist, Emery et al. 2002). Greater heterogeneity of gas 
mixing results in a steeper phase III slope and an earlier onset of the phase IV 
(closing volume). 
 































Figure 1.6: A typical plot of a single breath washout. Phase I corresponds to the 
equipment and upper airway deadspace, Phase II is the bronchial phase, Phase III 
corresponds to mixed alveolar gas and Phase IV to gas expired below the closing 
volume. This figure was derived from a multiple breath washout of a CF patient, and 
is also shown in more detail in Figure 5.2. 
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SBW tests have been used to demonstrate changes in phase III slope in patients 
with numerous different conditions, including CF. In addition, the slope has been 
shown to correlate with histological measures of small airways pathology, albeit in 
those with already well established disease (Cosio, Ghezzo et al. 1978). Although 
SBW tests have been used for many years in research, and have also been used in 
longitudinal clinical studies (Estenne, Van Muylem et al. 2000), they are not 
commonly used in clinical practice. Firstly the test requires a cooperative subject, 
though they have been performed successfully in children down to the age of 8 yrs 
(Ljungberg and Gustafsson 2003). Secondly there are differences in technique, 
including the nature of the tracer gas and the volume of gas inspired, and little 
standardisation between different units. Finally, there is no commercial apparatus 
available to conduct these tests, and the equipment required is very similar to that 
necessary for multiple breath washout studies which are easier to perform and more 
reproducible. Multiple breath washouts have the additional advantage that a number 
of different indices of ventilation maldistribution can be calculated from them since 
they contain data on the evolution of gas mixing over the course of several breaths.  
 
2. Multiple breath washout 
The basic principles behind multiple breath washouts (MBW) are relatively 
simple, and were first described more than 50 years ago (Becklake 1952). The test 
involves following the washout of an inert tracer gas from the lungs during relaxed 
tidal breathing (Figure 1.7). The tracer gas can either be resident nitrogen, washed 
out when the subject is switched to breathing 100% oxygen, or it can be an 
exogenous tracer gas that must first be washed into the lungs to equilibrium. Each 
approach has its own advantages and challenges, but the principle is the same: 
namely that the tracer gas should be inert and neither absorbed nor excreted by the 
body to any significant degree. As airways disease progresses, heterogeneity of 
ventilation distribution increases, gas mixing efficiency is reduced, and more tracer 
gas is retained after each breath. Washout of a defined fraction of the tracer therefore 
takes longer to complete and requires a greater cumulative expired volume. There are 
additional effects on the shape of the alveolar (phase III) slope of successive breaths 
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(Dutrieue, Vanholsbeeck et al. 2000). Indices of deranged ventilation calculated from 
washout curves include the lung clearance index (LCI) (Gustafsson, Aurora et al. 
2003), moment ratios (Wall 1985) and normalised phase III slopes (Verbanck, 
Schuermans et al. 1997). These will be described in more detail in subsequent 
chapters. 
 
Clinical use of MBW tests 
Interest in MBW tests has experienced resurgence in recent years due to an 
increasing recognition of their usefulness at measuring gas mixing indices in 
children, combined with improvements in gas analyser technology.  These tests were 
first described over 50 years ago, and originally involved nitrogen washouts 
(Becklake 1952). A major advance came about with the availability of personal 
computers to display and analyse the washout data. A number of studies, comparing 
small numbers of groups of subjects with different respiratory diseases, were 
performed in the 1970s-1980s (Saniie, Saidel et al. 1979; Fleming, Chester et al. 
1980; Lutchen, Habib et al. 1990). These reported on moment ratios, a measure of 
overall ventilation heterogeneity derived from a plot of lung volume turnover versus 
normalized end tidal marker gas concentration. Moment ratios were found to be 
elevated in patients with CF, in asthmatics, in diffuse interstitial lung disease and in 
smokers. All of these studies were observational and involved small numbers with 
little appreciation of a clinical use of the measurements. Moment ratios, derived from 
MBNW, were also reported in 24 children with CF (aged 3.9 to 6.5 yrs) and 58 
healthy controls (Couriel, Schier et al. 1985). Although they showed that moment 
ratios were higher in the children with CF, the authors reported considerable 
difficulty in collecting measurements in these young subjects. Wall et al. also 
reported moment ratios in 10 children with CF over a similar age range (3-6 yrs) and 
36 controls, using distraction to improve the reproducibility of the results. They 
found elevated moment ratios in the subjects with CF and also reported a negative 
correlation between moment ratios and Shwachmann score, an index of CF disease 
severity (Shwachman and Kulczycki 1958). This time, there was an appreciation that 
these measurements had distinct advantages in young subjects over standard 
measures of lung function, which are difficult to perform in these young subjects. 






























Figure 1.7: Principle of inert gas washout using an exogenous tracer gas. The subject 
first inhales inert tracer to equilibrium (A). With each successive breath the expired 
tracer gas concentration rises until it is equal to the inspired concentration (top 
tracing). The flowpast circuit is then removed, the subject breathes room air, and the 
washout of the gas measured (B). Tidal breathing is employed throughout. The 
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The next major advance in this field occurred with the use of a mass 
spectrometer to measure 4% SF6 as the inert tracer gas. This system was initially 
devised by Per Gustafsson and was used to demonstrate that lung clearance index 
(LCI) was elevated in 43 children with CF (aged 3-18 yrs) compared to 28 healthy 
controls (Gustafsson, Aurora et al. 2003). In addition, LCI was more sensitive than 
spirometry, being elevated in 22 of the 33 CF patients with normal spirometry. An 
identical system, using the same technique and analysis software, was subsequently 
established at Great Ormond Street children’s hospital in London. Using this 
apparatus, Aurora et al. confirmed the findings in Sweden in school age children 
(Aurora, Gustafsson et al. 2004), and then went on to use the technique in pre-school 
children (Aurora, Bush et al. 2005). They also showed that in pre-school children 
LCI was higher in those patients infected with Pseudomonas aeruginosa. More 
recently, the same group have reported on LCI in infants as young as 10 weeks old. 
They reported that LCI was elevated in infants with CF (mean age 41weeks) 
compared to age matched healthy controls, and that these infants also had raised FRC 
and measurable impairments in spirometric indices generated using raised lung 
volume rapid thoraco-abdominal compression. LCI in normal subjects in all four of 
these studies was remarkably narrowly distributed (Figure 1.8). Although LCI was 
slightly higher in the infants, this may be due to differences in protocol (the test was 
performed supine) or due to the effects of serial deadspace (Schmalisch, Proquitte et 
al. 2006). 
 





































Figure 1.8: Mean and standard deviation of LCI obtained from CF patients and 
healthy controls in four separate paediatric studies. The two studies performed in 
school age children, #3 and #4 were performed on Swedish and UK populations 
respectively. 
1. (Lum, Gustafsson et al. 2007) 
2. (Aurora, Bush et al. 2005) 
3. (Gustafsson, Aurora et al. 2003) 
4. (Aurora, Gustafsson et al. 2004) 
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Longitudinal studies of gas mixing measurements are more complex to 
complete but a large Swiss cohort has been followed between the ages of 6 and 20 
yrs by a group led by Richard Kraemer (Kraemer, Blum et al. 2005). 142 children 
with CF have had at least 4 serial annual evaluations of conventional lung function 
(spirometry, airways resistance and FRC at plethysmography), Pseudomonas 
aeruginosa infection status, and LCI (performed using a nitrogen washout 
apparatus).  They found that LCI deteriorated first, followed by FEF50, FVC and 
finally FEV1. LCI was elevated in more than half of those with FEV1 within the 
normal range. Furthermore LCI continued to increase, along with pulmonary 
hyperinflation and trapped gas, beyond the age of 12 yrs, whereas FEV1 z-scores 
stabilised. In subsequent papers derived from the same dataset, they also showed that 
LCI was more elevated in those with allergic broncho-pulmonary aspergillosis 
(ABPA), but that the slope of longitudinal progression of LCI was greatest in those 
chronically infected with Pseudomonas (Kraemer, Delosea et al. 2006). Functional 
residual capacity (FRC, obtained from MBW) decreased with age, as gas trapping 
and LCI increased (Kraemer, Baldwin et al. 2006). LCI was the most sensitive 
discriminator between groups divided on the basis of chronic and intermittent 
Pseudomonas aeruginosa colonization of the lower airway, chronic Staphylococcus 
aureus infection, and those free from bacterial colonization. 
Much of the recent work on MBW has focussed on measurements in children 
with CF. An exception to this is the work by the group headed by Sylvia Verbanck 
and Manuel Paiva. They have used a nitrogen washout apparatus to calculate 
progression of the phase III slope with sequential breaths of a washout and to 
generate measurements that are purported to reflect heterogeneity of gas mixing in 
the conducting airways (Scond) and in the acinar (Sacin) compartment (discussed in 
detail in Chapter 5). In asthmatics, Scond is a predictor of airways hyper-
responsiveness and responds to treatment with bronchodilators, whilst in smokers 
Scond shows a persistent improvement with smoking cessation (Verbanck, 





Other factors which affect gas mixing efficiency 
There are a number of technical and subject factors which can impact on gas 
mixing efficiency and affect measures of FRC or ventilation inhomogeneity. The 
fraction of a tidal breath that ventilates equipment dead space (i.e. the mouthpiece or 
mask, flowmeter and connections) is an additional component of overall ventilation 
heterogeneity. Dead space to tidal volume ratio (VD/VT) can affect measurement of 
LCI, with exponential increase in LCI as VD/VT increases above 0.5 (Schmalisch, 
Proquitte et al. 2006). This level of VD/VT however is well outwith the normal 
physiological range for adults, which lies between 0.05 to 0.2 (Habib and Lutchen 
1991), and would require considerable equipment deadspace to raise it to a level at 
which it was likely to interfere with measurement. In children, and particularly in 
infants, VD/VT is greater, and, since tidal volumes are less, it is essential to maintain 
apparatus dead space as small as possible. This is currently recommended to be not 
more than 2ml per kg (Beydon, Davis et al. 2007).  
Tidal volume can also affect LCI in the opposite direction if it is increased 
(Bouhuys, Lichtneckert et al. 1961). Increasing tidal volume voluntarily in healthy 
adults can result in an increase in FRC, but LCI remains unaffected except at 
extremes of tidal volume (Gronkvist, Bergsten et al. 2002). Increasing VT /FRC ratio 
also reduces LCI in single compartment lung models (Bouhuys, Lichtneckert et al. 
1961; Larsson, Jonmarker et al. 1988). On the basis of these findings, Larsson et al. 
proposed that measures of ventilation inhomogeneity that either took into account 
dead space, or were intrinsically independent of it, were superior to those such as 
LCI which appeared to be more susceptible to changes in VD and VT (Larsson, 
Jonmarker et al. 1988). The effects of changes in these variables in vivo, within the 
physiological range, are however far less than those demonstrated in simple lung 
models (Larsson, Jonmarker et al. 1988; Gronkvist, Bergsten et al. 2002). This may 
reflect the opposing effects of falling VD/VT and rising VT /FRC, but increased VT 
may also direct ventilation to previously less well ventilated lung regions with 
greater inhomogeneity. 
Irregular breathing will result in an unstable end expiratory level, and changes 
in end tidal marker concentration will also generate changes in calculated FRC. In 
addition, apnoeas in infants have been shown to significantly decrease FRC and sighs 
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may lead to an elevation in FRC (Poets, Rau et al. 1997). In ventilated adults, slow 
insufflation times can increase some measures of ventilation inhomogeneity in those 
with impaired gas mixing, whilst end expiratory pauses reduce them (Larsson, 
Jonmarker et al. 1988). LCI however was relatively insensitive to changes in 
ventilatory pattern and has not been shown to change with increases in respiratory 
rate (Bouhuys, Lichtneckert et al. 1961). Finally, supine posture is known to reduce 
measures of FRC and to affect phase III slope analysis, but has no significant effect 
on LCI in adults (Gronkvist, Bergsten et al. 2002).  
In summary, the documented effects on LCI of equipment dead space, and 
changes in respiratory pattern or tidal volume are small in healthy adults. In very 
young children, and particularly in infants, the effects are likely to be more 
pronounced and remain poorly understood (Beydon, Davis et al. 2007). In addition, it 
is possible that in diseased lungs breathing pattern and tidal volume may have greater 
effect on measures of ventilation inhomogeneity. 
 
Practicalities of performing MBW tests 
Although well established in a research setting, multiple breath nitrogen 
washout (MBNW) is a considerably more complex technique than it at first appears. 
Until recently, there has been no commercial equipment available, and all the studies 
so far have relied on apparatus developed in-house. The standard nitrogen gas 
analyser works by detecting the light produced by ionization of the gas sample in a 
high voltage ionization tube. The light intensity is proportional to the nitrogen 
concentration. This is filtered and measured by a photodiode and converted into an 
electronic output. The analyzer uses a vacuum pump to draw the sample into the 
ionization chamber and to maintain the pressure in the ionization tube. The output 
from the ionization chamber is very sensitive to the operation of this vacuum pump, 
and in particular to the setting of a small bore needle valve at the end of the gas 
sample line. Small alterations in the bore of the needle valve can cause large 
alterations in the measured concentration of nitrogen. The analyser and needle valve 
require frequent calibration. In addition, there can be quite pronounced drift of the 
gas analyser signal, which continues even after 1 hour of warming up. 
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During MBNW, the fractional nitrogen and oxygen concentrations alter during 
the course of both individual breaths and the washout as a whole. This alters the 
viscosity of the expirate, and hence the measured flow, by up to 12% (Saniie, Saidel 
et al. 1979). In order to accommodate this, continuous adjustment of flowmeter 
output is required according to the measured nitrogen concentration. With the 
availability of personal computers, this became possible electronically, but in the 
absence of an off-the-shelf commercial system, still requires individual programming 
by the user. 
An alternative approach to this latter problem was developed by Verbanck et al. 
(Verbanck, Schuermans et al. 1997), and has subsequently been adopted by Downie 
et al. (Downie, Salome et al. 2007). Rather than measuring flow at the mouth, where 
the gas composition is changing, they have used a bag-in-box system. This involves 
the subject breathing into and out of separate inspiratory and expiratory bags 
contained with a sealed box. A flowmeter is fitted through the wall of the box so that 
changes in volume of the bags are registered as flow into or out of the box. This 
avoids the need for complex correction of the flow signal, and since the expired air is 
collected in a sealed bag also provides a method of verifying the calculated volume 
of expired nitrogen. However, the flow meter is distant from the mouth, and may be 
less effective at following small expiratory volumes or rapid respiratory rates, as are 
found in children. In addition the box is subject to thermal drift as the contents of the 
box warm up. 
Finally, with all nitrogen washout systems, the contribution of additional body 
nitrogen excreted during the procedure may become significant with prolonged 
washouts, though is not considered to be significant in normal subjects (Crawford, 
Makowska et al. 1985). Also, sufficient time must be left between washouts for 
additional oxygen to be expired or absorbed, and the resting gas concentrations 
return to baseline. This is recommended to be at least 15 minutes (Wanger, Clausen 
et al. 2005), but in some cases, with severe obstructive or bullous disease, it has been 
suggested that this should be over 1 hour (Emmanuel, Briscoe et al. 1961). 
An alternative approach is to use an exogenous inert marker gas that the subject 
must first breathe in, until inspiratory and expiratory marker gas concentrations are 
equal. The supply of gas is then disconnected and as the subject breathes room air the 
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marker gas is washed out from the lungs in the same way as nitrogen during the 
MBNW. This approach relies on the availability of an inert marker gas, and the two 
gases that have been used in previous studies are helium and SF6. Helium is readily 
available in respiratory function labs, and is used in the determination of lung 
volumes in commercial closed rebreathing systems (Wanger, Clausen et al. 2005). 
The analyser used in these systems does not require a fast response time or high 
quality signal resolution and for multiple breath washout analysis a respiratory mass 
spectrometer is required. Both helium and SF6 have been used in multiple breath 
washout studies, though only data from SF6 washouts have been reported 
(Gustafsson, Aurora et al. 2003; Aurora, Gustafsson et al. 2004; Aurora, Bush et al. 
2005; Aurora, Kozlowska et al. 2005).  
The use of a respiratory mass spectrometer to measure SF6 in multiple breath 
washouts has been a major advance in the understanding and use of this technique. 
The system was developed by Per Gustafsson in Sweden as a means to measure gas 
mixing in young children. The advantages of the mass spectrometer are that it offers 
a stable gas signal, with a rapid analyser response time (Aurora, Kozlowska et al. 
2005). This has been crucial in the development of this technology in the assessment 
of very young subjects, including infants (Lum, Gustafsson et al. 2007). The mass 
spectrometer also offers the possibility of measuring more than one gas, so that 
simultaneous washouts of gas species with different diffusion coefficients (helium 
and SF6) can be performed in order to explore the effects of diffusion on gas mixing 
(von Nieding, Lollgen et al. 1977; Gronkvist, Emery et al. 2002).  
There are however a number of drawbacks to using a mass spectrometer in 
these measurements. Firstly, the cost of the mass spectrometer itself is considerable. 
Secondly, mass spectrometers are complex and temperamental devices, and spend a 
considerable portion of their time awaiting or being repaired. In addition, the 
equipment is bulky and static, and a separate supply of tracer gas is required (unlike 
the nitrogen washout system which can use the hospitals’ piped oxygen).  
For these reasons, MBW tests remain restricted to a small number of 
laboratories, where they are used primarily as research tools. Few units have reported 
on attempts to integrate these measurements into their annual assessments of CF lung 
function (Kraemer, Blum et al. 2005; Gustafsson, de Jong et al. 2007). The 
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technology has been developed by each group separately, and it has not been 
disseminated beyond close collaborations. Finally, no-one has previously attempted 
to use MBW tests in a multi-centre setting. The complexity of the equipment, and the 
individual experience required to conduct and analyse these tests, have made this an 





Chapter 2 - Adaptation of Innocor gas exchange 
device to measure inert gas washout 
 
Background 
In order to measure inert gas multiple breath washout (MBW), a sensitive gas 
analyser and a flow meter are required. At time of preparation, no commercial 
system was available, and different techniques and gas analyser technologies were 
employed in different laboratories. It is important that any new apparatus be at least 
comparable in terms of performance to those used in previous studies, and any 
deficiencies of the apparatus be clearly recognised and assessed. To this end, 
technical recommendations are available for nitrogen washout apparatus in adults 
(Wanger, Clausen et al. 2005) and for using a mass spectrometer to perform MBW in 
children (Gustafsson 2005). Neither of these is exactly applicable to the technology 
and intended patient populations described here.  
This chapter concerns the assessment of the Innocor gas analyser, in terms of 
gas analyser response time and signal quality. This performance is placed in context 
of previously described systems and guidelines. Modifications required to adapt 






Innocor gas analyser 
The Innocor
TM
 gas analyser (Innovision, Odense, Denmark) is designed to 
measure cardiac output at rest and during exercise by inert gas rebreathing (Agostoni, 
Cattadori et al. 2005). It does this by following the concentration of an absorbed gas 
(nitrous oxide, N2O) and a non-absorbed gas (sulphur hexafluoride, SF6) during an 
incremental exercise test using a photoacoustic multi-gas analyser. The difference in 
absorption of the two gases is proportional to pulmonary blood flow, and hence 
cardiac output. The device also measures oxygen uptake (O2) and carbon dioxide 
production (CO2) by following the concentration of O2 and CO2 in the expired air. 
Innocor measures flow using a standard mesh-type flowmeter connected to an 
on-board differential pressure transducer. Oxygen concentration is measured using a 
laser diode absorption spectroscopy oxygen analyser. This is placed in series with the 
photoacoustic multi-gas analyser. 
It is this photoacoustic gas analyser that represents the major advance of the 
device. This was originally developed for the space programme as a more robust and 
compact alternative to a respiratory mass spectrometer. Gas is drawn through the 
sample line and into an acoustically semi-closed measurement chamber by a pump. 
The chamber is pulsed with narrow-band infra red light at three different 
wavelengths. Different gases absorb the light energy at different wavelengths, 
proportional to their respective concentrations, and convert it to heat. The light 
energy is pulsed at three different frequencies using a rotating disk chopper. Thus 
gases heat and cool at different frequencies depending on the wavelength of light 
they absorb. These temperature fluctuations generate pressure waves as sound, which 
are detected by a highly sensitive microphone. The microphone signal is then filtered 
to separate the three modulation frequencies that correspond to the different gas 
concentrations. The amplitude of the sound wave is directly proportional to the gas 
concentration. 
The chamber is insulated against external noise, with both upstream and 
downstream acoustic filters. The pulsations of the sampling pump are also 
attenuated. Temperature and pressure of the chamber are monitored and adjusted for. 
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The end result is a compact multi-gas analyser that is able to fit into a device no 
bigger than a computer monitor. The gas analyser can only measure gases consisting 
of two different atomic species. In the Innocor device, the selected light wavelengths 
are those absorbed by CO2, SF6 and N2O. However, the machine could not be 
adapted to measure concentrations of monoatomic gases such as O2 or Helium for 
instance. This is the reason for using a separate O2 analyser placed in series with the 
photoacoustic gas analyser. The photoacoustic analyser is intrinsically stable and 
external calibration of the multi-gas analyser is only required every 12 months. 
 
Comparison of Innocor with a respiratory mass spectrometer 
Since the current standard method of performing MBW using SF6 involves a 
mass spectrometer (MS), the performance of the modified Innocor gas analyser was 
compared to a MS used routinely for this purpose. The two devices operate at very 
different gas concentration ranges. Innocor is sensitive to very low concentrations of 
SF6 and is linear only up to 0.4% SF6. By contrast, the MS is normally used to 
perform washouts from 4% to 0.1% SF6.  
The respiratory MS used for this comparison was an Amis 2000 (Innovision, 
Odense, Denmark), used routinely for LCI measurements in children in the 
Children’s Physiology Department at Queen Silvia Hospital, Gothenburg, Sweden. 
In order to make a simultaneous comparison between the MS and Innocor, a 
connector was prepared with two gas sample ports placed between the mouthpiece 
and a Fleisch no.1 flowmeter (Figure 2.1). This allowed a washout to be performed 
from 0.2% SF6 while the two devices sampled the SF6 concentration of the expired 
air simultaneously. An example of washout is shown in Figure 2.2, with the first and 
last breaths expanded to illustrate the differences in gas analyser response and signal 
quality. These measurements were made in Professor Gustafsson’s laboratory in 









Figure 2.1: Apparatus used for simultaneous comparison of MS and Innocor 
multiple breath washout with key components identified. 
T-piece and flowpast 
circuit containing 0.2% 













Figure 2.2a: Multiple breath washout from 0.2% SF6 showing simultaneous mass 
spectrometer (purple) and Innocor (blue) gas signals. The two outputs have been 
aligned manually, but there is good overlay between the two outputs. 
The first and last breaths of the washout are expanded in the lower panels, 2.2b and 
2.2c respectively. Figure 2.2c illustrates the poor gas signal resolution of the mass 






















































MS signal quality is insufficient for accurate washout analysis at the lower 
concentration range. Because of the limitations imposed by this difference in SF6 
concentration operating range, it has not yet been possible directly to compare 
washout calculations using the mass spectrometer and Innocor simultaneously in 
vivo. As an alternative to this, the first part of this chapter concerns non-synchronous 
comparison of Innocor gas analyser performance, in terms of signal quality and 
signal response time, to that of the same mass spectrometer. This also permits 
comparison of Innocor performance with published technical recommendations 
(Gustafsson 2005; Wanger, Clausen et al. 2005; Beydon, Davis et al. 2007). The 
second part of this chapter, describes the modifications to Innocor required to permit 
multiple breath washout measurements. The third part of this chapter concerns data 
analysis and adjustment of the raw gas signal data. In the final section, accuracy of 
the complete system is assessed. 
 
 
2.1 - Technical validation of Innocor gas analyser  
i) Signal:noise ratio of Innocor and Mass Spectrometer 
Methods 
Signal quality is expressed as the signal:noise (S:N) ratio. This is calculated as 
the ratio between the mean and standard deviation of a stable gas signal over 10 
seconds (Beydon, Davis et al. 2007).  
To assess the Innocor signal quality, a 3L gas bag was filled with air enriched 
with 0.2% SF6 from a cylinder (BOC, Guildford, UK). The bag was then sealed 
except for the gas analyser sample port, and the contents mixed. Innocor was left to 
sample the gas within the bag for 5-6 minutes, in order to allow complete gas mixing. 
Signal quality was assessed on the final 10 seconds of this period. In order to assess 
signal quality at the lower SF6 concentrations found at the end of a washout, the gas 
within the bag was partially emptied, diluted with oxygen from a cylinder, and mixed 
again. This was repeated until the Innocor analyser gave the SF6 concentration at 
between 0.004 - 0.006%. Innocor was then left to sample the bag for a further 5-6 
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minutes and the final 10 seconds of this used for the signal quality assessment. 
Innocor samples at 100Hz. This was repeated 4 times, and an additional start of 
washout sample was also included. 
The signal quality of the MS is determined by the number of channels open (i.e. 
the number of gases sampled) and the rate of sampling. The best quality signals (in 
terms of signal:noise) are achieved by sampling the fewest channels at the lowest 
rate. The MS was set to sample 4 channels at a rate of 33Hz (the same as the settings 
used during LCI measurement). MS signal:noise ratio was assessed in the physiology 
laboratory of Queen Silvia’s Children’s Hospital in Gothenburg. A stream of 4% or 
0.1% SF6 in air was generated by mixing 4% SF6 with medical air, both supplied 
from separate cylinders. The MS sampled the gas stream for 10 secs. 
 
Results 
Since the Innocor device has a lower gas concentration operating range than the 
MS, signal quality is given at the starting and finishing concentrations of a washout, 
which are different for the two devices (Table 2.1). For both devices, there is a fall in 
signal:noise ratio as the gas concentration falls, but the Innocor signal quality 




The Innocor signal quality is well above that recommended for apparatus used 
in MBW analyses (Beydon, Davis et al. 2007). This signal quality allows accurate 
rendition of expiratory volume vs concentration plots, and calculation of phase III 







SF6 Concentration (%) 
Mean (SD) 
Signal:Noise ratio 
Start End Start End 
Mass spectrometer 4.0 0.1 200 13 
Innocor 0.2051 0.0051 944 (46)  53 (6) 
 
Table 2.1: Signal:noise ratios of Innocor and mass spectrometer at gas 
concentrations encountered at start and end of washout. The signal:noise is 
calculated as the ratio of mean to standard deviation of a stable gas signal over ten 
seconds. For the Innocor device, the figure represent the mean (SD) signal noise ratio 
of 5 repeats (start of washout) and 4 repeats (end of washout). The mass spectrometer 
data are the mean of three repeats, no SD data are available. 
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ii) Rise time of Innocor gas signal. 
Methods 
Step changes in gas concentration were generated using a specially constructed 
syringe, according to the method described by Brunner et al. (Brunner, Wolff et al. 
1985) (Figure 2.3). The plunger end of the sealed syringe was filled with a test gas 
which was pumped into and out of a reservoir bag. A gas sample port half way down 
the syringe allowed rapid change of sampled gas from room air to test gas. The 
sample port was attached to the Innocor or MS gas sample line and a number of rapid 
changes in concentration performed. The response time is calculated as the 10-90% 
rise time of the signal, i.e. the time, in milliseconds, between 10 and 90% of the 
maximal gas signal deflection. The test gas used when assessing Innocor was a 
mixture of 0.2% SF6 in air supplied from a cylinder, and expired air. The inclusion of 
expired air in the bag allowed the rise times of CO2 and SF6 to be calculated 
simultaneously and compared with each other. This is important because the CO2 
response is used to calculate the flow-gas delay daily, and is reported by the 
manufacturers as being the same as the SF6 response. The plunger of the syringe used 
to assess Innocor gas rise times was sealed by a pair of o-rings. It has been assumed 
that leak between the o-rings is negligible, so that passage of the second o-ring over 
the gas sample port constitutes an instantaneous change in SF6 concentration.  
Raw data were exported to Excel for analysis. Resolution of the rise times was 
limited by the frequency of data sampling. For Innocor this is 10ms (100Hz). 
Mass spectrometer SF6 10-90% rise times were provided by Professor 
Gustafsson using his standard clinical system, a similar Brunner syringe, and 4% SF6 









Room air Test gas
 
Figure 2.3: Diagram of syringe used to generate rapid changes in gas concentration 
between test gas and room air. 
Test gas is contained within a sealed compartment at the plunger end of the syringe 
and moved in and out of a reservoir bag. A sample port half way down the syringe 
barrel allows rapid change of sampled gas from room air to test gas. If a flowmeter is 
attached to the syringe exhaust, near-simultaneous change in gas flow, and hence 
flow-gas delay, can also be calculated. 
 
 


































Figure 2.4: Comparison of SF6 and CO2 rise times. Each point represents the mean 
and SD of 10 repeat rise time manoeuvres. Step change in gas concentration was 




The mean (SD) SF6 10-90% rise time for Innocor was measured as 163 (7) ms, 
n=10. The mass spectrometer rise time was measured at 64 (5) ms, n=20, p<0.00001 
compared to Innocor (unpaired T-test). The CO2 rise time for Innocor was measured 
as 158 (10) ms, n=10, p=0.216 compared to that for SF6 using Innocor (unpaired t-
test). The CO2 and SF6 gas analyser responses are shown in Figure 2.4.  There was 
no statistically significant difference in analyser response time at any of the 
fractional response points sampled with the exception of the 70% response. This was 
measured as 110 (0) ms for SF6 and 101 (3) ms for CO2, p=<0.0001 (unpaired T-
test). It is possible that this represents an artefact, since the difference is less than the 
resolution (10ms), and further repeats may have reduced this. Importantly, the 50% 
rise times of the two gases were near-identical, and it is this that most closely 
approximates what Innocor uses to calculate the flow-gas delay. 
 
Conclusions 
CO2 and SF6 rise times are the same for the photoacoustic analyser, but are 
slower than the MS and also slower than those recommended for use in MBW tests 
in preschool children (Beydon, Davis et al. 2007). The implications of this rise time 
are considered in the discussion at the end of the chapter. 
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iii) Effect of expired air temperature and humidity on gas analyser 
accuracy 
Expired air is warmed and humidified compared to inspired air. A particular 
criticism of ultrasonic gas analysers, which have also been used to perform multiple 
breath washouts, is that they are affected by the moisture and temperature of expired 
air.  This must therefore be continuously monitored and adjusted for using complex 
empirically derived algorithms (Buess, Pietsch et al. 1986; Latzin, Sauteur et al. 
2007). The manufacturers of Innocor claim that the photoacoustic gas analyser is 
stable during respiration. There are two features of the system that allow this 
stability. 
Firstly, the temperature and pressure of the Innocor gas analyser chamber are 
sampled continuously at 2 KHz. The manufacturer has extensive knowledge of the 
effects of temperature and pressure on the detector and these data have been used to 
generate compensation algorithms.  
Secondly, humidity of expired gas is controlled for by the use of a Nafion
TM
 
gas sample line. Nafion is a synthetic polymer that selectively absorbs water vapour 
and releases it into a drier atmosphere. The humidity of the gas sample equilibrates 
with that of room air by the time the gas sample enters the machine itself. Since the 
temperature of the gas sample in the measurement chamber is already adjusted for, 
the analyser should be therefore unaffected by changes in humidity or temperature of 
the gas sample with phase of respiration.  
This section concerns investigation of the stability of the SF6 signal before and 
after humidification and warming. 
  
Methods 
0.2% SF6 in air, supplied from a compressed gas cylinder, was passed through a 
humidification system at 10L/min. The humidification system used was a Fisher 
Paykel HC 100 (Fisher Paykel, New Zealand), designed for use with non-invasive 
ventilators. This device warms and humidifies a flow of gas by passing it over 
warmed water. Air exiting the device is warmed to 37
o
C with 100% humidity, 
closely mimicking the conditions of expired air.  
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The exhaust port of the humidifier was connected to a length of 22mm diameter 
disposable plastic “elephant” tubing (Intersurgical, Berkshire, UK) The gas mix was 
sampled by inserting an 18G needle (Becton Dickinson, Oxford, UK), connected to 
the Innocor gas sample line, through the tubing into the stream of gas. The needle 
was inserted <1cm from the end of the tubing and temperature and humidity of the 
gas sample measured continuously using a digital thermohygrometr (Rotronic AG, 
Bassersdorf, Switzerland) (Figure 2.5). The thermometer and gas analyser were left 
in position for 2 minutes, and the average gas concentration measured over the final 
30 seconds was calculated. After 2 minutes, the needle was removed, and a length of 
tubing cut from the end. The needle was then re-inserted 1cm from the end of the 
now shortened tube, with the thermometer once again placed over the end of the 
tube. This allowed the gas stream to be sampled at several points along the length of 
the tube, becoming increasingly warm with proximity to the humidification chamber. 
The tube was held vertically so that any condensation would run back into the 
chamber. A fan was positioned to blow the exhausted gas away, so that local 
temperature or humidity were not altered. 
Controls included sampling the composition of the gas on the inlet side of the 
chamber and sampling the gas composition after passing it through the complete 
system but without water or heat added in the chamber. 
 
Results 
SF6 concentration remained the same throughout the assessment, whether it 
was dry air at room temperature (25
o
C), equivalent to inspired air conditions, or 
warmed and humidified air at 37
o
C, equivalent to expired air (Table 2.2). 
The difference between SF6 concentration measured in the inlet and that at the 
exhaust mouth was 0.0004% absolute SF6, or a 0.21% difference. The difference 
between air measured in the inlet and that at 35
o











line attached to 
19G needle
0.2% SF6 in air,
supplied from a 
cylinder at 10 Lpm
Needle moved proximally






Figure 2.5: Diagram of apparatus used to assess effects of warming and humidifying 
gas stream on measured SF6 concentration. The gas sample needle and 
thermohygrometer were placed at the end of a plastic tube attached to the exhaust of 
the humidifier.  The tube was then cut and the gas sampled from the end of the 
shortened tube. The final sample is taken directly from the humidifier exhaust. 
Although shown as horizontal for illustrative purposes, the exhaust tubing was held 


















3 76 31 100 0.205 
2 37 33 100 0.205 
1 0 37 100 0.205 
Inlet NA 25 0** 0.205 
Dry 
control 
20cm 25 0 0.205 
 
Table 2.2: Mean SF6 concentration and gas temperature recorded at different 
distances along exhaust tube from humidification chamber. Data are from a single 
experiment, but represent the mean SF6 concentration over a period of 30 seconds of 
gas sampling. 
* Recorded at humidifier exhaust 
** Dry gas from cylinder 
++





This assessment shows that the Innocor gas analyser [SF6] signal is not affected 
by changes in the temperature or moisture content of the gas sample over the range 
encountered in the use to which the machine is put. The effects of cooling the gas 
stream were not assessed since performance below 20
o




iv) Gas analyser drift. 
Methods 
A Douglas bag was filled with 0.2% SF6 in air, and the gas in the bag mixed. 
The gas sample line was attached to an 18G needle inserted into a short length of 
plastic anaesthetic tubing, sealed at one end, and attached to the opening of the bag. 
The Innocor gas analyser was switched on, and allowed to sample the gas in the bag 
for 60 minutes. The difference between mean gas concentration over the final 1 
minute was compared to that in the 2
nd
 minute. Raw data were also plotted and 
inspected to ensure that the start and end concentrations were representative of the 
tracings over the entire sampling period.  
 
Results 
Mean SF6 concentration in minute 2 was 0.2050%. Mean concentration in 
minute 60 was 0.2052%. This represents a drift of 0.0002% absolute change in SF6 
concentration, or 0.1% relative to baseline. 
 
Conclusions 
The Innocor gas analyser is stable, with no appreciable drift in gas 





v) Long term analyser drift 
Since the same cylinder of 0.2% SF6 is used for many washout assessments 
over the course of several months, any drift in the analyser would be noticeable as a 
fall in the peak inspired SF6 concentration. In addition to this, a small cylinder of 
0.2% SF6, retained as a spare, has been used to assess long term drift in the analyser 
over 7 months. 
A stream of gas from the same cylinder was sampled by the Innocor gas 
analyser for at least 60 seconds. The mean (SD) of the SF6 signal over a stable 30 
second period was calculated. At time 0, 2 days after re-calibration, mean (SD) SF6 
concentration was 0.21629 (0.0022) % and 0.21650 (0.0021) % for two different 
repeats, giving an overall mean of 0.21639%. Two months later, the mean (SD) SF6 
concentration measured from the same cylinder was 0.21554 (0.0023) %. Five 
months after this, the overall mean SF6 concentration was 0.21529 % (3 repeats). 
Over 7 months, a fall in the SF6 concentration had occurred of 0.001107 % absolute, 
or 0.51% relative to the starting concentration. This represents a drift in SF6 
concentration of 0.073% per month. 
The SF6 analyser in the Innocor machine is re-calibrated annually by an 
engineer to an external standard. 
 
Conclusions 
There is minimal drift in the SF6 analyser over an extended period. No short 
term drift has been observed between washouts or on consecutive days. 
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2.2 - Adaptation of Innocor device to permit MBW assessment 
i) Modifications to Innocor patient interface 
Because it is intended for measurements during an exercise test, the 
commercially supplied Innocor patient interface has been designed to be low 
resistance and consequently has a large deadspace of 136 ml. For accurate LCI 
measurement, deadspace must be at a minimum (Aurora, Kozlowska et al. 2005; 
Wanger, Clausen et al. 2005). The flowmeter was therefore replaced with a mesh 
type flowmeter (Hans Rudolph, Missouri, USA), equivalent to a Fleisch number 2 
pneumotachograph (flow range 0-160 l/min). An alternative to the Innocor-supplied 
microbiological filter was also used (Barrierbac S; Tyco Healthcare, Hampshire, 
UK). This was selected for its low volume (deadspace) and for ease of connection 
with the flowmeter. Use of a filter permits the apparatus to be used with different 
patients without requiring full disassembly and cleaning. It also traps expired water 
vapour and prevents respiratory secretions from fouling the flowmeter mesh. A 
mouthpiece (Ferraris, Hertford, UK) was cut to fit over the filter end with minimal 
additional deadspace.  
The gas sample needle was positioned on the supply rather than the mouthpiece 
side of the pneumotachograph. This is to avoid the possibility of the gas sample flow 
interfering with pneumotachograph function and to reduce re-inspired SF6, as 
explained in the discussion. The gas sample line was attached to a shortened 20 
Gauge needle (Becton Dickinson, Oxford, UK) in a hole drilled through the 





Figure 2.6: Modified patient interface used for inert gas washout measurements with 
Innocor gas analyser. The T-piece connects the patient to a bias flow circuit 





Pre-capillary dead space (that between needle and patient mouth) of the system, 
was calculated to be 46 ml for the complete apparatus. Calculations were based upon 
the known volumes of key components as described by the manufacturers, with 
volume of altered components (e.g. mouthpiece) calculated by filling with water. 
Post-capillary dead space (that between needle and end of flowmeter casing) was 
calculated mathematically to be less than 5ml, i.e. less than 1% of the typical 
minimum tidal volume. A fan was used to create a stream of air across the patient 
during washout so that additional expired SF6 was not re-inspired.  
The lines to the pressure transducer on the standard Innocor device are 
integrated into a large plastic cable that also contains lines supplying the rebreathing 
apparatus. This in turn is attached to a bulky unit which normally contains the 
flowmeter and valve assembly. The gas sample line runs separately. Since the only 
parts of this system required for MBW measurements are the gas sample line and 
pressure transducer line, a separate connector was constructed by the manufacturers 
which had all the ports occluded except those to the pressure transducer. This was 
connected to the flowmeter using equal lengths of tubing (Guttasyn, Hamburg, 
Germany), and permitted a lightweight patient interface consisting of the flowmeter 
and filter arrangement alone. This was then mounted on a swing arm, and attached 
using a retort clamp. The swing arm was clamped to the side of a wheeled table so 
that it could be brought to the subject and adjusted to ensure optimal comfort (Figure 
2.7) 
Details of the software settings required to perform a multiple breath washout 
using Innocor’s operating system are found in a manual prepared for the 





Figure 2.7: Standard Innocor set-up on left, with patient interface for cardiac output 
assessments. The interface consists of the main control unit (1), containing switching 
valves, a rebreathe bag (2), flow-meter (3) and filter (4), attached to Innocor analyzer 
by a cable (5) containing gas supply and pressure transducer lines. 
The modified Innocor machine, for multiple breath washout assessments, is shown 
on the right. The cable has been replaced by two lines from the flow-meter (1), split 
to supply a separate pressure transducer for breath volume display (2), and a much 













Innocor for measuring cardiac output Innocor for multiple breath washouts 
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ii) Flowmeter accuracy 
The flowmeter output was linearised using Innocor’s onboard software 
according to the method of Yeh et al. (Yeh, Gardner et al. 1982). There is an 
additional daily calibration procedure of the flowmeter, in accordance with American 
Thoracic Society / European Respiratory Society guidelines on volume measurement 
(Wanger, Clausen et al. 2005). This involves emptying a 3L calibration syringe over 
0.5 to 6s. Because the filter may alter airflow characteristics, a filter was also used 
during the calibration process. If the calculated gain was more than +/- 5%, or if the 
range of syringe volumes was greater than +/-3%, the system was checked for 
presence of leaks at connectors, and the calibration process repeated. If the error 
remained, a new flowmeter calibration was performed using Innocor’s onboard 
software. 
Because very low concentrations of SF6 are used in the washout, it is not 
necessary to make adjustment for changing gas viscosity caused by changing gas 
composition of expirate. This is not the case with nitrogen washouts, for example, 
where the change in expired oxygen concentration (and hence expirate viscosity) can 
be considerable over the course of a single breath. During nitrogen washouts, this 
results in a difference in flow meter output of up to 12%, unless there is continuous 
adjustment of flowmeter response (Saniie, Saidel et al. 1979). In contrast, SF6 has a 
viscosity similar to that of CO2. Adding 0.2% SF6 to dry inspired air reduces 
viscosity by less than 0.4%.  
Since the apparatus was intended for use in multi-centre trials, it was important 
to ensure that the system was as simple as possible. For this reason, it was felt 
preferable to use a non-heated flowmeter. Previous studies have shown a fall in 
accuracy of such flowmeters due to formation of condensation on the mesh from 
exhaled breath water vapour, though this is more likely to be significant if a Fleisch-
type of flowmeter is used (Miller and Sigsgaard 1994). The effects of a filter on 
condensation are however unknown. The following experiments were therefore 





In order to assess effects of prolonged breathing on flowmeter accuracy, a 
single subject breathed through the filter and flowmeter for a range of times, up to 20 
minutes. The subject established tidal breathing and a noseclip was applied to ensure 
that all ventilation occurred through the flowmeter, as in a washout test. Flowmeter 
accuracy was assessed before and after rebreathing using a 3L calibration syringe at a 
range of different flow rates. Five fill-empty syringe manoeuvres were performed 
before rebreathing, and three afterwards. Continued fill-empty manoeuvres beyond 
this are likely to dry any condensation on the mesh and reduce the magnitude of any 
error caused by vapour condensation (Miller and Sigsgaard 1994). In addition, the 
flowmeter and mesh were visually inspected, after each rebreathing test, for the 
presence of condensation. Following testing, the data were exported and flow signals 
integrated to yield the calculated syringe volume. Pre-and post-rebreathing mean 
integrated volumes for syringe filling (inspiration) and emptying (expiration) were 
pooled to compare all data from each time-point. 
 
Results 
A total of seven trials were performed with different periods of rebreathing 
through the flowmeter; 3 x 5 minutes, 2 x 15 minutes and 2 x 20 minutes. No 
consistent changes were seen from the individual trials. Pooled data are summarised 
in Table 2.3 and illustrated in Figure 2.8. Mean (SD) measured syringe volume was 
3.003 (0.021) L for syringe filling before and 3.023 (0.024) L for syringe filling after 
rebreathing. This difference was statistically significant, p<0.0001 (unpaired T-test), 
but represents an error of 20ml, or 0.67% of the delivered volume. For syringe 
emptying, measured volume was 3.005 (0.018) L before and 3.006 (0.016) L after 
rebreathing, p=0.1752. 
A total of 110 manoeuvres were analysed, of which only a single one was 
outwith the range of accuracy ±3%, and only 9 (8%) were outwith the range ±1%. 
No moisture or debris were visible on the mesh when visually inspected. 
 
Conclusions 
The difference in volume signal observed after rebreathing is below the level of 












 (syringe fill pre-test) 
2.955-3.056 
 (98.5-101.9) 
3.003 0.003662 0.71% 
Inspire End 
 (syringe fill post-test) 
2.987-3.095 
 (99.6-103.2) 
3.023 0.005336 0.81% 
Expire Start 
 (syringe empty pre-test) 
2.975-3.036 
 (99.2-101.2) 
3.005 0.003031 0.59% 
Expire End 
 (syringe empty post-test) 
2.973-3.040 
 (99.1-101.3) 
3.006 0.003446 0.53% 
 
Table 2.3: Measured volume of 3L calibration syringe using mesh flowmeter 
(equivalent to a Fleisch No.2) connected to Innocor pressure transducer pre and post 
prolonged (5-20 min) tidal breathing through flowmeter. 
SEM – Standard error of the mean 
 
 

















































Figure 2.8: Flowmeter accuracy before and after prolonged rebreathing. Graph 
shows data pooled from 7 tests, representing different periods of rebreathing through 
the flowmeter (3 x 5 minutes, 2 x 15 minutes, 2 x 20 minutes). Five syringe fill and 
empty manoeuvres were performed before rebreathing and three afterwards. 
Horizontal solid lines in each group represent the group mean measured volumes. 




iii)  Flow-gas delay 
Flow-gas delay is calculated on Innocor by the operator performing a series of 
slow expirations followed by fast inspirations. This manoeuvre generates a sudden 
change in flow at the same time as a sudden fall in CO2 concentration. Flow-gas 
delay is calculated as the delay during this forced inspiration between change in flow 
(zero crossing) and change in CO2 concentration (50% change in area under the 
curve, as described by Fowler (Fowler 1949)), taking into account the deadspace 
from the gas sampling point to the ambient air port. The flow-gas delay for SF6 is 
claimed to be the same as that of CO2. The recorded flow-gas delay is the mean of 




The assumptions behind Innocor’s on-board assessment of gas signal delay 
were verified using the Brunner syringe (Figure 2.3) and by manual review of the 
flow-gas delay data. 
CO2 and SF6 delay times were compared using the Brunner syringe. If the 
plunger is moved so that it is just obstructing the gas sample port, further sudden 
movement of the plunger will generate a near-simultaneous flow signal and change 
in SF6 concentration. Attaching the flowmeter to the main syringe exhaust allows 
measurement of change in flow. To compare the delay of the two different gases, the 
reservoir bag of the syringe was filled with a mixture of 0.2% SF6 and expired air 
(containing CO2). 
For comparison of the syringe-generated and breathing manoeuvre-generated 
calculations of gas delay, allowance must be made for the fact that the changes in 
flow and gas concentration signals are not perfectly simultaneous. This is because the 
depth of the plunger means that it must move 15mm before the gas sample port is 
exposed to the test gas. This displaces a volume of around 20ml, and takes an 
average time of around 70ms, dependent upon the speed of the plunger. For this 
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analysis, the zero time point for calculation of gas signal delay was after expulsion of 
20ml from the syringe, derived from integration of the flow signal. 
Finally, the delay obtained by Innocor’s onboard software was compared to that 
derived manually from identical breathing manoeuvres. 
All data were exported and analysed in Excel. Flow-gas delays derived from 
the Brunner syringe were calculated to the 50% maximal increment in gas 
concentration. Flow-gas delay derived from breathing manoeuvres was calculated as 
the delay between flow crossing zero on rapid inspiration, and 50% maximal fall in 
CO2 concentration. 
Repeatability of flow-gas delay calculations was assessed by repeat 
manoeuvres performed on the same day. A daily record of the flow-gas delay was 




When assessed simultaneously using the Brunner syringe, mean (SD) SF6 flow-
gas delay was 1472 (10) ms and CO2 flow-gas delay was 1469 (12) ms, n=12. This 
difference of 3ms was not statistically significant, p=0.56 by unpaired T-test. 
At a different time point, mean (SD) of repeated flow-gas delay calculations 
performed by Innocor was measured at 1424 (4) ms. This was derived from 10 flow-
gas delay calculations, each of which is the mean of 9 respiratory manoeuvres. 
Individual flow-gas delay repeats varied from 1391-1440 ms, but range of delivered 
mean delays varied by only 9 ms (range 1419-1428 ms). Mean (SD) SF6 flow-gas 
delay on the same day, calculated from the time between expulsion of 20 ml from the 
Brunner syringe and 50% maximal increment in SF6 concentration, was 1407 (8) ms 
(n=10). 
Mean (SD) flow gas delay calculated manually from 50% fall in CO2 
concentration during rapid inspiration, was 1440 (6) ms (n=11).  
 
Conclusions 
The delays calculated using the Brunner syringe verified that CO2 and SF6 have 
equivalent delay times, confirming the validity of this assumption used by Innocor to 
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determine flow-gas delay. Since concentrations of both gases are measured in the 
photoacoustic gas analyser identically, this is as expected. 
Flow gas delay calculated using Innocor’s on-board method appears to be 
highly reproducible, with a narrow range for assessments conducted on the same day 
(1419-1428ms). The assessments are themselves an average of 9 repeat manoeuvres 
however, and the individual repeats show a wider range of almost 50ms. 
Reproducibility can also be adversely affected if the manoeuvres are not identical. 
For instance if expiration is re-commenced as soon as inspiration is complete, the 
flow-gas delay is shortened, presumably since the final (slowest) part of the CO2 fall 
time is attenuated. In order to obtain consistent results, it is necessary to pause for 1-
2 seconds after each rapid inspiration before starting the next expiration. 
Flow-gas delay calculated using the Brunner syringe was, on average, 17ms 
less than that calculated by Innocor. There are a number of reasons why this 
discrepancy may have occurred. The gas sample line attached directly to the syringe, 
whereas during a breathing manoeuvre the gas must first pass through the gas sample 
needle. Removing the needle will shorten the delay time by reducing resistance and 
increasing sample flow rate. Accuracy is also limited both by the resolution of the 
time delay (down to the nearest 10ms) and by the accuracy of the Brunner syringe. 
As discussed earlier, this does not generate a truly simultaneous flow and gas 
concentration change due to the distance the plunger must pass before the new gas 
mix is exposed to the sample port. The correction for this is based upon an estimated 
expired volume.   
In contrast, the manually calculated CO2 fall time delay, derived from breathing 
manoeuvres identical to those used by Innocor, was 1440ms – a mean increase of 
16ms (1.1%) over that derived by Innocor’s on-board software. Again, this analysis 
is limited by the 10ms resolution of the time signal.  
Finally, the algorithm used in the manual analyses is slightly different to that 
used by Innocor. The measurement after 50% rise in SF6 concentration for syringe 
manoeuvres, or 50% fall in CO2 concentration for rapid inspirations, was taken as 
being the end point for the gas signal. Innocor however uses equality of areas above 
and below the gas concentration-time curve (as per calculation of Fowler dead 
space). Differences in method may explain some of the difference in results. 
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Despite the discrepancies, all assessments of gas delay were reproducible, and 
the Innocor method was between that derived from the syringe and that derived from 
rapid inspiration. More importantly, when gas and flow signals are aligned in the 




iv) Expiratory volume feedback 
In order to improve reproducibility of expired breath volumes, a system for 
dynamic inspiratory or expiratory volume feedback was developed. Innocor displays 
a three-breath sliding average tidal volume after a breath has completed, but does not 
provide real-time feedback. In addition, there are no outputs from the onboard 
differential pressure transducer, other than that to the on-board computer. In order to 
establish a separate flowmeter output, the lines to the pressure transducer were split 
using a Y-piece connector (Portex, Watford, UK), with one arm entering the Innocor 
device and the other a separate differential pressure sensor (GM instruments, 
Kilwinning, UK). This generates analogue outputs corresponding to flow, or 
integrates the signal itself to produce a volume output. The analogue volume output 
from this pneumotachograph was then converted to a digital signal using a 16-bit 
analogue-digital converter (Measurement Computing, Massachusetts, USA) and fed 
into a laptop via the USB port (Figure 2.9). The volume was displayed on a laptop 
screen using software written with Visual Studio (Microsoft, Washington, USA). As 
the subject expires a bar rises to represent the cumulative expired volume. This is 
reset to zero on inspiration by the software. An empirical adjustment factor to 
convert the voltage output to expired volume was derived using a 1L calibration 
syringe. The system was found to be sensitive to expiratory flow rate, with the total 
expired volume greater at high flow rates. However, the accuracy was found to be 
within +/-10%, which was satisfactory for the purpose of expiratory volume 
feedback. Subjects were first allowed to establish a relaxed breathing pattern. A 
paper arrow was then affixed to the computer screen at the expiratory volume level 
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they achieved. Subjects with very shallow or deep breathing patterns were 
encouraged, with the assistance of the visual feedback, to establish tidal volumes 
between 500-1000ml. Other than this, the system was used to aid reproducibility of 
tidal breath volumes rather than targeting to a specific expired volume. 
The approach adopted in all the clinical studies contained within this thesis was 
to display the expired volume. It subsequently became apparent that this resulted in a 
tendency for some subjects to expire below their relaxed FRC. A cohort of nine 
healthy volunteers were reviewed, with washouts performed before and after the 
development and use of expiratory volume feedback. Mean (SD) VT increased 
significantly with the use of expiratory feedback from 686 (112) ml to 880 (136) ml 
(p=0.018, paired t-test). This represents a mean increase of 32%. In contrast mean 
(SD) FRC fell significantly by 13% from 2.81 (0.76) to 2.43 (0.71) L (p=0.036). 
Mean LCI was unchanged: 6.85 (0.5) before using feedback to 6.89 (0.5) after its 
introduction (p=0.78). This is illustrated in Figure 2.10, which shows the change in 
mean VT (averaged for three washout repeats) before and after expiratory volume 
targeting, against the change in FRC (red) and LCI (blue). Substantial changes in VT 
and FRC have little effect on LCI. 
As a refinement of this system, the tidal volume targeting has since been altered 
so that patients target their inspiratory volume and then expire to a relaxed FRC. In 
the studies presented in this thesis however, expiratory volume feedback has been 



















Figure 2.9: Diagram of tidal volume feedback system. The pressure lines from the 
flowmeter are split and fed into a separate pressure transducer, the output from which 
is interpreted and read by a laptop computer. As the breath volume increases, the bar 
on the left rises. Targeting of expiratory volume was achieved by affixing a paper 
arrow to the screen – this was found to be the most visually effective method of 
concentrating subject’s attention on the expired volume. 
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Figure 2.10: Effect of expiratory volume targeting on tidal volume (VT), functional 
residual capacity (FRC) and lung clearance index (LCI) in nine healthy volunteers. 
The x axis represents the intra-subject absolute change in mean VT between washouts 
performed before and after expiratory volume targeting. A positive value represents 
an increase in mean VT with expiratory volume targeting. Change in FRC and change 
in LCI are plotted on the y axis and represented as red and blue circles respectively. 
A negative change in FRC or LCI represents a fall in that parameter with expiratory 
volume targeting. Overall mean change in VT is represented by the vertical dotted 
black line, mean change in FRC by the dotted red horizontal line and mean change in 




2.3 - Multiple breath washout analysis 
Innocor generates raw flow and gas concentration data, sampled at 100Hz. 
These files are converted to text files and exported to custom-written software 
prepared using Testpoint (Capital Equipment, Massachusetts, USA). This software 
was adapted from the programme used in Professor Per Gustafsson’s laboratory in 
Sweden, and has been used in a number of previous studies (Gustafsson, Aurora et 
al. 2003; Aurora, Gustafsson et al. 2004; Aurora, Bush et al. 2005). Modifications 
and revisions to the original analysis system were necessary – these were developed 
in collaboration with Per Gustafsson and his software engineer Eddie Bergsten. A 
screenshot of the analysis software is shown in Figure 2.11. 
Zero flow is set by the Innocor device using a mechanical zeroing of the 
pressure transducer. This occurs every 60 seconds, and results in the loss of 1 
second’s worth of flow data whilst the pressure transducer is re-zeroed. A flow signal 
of 100L/s is generated for this second, easily visible on the flow vs time plot. For the 
purposes of washout analysis, it is important to maintain an un-interrupted flow 
signal. The flow-meter re-zeroing was therefore altered to occur after between 3-5 
minutes, depending on the predicted length of wash-in of the subject. The wash-in 
was then continued beyond the point at which inspiratory and expiratory SF6 
concentrations had adequately equilibrated, until the re-zero had occurred. Wash-out 
was commenced immediately after this. Thus, at the start of a washout the flow-
meter was re-zeroed. If wash-in was incomplete, it was continued until either the 
next re-zero (providing this was logistically possible), or until complete.  
Inspiration is recorded as negative flow and expiration as positive. A change in 
phase of respiratory cycle was recorded as flow crossing zero. A filter is included to 
exclude very small variations around zero, as occur for instance at zero flow (e.g. 
pauses in respiration). 
The full wash-in and wash-out were loaded and displayed, with the signals 
realigned according to the flow-gas delay, which was entered manually. The data 
were then cropped to focus on the wash-out only. New breaths were automatically 
identified as the flow crossing zero, but the start and end of breaths can be adjusted 
manually in case of error. Breath volume was derived by integration of flow, and 
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total SF6 volume was derived from the integration of flow and gas concentration. The 
software also plots a graph of volume expired versus gas concentration in a separate 
window, and performs a linear regression of the phase III slope (Figure 2.11B). The 
default limits for calculating the phase III slope were between 65% and 95% of the 
expired breath volume, but these can be adjusted manually to achieve a best fit with 
the linear phase III segment.  A washout is defined by convention to be complete 
when the end tidal SF6 concentration has fallen to less than (or equal to) 1/40
th
 of the 
starting concentration  (Gustafsson, Aurora et al. 2003). This convention is largely 
historical, being based upon the linear operating range of the nitrogen analysers 
originally used for multiple breath washout tests (2 – 80%). However, it has stood 
the test of time and represents a workable compromise between ending a washout too 
soon (and therefore losing sensitivity) and an excessively protracted procedure. 
Functional residual capacity (FRC) is calculated from the starting fraction of 
SF6 (CInit), the final fraction of SF6 (CEnd), and the amount of exhaled SF6 (VSF6). 
 
 (CInit x FRC) = (CEnd x FRC) + VSF6 
 
So:    FRC = VSF6 / (CInit - CEnd)     
 
LCI is defined as the number of lung turnovers required to washout the gas to 1/40
th
 
of the starting concentration. In other words, the cumulative expired volume (CEV) 
divided by the FRC: 
    LCI = CEV / FRC 
 
The other data outputs from the analysis software are: 
1. Cumulative expired volume (L) 
2. Number of breaths 
3. Inspiratory and expiratory volume (L)  
4. Raw and normalised phase III slope data for each breath of the washout (this 
is covered in more detail in Chapter 5) 
5. 1st and 2nd order Moment ratios 





Figure 2.11: Screenshot of data analysis software. The upper window (A) shows the 
entire washout (flow signal in black, SF6 signal in green). Expiratory SF6 is 
integrated with flow to calculate the volume of expired SF6, which is used in the 
calculation of functional residual capacity as described in the text. Each breath is 






Moment ratios are derived from a plot of lung volume turnover (TO) against 
end tidal gas concentration (CET), normalised to 1.0 for CET at the start of the 
washout. The 0
th
 moment is the area under this curve, the 1
st
 moment the area under 
the curve of TO
2
 versus CET and so on. The moment ratios are the ratios between 
these areas (Saniie, Saidel et al. 1979). Slope index is derived from the ratio 
between the slopes of CET versus TO at the start and end of the washout. Both of 
these indices emphasise the differences in the fall in CET between healthy subjects 
and those with lung disease. However, initial work identified problems with both of 
these indices, and they have therefore not been considered further in this thesis. 
Moment ratios showed poorer separation between health and disease than LCI, and 
were affected by the TO range analysed (Horsley, Macleod et al. 2007). Fleming et 
al. also showed greater sensitivity of LCI compared to moment ratios (measured to 
TO=10), but by contrast found LCI to be poorly reproducible (Fleming, Chester et 
al. 1980). Although they used a nitrogen rather than an SF6 washout system, it is not 
clear why they found LCI so difficult to reproduce. The inclusion of more severely 
affected patients in the current studies may explain the poorer performance of 
moment ratios, since they are limited by the TO range over which they are analysed. 
Slope index appears to be highly variable. Neither index is currently reported by any 
other group working in this field.  
Because of irregularities or pauses in breathing pattern, it is possible for errors 
in breath identification to occur if the automatic analysis is relied upon uncritically. 
For this reason, each breath was inspected in turn, and phase III slope and breath 
parameters adjusted if necessary. In collaboration with colleagues, guidelines have 




The raw data signals from Innocor are not BTPS corrected, nor is this 
correction applied in the analysis software. Cumulative expired volume, tidal 
volume and FRC were therefore exported into an Excel database and multiplied by 
an appropriate correction factor before entry into the results database. Since inspired 
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SF6 concentrations were not being measured, it was unnecessary to apply any 
correction to inspiratory volumes. The temperature and humidity of the expired air 
was measured using an apparatus originally developed in our laboratory to monitor 
respiratory heat and moisture loss during tidal breathing (Noble, McCafferty et al. 
2007). The sensor array was positioned distal to the mouthpiece and filter, and the 
temperature and humidity of the expirate measured over several breaths. This was 
found to be reliably stable at 35
o
C and 98% relative humidity.  
Environmental conditions in the test room were maintained in a steady state by 
the use of air conditioning (20
o
C and 40% relative humidity). Temperature was 
recorded, and adjusted for if necessary. No dynamic adjustments were made for 
relative humidity or barometric pressure, which were not directly measured, and 
were taken 40% and 760 mmHg respectively.  





Background & Methods 
Gas analyser response may limit the use of Innocor at faster respiratory rates, 
and in particular in pre-school children who typically have respiratory rates greater 
than 20-30 breaths per minute. The measured signal rise time of 163ms is greater 
than the 120ms quoted by the manufacturers, and is slower than the maximum of 
100ms recommended for MBW tests in pre-school children (Gustafsson 2005; 
Beydon, Davis et al. 2007). The relatively slow signal rise time has at least two 
physical components that are amenable to improvement. Firstly, there is spreading 
of the gas concentration front within the gas sample line and in the in-line oxygen 
analyser. Spreading in the line could be reduced by shortening the gas sample line or 
altering its bore, but only at the expense of affecting the ability of the line to 
equilibrate gas sample humidity with room air. The second component relates to the 
intrinsic response time of the photoacoustic gas analyser itself, and is not alterable. 
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In Innocor, response time can be additionally altered by removing the separate 
oxygen analyser that is placed in series with the photoacoustic gas analyser. 
However this also disables the ability of Innocor to measure the flow-gas delay 
(since the on-board software will not perform the analysis in the absence of an 
oxygen signal). This renders the process of LCI assessment far more complex, and 
unsuitable at this stage for multi-centre trials. An alternative method of flow gas 
delay calculation would resolve this problem, but would require additional hardware 
and software. Further investigation of these restraints on gas analyser response 
ideally requires adjustment of Innocor’s hardware and/or embedded software. This 
can only be done with the aid of the manufacturers, and is now being pursued by 
another researcher.  
As an alternative, attempts were made to digitally enhance the signal response 
time according to the method of Arieli et al. (Arieli and Van Liew 1981). In this 
paper, the authors describe a mathematical correction that can be applied to a gas 
signal, which has the effect reducing the 10-90% response time of the gas analyser. 
First and second order corrections were calculated in Excel according to the 
following equations: 
 
First order correction:  C1=C0 + γ1.dC0/dt 






Where C0 is the original concentration output, and C1 and C2 are the first and 
second order corrected concentrations respectively. γ1 and γ2 are first and second 
order time constants, calculated from the positive reciprocal of the slope of the 
linear regression of ln(1-response fraction) as a function of time. This was derived 
empirically from step changes in SF6 concentration generated as described 
previously. In order to assess the usefulness of this correction, it was then applied to 
a sample washout to determine the effects on calculated FRC and on signal quality 
at both ends of the washout. 
The same paper also describes the effect on calculated gas volume of 
realigning the flow gas delay to correspond to 80% of the maximum increment in 
gas concentration signal, rather than the standard 50% maximum increment (Figure 
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2.12). This has the effect of increasing the flow gas delay, and reducing error in 
determination of FRC. However, the misalignment of the signals will cause error on 
integration of falling gas concentration during inspiration. If re-inspired SF6 is not 
being calculated, then adjustment of the flow-gas delay to correspond to the 75% 
response fraction should provide a simple alternative that will not have any 
detrimental effect on signal quality. In order to assess the effects of such an 
adjustment, the 50-75% response time was calculated from the same gas 
concentration curves used to calculate 10-90% response time. This additional time 
delay was then added to the flow-gas delay calculated during the standard Innocor 
calibration. A sample washout was analysed using the calculated flow-gas delay, 
and a range of adjustments to this. Finally, the effects of adjusting the flow-gas 






Figure 2.12: Taken from Arieli & Van Liew. J Appl Physiol 51 (6): 1417-22  
Differences between calculated and measured amounts of Argon in a syringe, as a 
function of response fraction for which delay time is measured (i.e. a response 
fraction of 0.5 represents flow-gas delay measured to a 50% maximal rise in tracer 
concentration during a step-change in flow and gas concentration). The three curves 
in each graph (0-3) represent the effect of increasing correction orders 
(0=uncorrected, 1=first order correction etc.).  
Left panel shows errors when concentration changed in inspiration only, as 
calculated at end inspiration, and right panel shows errors when concentration 
changed in expiration only, as calculated at end expiration. The circles represent the 
authors choice of correction order and response fraction, but the same accuracy can 
be achieved by using a response fraction of 0.8 and not applying any correction to 
the gas signal (red arrow). This has the advantage of being simpler to perform and 




First and second order Arieli corrections were applied to step changes in SF6 
concentration. The effects of these are illustrated in Figures 2.13 and 2.14. The first 
order correction reduced the 10-90% rise time of the SF6 signal from 160ms to 
135ms, a 16% reduction (Figure 2.14). However, the signal quality was adversely 
affected by these manipulations, with an overshoot in the peak SF6 concentration 
and increased signal noise (Figure 2.13). Both of these effects were more 
pronounced in the second order corrections. In order to reduce these effects, values 
of γ1 and γ2 were adjusted to 2/3 of their calculated value, as suggested in the 
original paper (Arieli and Van Liew 1981). The adjusted corrections were then 
applied to a washout to determine the effects on signal quality and FRC. The first 
and last breaths of a washout performed by a normal volunteer (respiratory rate 11 
breaths per min), and subjected to these corrections, is shown in Figure 2.15. 
Although the SF6 concentration appears to rise faster after correction, the noise 
produced by the adjustment is excessive. 
The effect of the 1
st
 order correction on calculated FRC of the same washout is 
shown in Figure 2.16. This also illustrates the effect of adjusting the flow-gas delay 
to realign the signals. In this washout, the 1
st
 order correction resulted in an increase 
in measured FRC of 1.8% (from 2.33 to 2.37 L) and the second order correction 
resulted in an increase in FRC of 3.7% (to 2.41 L). A similar effect was achieved by 
realigning the flow and gas signals by an adding 50ms to the flow gas delay. This 
resulted in a measured FRC of 2.39 L, an increase of 2.7%, and this method does not 
cause any deterioration in signal quality. Further adjustment of the flow-gas delay 
continues to increase the measured FRC. Accurate alignment of flow and gas signals 
is important for accurate calculation of FRC (and hence LCI), but variations of less 
than 25ms appear to have minimal effect on these measurements (up to 1.6%). 
Because the subject’s exact FRC cannot be known, and is variable with repeat 
washouts, this analysis was subsequently performed using a calibration syringe to 


















Figure 2.13: Effect of applying first and second order signal speeding corrections to 
a step change in SF6 concentration, generated using a Brunner syringe. The raw SF6 
data are shown in black. The first order correction (blue) results in a steeper rise and 
fall in SF6 concentration, but there is an overshoot of the gas signal and greater 
signal noise. These features are all exaggerated after a second signal speeding 

























































Figure 2.14: Effect of gas signal adjustments on analyser response. The simulated 
step change in gas concentration is shown by the black dotted line, and the Innocor 
gas analyser response by the solid blue line. The 10-90% rise time is also illustrated. 
The effect on rise time of a modified 1
st
 order signal speeding correction is shown 
(red curve), as well as the effect of realigning to the 75% response fraction (purple 






































Figure 2.15: Effect of applying a gas signal speeding correction, as described by 
Arieli et al. (Arieli and Van Liew 1981), to a multiple breath washout of a healthy 
volunteer. The first and last breaths are shown in upper and lower panels 
respectively. The unaltered gas concentration signal is shown in blue. The pink and 
yellow traces represent the same gas concentration signal after first and second order 
signal speeding corrections respectively. The effects on signal quality are clearly 
shown in the lower panel, where the greater noise at low SF6 concentrations is 
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 Figure 2.16: Effect of manipulating the gas concentration signal on measured FRC 




 order corrections refer 
to the mathematical speeding of the SF6 concentration signal according to the 
method of Arieli et al., as explained in the text. The effects of adjusting the flow-gas 







Digitally enhancing Innocor gas analyser performance by applying signal 
speeding corrections to the gas signal results in a modest improvement in gas 
analyser response time, but only at the expense of signal quality. The effects on 
signal quality are tolerable at the start of the washout, where the signal:noise ratio is 
high, but are excessive by the end of the washout, and preclude the use of these 
corrections.  
An alternative method of signal speeding has been described that does not 
affect signal quality. This involved the addition of a fixed time constant to the 
measured flow-gas delay in order to realign the flow signal with the 80% response 
fraction of the gas signal. Applying a similar time-shift correction to the Innocor 
derived washouts produces an effect on measured FRC similar to that of the digital 
speeding corrections. This was also seen by Bates et al., when they attempted to 
apply digital speeding to a MS signal using the Arieli’s method. They showed that a 
time shift adjustment provided a ten-fold reduction in error of gas volume 
integration over an uncorrected signal, and was of similar accuracy to the more 
complex calculations required by Arieli (Bates, Prisk et al. 1983).  The effects of 
this adjustment on accuracy of gas volume determination, and the modifying effects 
of respiratory rate, are explored in the next section. 
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2.4 - Accuracy of modified Innocor system. 
Methods 
The ability of the modified system to integrate flow and gas signals accurately 
and reproducibly was assessed using a gas calibration syringe which could be set to 
deliver different volumes (Hans Rudolph, Missouri, USA). This was filled with 
0.2% SF6 in air to starting volumes (FRCs) of 1 or 3L. Washouts were performed by 
incomplete filling and emptying of the syringe around this starting point, taking care 
to establish as regular and smooth a filling and emptying pattern as possible, at 
physiological rates. The volume of gas in the syringe was derived from the 
calculated “expired” volume of SF6, using the clinical MBW analysis software, and 
was compared with the known starting volume of the syringe. The effects of 
different signal alignments on the accuracy of this integration were assessed by re-
analysing the washouts with a series of adjustments to the measured flow-gas delay 
(-50, +25, +50 and +100ms). Because the syringe contains a substantial, but 
unknown, deadspace, it is not possible to know the volume of gas in the syringe at 
the start of the washout. Therefore the difference between mean volume in the 
syringe when set to deliver 1L, and mean volume when set to deliver 3L, was used 
to assess accuracy, since this should be measured accurately as 2L. 
If the slow gas analyser response time has a deleterious effect on Innocor 
accuracy, it will be accentuated by fast respiratory rates. In order to investigate the 
effects of respiratory rate on accuracy of gas volume integration, the syringe 
washouts were repeated, using a different calibration syringe (Hans Rudolph, 
Missouri, USA) set to deliver 1L. Washouts were performed at slow and fast fill-
empty rates, equivalent to slow and fast respiratory rates in a patient washout. These 
were analysed at the measured flow-gas delay, and after addition of a fixed time 
constant of 50ms.  
 
Results 
Six washouts were performed from a starting volume of 1L, and 4 from a 
starting volume of 3L, using a washout rate of between 15 to 30 fill-empty 
manoeuvres per minute. All washouts were analysed at the measured flow-gas delay 
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and 4 adjustments to this, corresponding to time constants of -50ms, +25ms, +50ms 
and +100ms. Accuracy was defined by the difference between the mean syringe 
volume when set to deliver 1L and when set to deliver 3L. The error +/- 95 
confidence intervals, in millilitres, between these measurements is shown in Figure 
2.17. A volume of 20ml represents a 1% error in gas volume integration. 
The accuracy of the gas volume integration is reduced by 1.01% by the 
realignment of the flow and gas signals by +50ms, though the 95% confidence 
intervals of this error include zero. 
 
Effect of increasing respiratory rate on accuracy 
Figure 2.18 and Table 2.3 show the effect of increasing syringe fill-empty rate 
on volume determination. It is not possible to assess “accuracy” of volume 
determination per se, since the exact volume in the syringe (including the 
deadspace) is not known. However, it can be seen that there is little difference in the 
measured syringe volume at slow fill-empty rates (mirroring the conditions during 
adult tidal respiratory rates) after addition of 50ms to the measured flow-gas delay. 
Addition of the 50ms time constant causes an increase of 18ml (1.5%) in the 
measured gas volume. At higher rates (average 67 per min, range 54-78per min), 
using the uncorrected flow-gas delay, there is a much greater change in the 
measured syringe volume of -36ml (3.0 %). This has been presumed to be due to 
error in accuracy of integration of flow and gas signals and higher fill-empty rates. 
Use of the additional time delay method of signal speeding however corrects the 
measured syringe volume to that measured at slower rates. Because of the small 
numbers of repeats, none of these differences were statistically significant.  
It can also be seen that the error caused by rapid rates is modest. Without the 
additional time constant, there is only a 3% fall in measured volume at rates of up to 
78 per minute. Above a rate of 60 “breaths” per minute however, the software is 



















Time delay selected for
clinical system





























Figure 2.17: Mean and 95% confidence interval of effect of altering the measured 
flow-gas delay on accuracy of determination of 2000ml volume difference between 
syringe set at 1L and at 3L. Six washouts were performed from a starting volume of 






  Additional time delay 




Mean (SD) measured syringe volume (L) 
Mean (range) fill-empty rate: 10 (9-12) 






Mean (SD) measured syringe volume at (L) 
Mean (range) fill-empty rate: 67 (54-78) 






Table 2.4: Effect of increasing empty rate and adding to measure flow-gas delay on 
volume determination of a calibration syringe set to 1L. The measured FRC includes 
46ml of apparatus deadspace and an unknown dead space volume in the end of the 
syringe. This deadspace is constant and does not alter if the syringe is set at a greater 
starting volume. 


























Figure 2.18: Measured syringe volume at fast and slow washout fill-empty rates, 
and two different flow gas delays: that measured by Innocor, and after addition of 
50ms. Each point represents a separate assessment, mean is indicated by the 





The system is able to integrate expired SF6 accurately and changes in the flow-
gas delay of 10-20ms have little effect on the accuracy of volume determination at 
physiological “respiratory” (fill-empty) rates. The addition of a 50ms time constant 
increases the measured volume of the gas in the syringe, and reduces accuracy, by 
1%. At faster rates however, the additional time constant increases accuracy. An 
additional delay of 50ms corresponds to the 50-75% gas signal rise time, and would 
be expected to improve accuracy as per the findings of Arieli et al. (Arieli and Van 
Liew 1981). However, even without any adjustment to the flow-gas delay, the 
effects of faster breath rates are modest, and within the 3% error of volume 
determination generally permitted in physiological apparatus.  
The software has a default setting to correct for re-inspired SF6, i.e. integrating 
the inspiratory flow and SF6 concentrations in order to measure and account for 
tracer gas residing in the post-capillary deadspace at the start of inspiration. This 
setting was in response to the problems faced by Professor Gustafsson when 
performing washouts on children. In the apparatus described here, post capillary 
deadspace is only 5ml, and tidal volume is greater, so the possible contribution of 
re-inspired SF6 is much less. The analysis software was modified to remove the 
automatic adjustment for re-inspired SF6. When the re-inspired SF6 adjustment was 
included, accuracy was reduced at all time points and fill-empty rates (data not 
shown). This adjustment has therefore been omitted from calculations in the studies 





The modifications described in this chapter are designed to permit the use of 
an Innocor gas analyser in assessments of multiple breath washout tests. The device 
lends itself well to this purpose, since it contains both a differential pressure 
transducer for a flowmeter, and a highly sensitive gas analyser. In order to adapt the 
device, a new patient interface has been constructed with a low dead space. A 
separate pressure transducer has also been added in order to allow dynamic feedback 
of expired volume. Finally, in collaboration with Professor Gustafsson, the analysis 
software has been reformatted and adjusted to analyse raw data generated by 
Innocor. 
The ideal comparison would be to compare performance of both the mass 
spectrometer and Innocor simultaneously, as has been done for other gas analysers 
(Fuchs, Buess et al. 2006). However washouts would have to be performed at the 
operating range of the Innocor gas analyser, since the response is not linear above 
0.4% SF6. Without altering the sampling protocol, the signal resolution of the mass 
spectrometer shows excessive noise at this level, making such a comparison invalid; 
this is an unavoidable limitation of the current comparison. Since a simultaneous 
comparison of the two devices has not been possible, the gas analyser has instead 
been evaluated in terms of signal quality and response time and these features have 
been compared to those of a mass spectrometer used to measure LCI in children. 
Finally, the accuracy of the system has been confirmed, and methods explored of 
improving this using signal speeding manipulations. 
The performance of the Innocor and MS apparatuses are compared in Table 
2.5. Also included in this table are a summary of the equipment recommendations. 
These come from the ATS/ERS guidelines on multiple breath nitrogen washouts in 
adults (Wanger, Clausen et al. 2005), and from the recent ATS/ERS guidelines on 
pulmonary function testing in pre-school children - this also contains a section on 
multiple breath washout analysis (Beydon, Davis et al. 2007). Although neither of 
these scenarios exactly reflects the application for which the Innocor has been 
























Deadspace 1-2ml/kg <100ml 12.5ml* 46/36ml** 
Gas sample flow <100ml/min N/A 20ml/min 120ml/min 
10-90% response 
time 
100 ms <60 ms 64 ms 160 ms 
Sample rate 50Hz >40Hz Up to 100Hz
+
 100 Hz 
Signal:noise ratio 
 (start of washout) 
>100 N/A 200 944 
 
Table 2.5: Technical comparison of mass spectrometer and Innocor with ATS/ERS 
guidelines for lung clearance measurement in children and for multiple breath 
nitrogen washout (MBNW) in adults. 
N/A – this parameter not covered in the guidelines. 
* This system does not include a filter, which contributes to the majority of the 
deadspace in the adapted Innocor system. 
** Deadspace can be reduced for children by the use of a smaller filter 
+
 Sample rate can be varied depending on number of channels open 
1: Beydon, Davis et al. 2007 
2: Wanger, Clausen et al. 2005 
3: Aurora, Kozlowska et al. 2005 
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Despite operating at a much lower SF6 concentration range, Innocor has a 
superior signal resolution throughout the range of concentrations experienced in a 
washout. The resolution of the MS signal can be improved, but only at the expense 
of the analyzer sample rate. Accurate signal resolution is particularly important 
when performing analysis of phase III alveolar slopes (Verbanck, Schuermans et al. 
1997) (see Chapter 5).  
However, when the modified Innocor is compared to the nitrogen washout or 
the paediatric washout recommendations, the gas sample flow rate and the rise time 
of the gas signal fall short of the recommendations. Gas sample flow is particularly 
important with paediatric subjects, since a sample rate of 120ml/minute may 
represent a significant proportion of the minute ventilation and there is an additional 
risk of back sampling ambient air at low expiratory flows. The guidelines therefore 
specifically recommend that gas sample flows of greater than 100 ml/min are 
undesirable and that compensation for this is required. 
In adults however, this is far less likely to be relevant. Adult minute ventilation 
is usually greater than 7 L/min, and a gas sample flow rate of 120 ml/min therefore 
represents a far smaller proportion of minute ventilation. Another problem of the 
sample rate is that, if the sample port was placed between the patient and the 
flowmeter, it might be sufficiently high to cause a bias-flow across the flowmeter. In 
order to resolve these problems, the gas sample port of the patient interface has been 
placed distal to the flowmeter (Figure 2.6). Air drawn in by the sample needle will 
follow the path of least resistance. With the distal placement of the gas sample 
needle described above, this will be ambient air drawn 5cm into the tube rather than 
air drawn through the apparatus across the flowmeter. With the sample needle 
placed between mouth and flowmeter, air may be drawn across the flowmeter. 
Observations of measured flow with the needle connected and disconnected did not 
identify any excess flow meter inaccuracy attributable to gas sampling. 
This positioning of the gas sample line is important when using Innocor for 
another reason. If there were significant dead space distal to the gas sample line 
(post-capillary dead space), then this would be re-inspired when the patient breathed 
in. On expiration, this volume of gas would be counted towards the total, leading to 
a falsely elevated FRC. The volume of gas re-inspired can be calculated, and indeed 
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the analysis software has the ability to do this. However, a slow gas signal fall time 
leads to additional error in this process. By positioning the gas sample line at the 
distal end of the patient interface, with a post capillary dead space volume of less 
than 5ml, the volume of re-inspired SF6 can be ignored. This simplifies the 
calculations, and removes the error due to the slow signal fall time. 
The adverse effect of this gas sample line positioning is to increase the pre-
capillary dead space to 46ml (this includes the mouthpiece, filter and flowmeter). 
This volume is subtracted from the derived FRC at the end of the washout, but is 
included in the CEV and FRC for calculation of LCI. This is an important 
distinction, and there has been some discussion amongst those involved in 
measuring gas mixing about whether to include pre-capillary deadspace in these 
calculations. However, they form a part of the FRC involved in gas mixing, and 
larger pre-capillary deadspace will alter measures of heterogeneity. In this thesis 
therefore all measurements of gas mixing, including SnIII analysis, include the pre-
capillary deadspace as part of the measurement. 
It has been assumed that, with the typical tidal volumes and respiratory rates 
encountered in adult subjects, the positioning does not adversely affect response of 
the system. This assumption may not be correct in very young children, or in 
subjects breathing very rapidly with small breath volumes. In order to achieve this 
small deadspace, low volume components have been used which means relatively 
high resistance to flow. At tidal breathing flow rates, this is not a problem for 
subjects. Resistance becomes more noticeable at higher flow rates and the system 
would be unsuitable for use in exercise testing.  
The majority of the deadspace (20ml) is due to the presence of the bacterial 
filter. This is not used in the mass spectrometer-based apparatus, but is necessary for 
the current application. By doing this, the need to dismantle and clean the flowmeter 
after every patient is removed, which greatly simplifies the procedure and permits 
increased patient throughput, an essential feature for use in clinical trials outside of 
the laboratory. For adult subjects, the total dead space remains well within the limits 
set by both sets of recommendations. 
The only important compromise for Innocor compared to the MS is the gas 
analyser response time, which is slower than that recommended for use in pre-Air 
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drthat gas analyser response times slower than 100ms will introduce error into the 
monitoring of gas concentration changes at fast respiratory rates. Support for this 
comes from a paper by Tang et al. (Tang, Turner et al. 2005). In this study, the 
authors looked at the effects on the derivation of Fowler dead space (DS) (Fowler 
1948) of varying the rise time, and flow-gas signal alignment, of a computer 
generated CO2 expirogram. Since the expirogram was generated by a computer 
model of the lung, they were also able to investigate the effects of expiratory time 
constant. The computer modelling was supplemented by real data from ventilated 
patients. The authors showed that there is a linear relationship between 10-90% rise 
time and error in determination of Fowler DS. This is affected by the expiratory 
time constant, and increases exponentially when this falls below about 0.8 
(equivalent to a respiratory rate of 25 per minute).  It was also shown however that 
mis-alignment of the flow-gas delay has a greater effect on accuracy, and that this 
too rises exponentially with a time constant of less than 0.8.  
This paper provides comprehensive support both for a fast rise time when 
integrating flow and gas signals, and for accurate flow-gas delay correction. 
However, in the scenarios described, rise time was a theoretical 0ms when assessing 
signal alignment, and it is likely that the effects of signal alignment will be less 
profound when the rise time is slower. What the authors also demonstrated was that 
a re-alignment of the flow-gas signals, as described in this chapter, corrects for the 
error of the rise time.  
An earlier study by Schena et al. (Schena, Thompson et al. 1984) also 
considered the effects of rise time on capnogram. They altered the rise time in a 
mechanical lung model by varying the gas sample tubing length and gas sample 
flow rate. They found that increasing rise time shifted the capnogram to the right, 
and that predicted end-tidal CO2 values could not be achieved if the rise time was 
excessive compared to the respiratory cycle time. However, in the example they 
quote, the rise time is 0.94 seconds, and the respiratory rate is 60 per minute, both of 
which are considerably in excess of the circumstances in which Innocor has been 
employed in the present studies. 
Neither study presents any evidence for the use of 100ms as a definitive cut off 
value for signal rise time in all circumstances. Both demonstrate that errors caused 
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by rise time are increased at fast respiratory rates, and the selection of 100ms as a 
cut-off by the guidelines’ authors appears to have been a pragmatic choice of upper 
limit in order to reduce error in subjects with known fast respiratory rates (i.e. 
infants) (Beydon, Davis et al. 2007). In adults however, with respiratory rates of 
typically 10-20 per minute, the effects of rise time are likely to be far less 
significant, and a 10-90% rise time of 160 ms should not by itself be a contra-
indication to the use of Innocor for this purpose. 
In order to investigate this, the accuracy of the system was assessed using a 
calibration syringe as a single compartment lung model. Different volumes of gas 
were then washed out at different fill-empty (“respiratory”) rates to assess the 
accuracy of the system at faster breathing rates. The system can accurately and 
reproducibly determine the volume of gas in the syringe at washout fill-empty rates 
similar to those experienced during adult tidal breathing. At faster fill-empty rates, 
error is introduced into determination of gas volume, presumably as a result of lag in 
the gas signal. This error is modest (3%), but confirms the assertion that analyser 
response time will impact on accuracy at faster respiratory rates (Tang, Turner et al. 
2005; Beydon, Davis et al. 2007). 
In order to improve this, methods of digitally speeding the gas signal have also 
been explored, according to the method described by Arieli et al. (Arieli and Van 
Liew 1981). Although this results in a modest improvement in rise time, the signal 
quality suffered excessively and that the signal:noise ratio at the end of the washout 
was unacceptable. As an alternative to this, the flow signal has been realigned with 
the 75% response fraction of the gas signal by the addition of a fixed time constant 
to the calculated flow-gas delay, a device that has previously been shown to provide 
similar accuracy to more complex mathematical manipulations (Bates, Prisk et al. 
1983).  This approach is facilitated by omitting calculation of the re-inspired SF6 
volume, as discussed above. If re-inspired SF6 was included, different time constants 
for inspiratory and expiratory flow would be needed in order to avoid excessive 
mal-alignment and additional slowing of analyser response during inspiration. This 
approach improves the accuracy of integration of expired SF6 volumes at higher 
respiratory rates but has little effect at the lower rates normally encountered in adult 
washouts. Indeed, the major limitation at rates above 60 breaths/min is that the 
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ability of the analysis software to automatically identify respiratory cycle change is 
diminished. The current set-up falls short of the recommendations for MBW 
apparatus in pre-school children, but in school age children (>5 yrs) and adults 
Innocor should be capable of accurately calculating FRC. 
There are alternative methods of improving analyser response time, including 
adjustment of gas sample flow rate and removing the oxygen analyser from the 
system. Initial investigation of these methods has established that they cannot be 
effected without the assistance of the manufacturers - work that is now ongoing and 
will be the subject of a separate thesis.  
 
The final system has been constructed with the intent that it be suitable for 
multi-centre use and relatively high patient throughput. In these regards it differs 
from apparatus previously used in single centre research studies. The use of a MS to 
measure LCI by following changes in exogenous SF6 is now well described in 
children (Aurora, Kozlowska et al. 2005; Gustafsson 2005), and is probably the 
accepted gold standard technique in this population. The MS offers the additional 
advantage that it can measure a wider range of different gases, which is a useful 
option when measuring vital capacity single breath washouts (Gronkvist, Emery et 
al. 2002). However, the MS is an expensive, temperamental and bulky piece of 
equipment that cannot readily be taken out of the laboratory. In contrast, Innocor 
contains both the gas analyzer and the pneumotachograph in a single portable unit. 
Indeed, Innocor has already been used (in its original capacity to measure cardiac 
output) at Everest base-camp (Ghofrani, Reichenberger et al. 2004). This advantage 
should not be underestimated: if the measurement of LCI is ever to achieve 
widespread usage outside of specialised units, then the size, robustness and cost of 
the apparatus are critical. Without substantial technical support, mass spectrometers 
are likely to prove more difficult to use in multi-centre studies. A supply of SF6 is 
required for both systems, but the concentration required for Innocor is 1/20
th
 of that 
used in the MS washouts, which reduces both gas wastage and costs.  
 
The disadvantages of Innocor are the high gas sample flow rate and slow 
analyser response time. As discussed above, the system has been modified to 
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account for the effects of both these aspects and accurate of gas volume 
determination has been demonstrated.  
 
 
There are a number of assumptions inherent in the final clinical system: 
1. Flow gas delay is accurate, and does not change appreciably during the 
washout.  
2. Pre-capillary deadspace (46ml) does not have any significant effects on gas 
mixing.  
3. Because the post-capillary deadspace is minimal (5ml), the amount of SF6 
re-inspired is negligible and does not need to be accounted for in the 
calculation of total volume of expired SF6. 
4. Resistance to tidal breathing is insufficient to have any significant effect on 
FRC or gas mixing. 
5. The effects of changing SF6 concentration on expirate viscosity are 
negligible, and no dynamic adjustment is required. 
 
These assumptions are reasonable for use of the apparatus in adult subjects and 
older children. Because of the small breath volumes and rapid respiratory rates 
encountered in pre-school children, they may not be valid in this population. 
 
The clinical use of the system described here is the subject of subsequent chapters. 
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This chapter concerns the measurement of lung clearance index (LCI) using 
the apparatus described in Chapter 2. Previous studies have established the 
feasibility and utility of multiple breath washout (MBW) for measuring CF lung 
disease in exclusively paediatric populations (Gustafsson, Aurora et al. 2003; 
Aurora, Gustafsson et al. 2004; Aurora, Bush et al. 2005; Kraemer, Blum et al. 
2005). The sensitivity to early airways disease, and ability to perform the manoeuvre 
in children too young to co-operate with spirometry, have driven the development of 
LCI measurements in children. There is less obvious need for a sensitive measure of 
early CF lung disease in adults. However, in the specific context of CF gene 
therapy, LCI offers the possibility of monitoring lung disease and subtle responses 
to treatment in milder CF patients, and also of being a more specific marker of small 
airways disease than conventional lung function assessments. The hypothesis behind 
this chapter was that LCI would be more sensitive in adults than FEV1 to lung 
disease in CF. 
 
The aims of this chapter are to: 
1. Establish the feasibility of LCI measurements using the modified Innocor 
apparatus. 
2. Establish a normal range in healthy adults. 
3. Compare LCI in CF patients with healthy adults. 
4. Investigate the associations between FEV1, FEF25-75 and LCI. 
5. Investigate the association of LCI with other markers of clinical severity. 






Cystic fibrosis patients were recruited from those attending the Scottish Adult 
CF Service, based at the Western General Hospital in Edinburgh. In order to 
maximise the numbers and quality of the data, the results presented here are an 
amalgamation of data from three separate studies. The majority of subjects were 
recruited for measurement of LCI whilst attending routine clinic appointments. A 
number of these patients were recruited at the time of their annual review, which 
also includes an assessment of full lung function. These additional data are also 
described in more detail in Chapter 5. Nine patients are drawn from those recruited 
to a study looking at the effects of physiotherapy on LCI (Chapter 6). This involved 
two assessments of LCI – the first (baseline) measurement is equivalent to the one-
off assessments in the other study. Finally, 10 patients are drawn from those 
recruited to the UK CFGT consortium Tracking study. This involves three 
longitudinal assessments of LCI over the course of treatment for a pulmonary 
exacerbation of CF (described in detail in Chapter 4). Data taken from this study are 
from the final visit that patients made. Ideally this represents an assessment of LCI 
at full recovery, though in practice not all patients attended for all visits.  
There is bound to be some variability in the clinical state of patients, as in any 
cross section of CF patients. Unstable or acutely unwell patients were not recruited 
and a summary of clinical condition was noted for each patient visit. However, since 
the aim of the chapter is to explore cross-sectional relationships between different 
lung function measurements, no additional attempt has been made to control for 
clinical condition 
A number of subjects were recruited to more than one study and underwent 
assessment of LCI on more than one occasion. Wherever possible the most recent 
measurement of LCI has been selected. The exceptions to this are if there was poor 
reproducibility of LCI within-day repeats at the later visit or if there were missing 
data (e.g. mid-expiratory flow data are not available for all subjects).  
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It should be noted that a deliberate attempt was made to recruit subjects from 
the least affected end of the severity spectrum; in other words those with the least 
impairment of FEV1 were targeted specifically. Furthermore, from initial 
observations it was clear that those with the most severe lung disease, and most 
impairment in FEV1, were also least suitable for this test. This is because both wash-
in and wash-out phases of the test were prolonged, making the test more 
burdensome for the patient. The subjects recruited do not therefore represent an un-
biased cross section of the patients attending the Scottish Adult CF Service. 
Healthy volunteers were recruited from amongst colleagues at the Molecular 
Medicine Centre and Department of Respiratory Medicine. Healthy volunteers were 
defined as non-smokers with less than 10 pack years smoking history, with no active 
lung disease, and taking no regular respiratory medications.  
All three of these studies were approved by the Lothian Research and Ethics 
committee and all patients and controls provided informed written consent. 
The majority of the healthy volunteer data, and a large proportion of the CF 
patient data, were included in a paper describing the development and use of 
Innocor to measure LCI (Horsley, Gustafsson et al. 2008). 
 
Washouts in subjects under 16 yrs 
In order to explore the change in LCI with age, data are included on LCI in 
healthy children, aged 5-16 yrs. These washouts were performed at the Royal 
Hospital for Sick Children in Edinburgh by Dr Kenny Macleod. Although the 
washouts were performed by Dr Macleod, the apparatus was configured to be 
compatible with the foregoing validation work (see Chapter 2), and the analysis 
used was that developed above for use in adults. The only additional modification 
for use in children was that a smaller filter was used (9070/01, Air Safety Ltd, 
Morecambe, UK), which reduced the pre-capillary deadspace to 36ml. Data analysis 
was also performed by Dr Macleod, using the same analysis protocol as used in 
adults, (described in Appendix B), and are presented here with his permission. 
Healthy paediatric controls were recruited at the Royal Hospital for Sick 
Children from those attending for follow-up of stable upper-limb fractures as well as 
children of hospital staff. Subjects had no history of recurrent wheeze, pertussis or 
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tuberculosis; no previous diagnosis of asthma or previous use of asthma medication; 
no prematurity (<34 completed weeks gestation); no neuromuscular weakness or 
bone disease likely to affect respiration; and no congenital cardiac disease requiring 
medication. This study was approved by the Lothian Research and Ethics 
Committee. Parents of children provided informed, written consent and children 
provided assent or written consent, depending on age and understanding. 
 
Multiple breath washout 
Washout tests were performed with the subject seated and suitably distracted 
by watching television. A noseclip was applied and tidal breathing established 
whilst the subject breathed through a mouthpiece attached to a filter and flowmeter. 
This was connected via a T-piece connector (Intersurgical, Berkshire, UK) to a 
flowpast circuit consisting of 22mm disposable plastic anaesthetic tubing 
(Intersurgical, Berkshire, UK) with a reservoir bag on the upstream (gas supply side) 
of the circuit.  
The first part of the test is the wash-in, during which the subject breathes 0.2% 
SF6 in air from the flow-past circuit.  This is supplied from a compressed gas 
cylinder, with the flow rate adjusted to ensure that rebreathing does not occur, 
confirmed by visual inspection of the gas concentration tracing - usually greater than 
12-14 L/min. During the wash-in, SF6 concentration and flow signals are displayed 
on the Innocor screen by selecting the option “Show online data” from the “Show 
results” menu (see Appendix A for full details). A 1 second average of SF6 
concentration is displayed alongside the graph of changing gas concentration versus 
time. In addition, an average expired tidal volume is calculated and displayed by 
Innocor, though there is no real-time tidal volume display. A separate display of 
expired volume is obtained on a separate laptop screen, as described in Chapter 2 
(Section 2.iv).  
During the first part of the wash-in, subjects were allowed to establish a 
comfortable breathing pattern. They were closely observed for evidence of air leak 
around the mouthpiece. Subjects unused to respiratory testing occasionally found 
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the mouthpiece and / or resistance of the system unusual at first. It commonly took 
up to 1 minute for some subjects to establish a comfortable breathing pattern. Once 
this had occurred, a paper arrow was affixed to the laptop screen at a position 
corresponding to the subject’s own tidal volume in order to aid expiratory volume 
reproducibility. Occasionally subjects continued to find the test difficult after the 
first minute, and breathed either with excessively shallow or deep breaths. If this 
occured, visual feedback of expired volume was used, along with verbal 
encouragement, to aid the subject in achieving a comfortable breathing pattern with 
a tidal volume of between 500 ml and 1 litre. During the test, subjects were 
encouraged to relax and to watch TV. Visual feedback was provided on an 
additional screen, and used to aid a regular relaxed breathing pattern, particularly in 
those who initially found this difficult. Both screens were visible to the patient in the 
same field of vision. 
The wash-in phase was continued for at least 4 minutes in adults, and in all 
cases until inspiratory and expiratory SF6 concentrations differed by less than 
0.004% (absolute difference in SF6 concentration). In normal adults, wash-in was 
usually complete after 3-4 minutes. In patients with mild-moderate CF, wash-in 
typically required 5-7 minutes of tidal breathing. In one early assessment in a 
subject with severe CF lung disease, wash-in was incomplete after 12 minutes. 
These data are not included here. Aside from this, wash-in was not continued 
beyond 10 minutes in any subjects.  
Once wash-in was deemed complete, based upon observation of the gas 
concentration versus time plot and the average SF6 concentration displayed on the 
graph, the flowpast circuit was manually detached during expiration by removing 
the T-piece from the flowmeter. The subject was warned that this was going to 
happen beforehand, and the process was demonstrated to the subject before the start 
of the test to familiarise them with the manoeuvre. Just before removal of the T-
piece, a stream of air was directed over the end of the flowmeter using a fan, to 
ensure that expired SF6 was blown away and not re-inspired.  
During the washout the subject breathes room air until the end tidal SF6 
concentration had fallen to less than 0.005% (1/40th of the SF6 concentration during 
wash-in). Because of the imprecision of the Innocor SF6 concentration display, it is 
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difficult to identify this point precisely. Washouts were therefore continued for 
several breaths beyond this point to ensure that this has been achieved successfully.  
 
Washout analysis 
Each subject completed three wash-outs. Data were extracted from Innocor’s 
hard disc and analysed after all three manoeuvres had been completed. If there was a 
clear problem with a washout test during the procedure (e.g. air leak, interruptions to 
breathing pattern), then the subject was asked to repeat it. Occasionally problems 
were only apparent during detailed analysis. Since these washouts could not be 
repeated at this stage, this necessitated excluding them from the analysis. As an 
additional quality control measure, washouts where the FRC differed by >10% from 
both of the other two repeats were also excluded. LCI is quoted as the mean of at 
least two reproducible repeats from washouts of satisfactory quality. Criteria for a 
satisfactory washout test include: 
 
1. Adequate wash-in, i.e. inspiratory and expiratory SF6 concentrations were 
within 2% of each other. 
2. No obvious air leak. 
3. Acceptably regular breathing pattern. Considerable variation in breath 
volume or frequency can still be analysed, but if excessive this makes the 
analysis very difficult and poorly reproducible. 
4. FRC within 10% of the other repeats. 
 
Occasional pauses in respiration, swallows and coughs were not a reason for 
exclusion of a washout on their own, but if excessively frequent could impair 
accuracy of FRC and LCI determination. 
A standardised operating procedure for the conduct of a washout test is given 
in Appendix A. Detailed instructions on data analysis and interpretation are 





Spirometry was measured according to American Thoracic Society / European 
Respiratory Society guidelines (Miller, Hankinson et al. 2005) using either an 
Easyone spirometer (ndd Medizintechnik AG, Zurich, Switzerland) or a Vitalograph 
2120 (Vitalograph, Buckingham, UK). Predicted values for FEV1 and mid-
expiratory flows are those provided by the European Community for Coal and Steel 
(adults≥17 yrs) (Quanjer, Tammeling et al. 1993) and Rosenthal et al. (children≤16 
yrs) (Rosenthal, Bain et al. 1993). Three reproducible measures were required for a 
satisfactory result. The best of the three manoeuvres, defined as the result with the 
greatest sum of FEV1 and FVC, was recorded. Measurements were performed 
without a noseclip. 
 
Statistical analysis 
Data were analysed using Prism (GraphPad Software Inc, CA, USA). Results 
are quoted as mean (SD) unless otherwise stated. Within test repeatability for LCI 
was determined by calculating the coefficient of variation (CV) as 100 x SD x  
mean
-1
. Inter-visit reproducibility was assessed using the Bland-Altman technique 
(Bland and Altman 1986). Numerical values for different measures of lung function 
were assessed for normality using the D’Agostino and Pearson Omnibus normality 
test. If both parameters were normally distributed, means were compared using 
unpaired t-test. If either parameter was not normally distributed then means were 
compared using a Mann-Whitney U test. For comparison of parameters across three 
or more groups, ANOVA or Kruskal-Wallis ANOVA was used, depending on 
whether data were normally distributed. The 95% limits of normality for LCI were 
calculated as mean +/- 1.96 x residual standard deviations. A p value of below 0.05 




53 healthy adult volunteers were enrolled for measurement of LCI. One of 
these was subsequently excluded because he was unable to establish a regular and 
relaxed breathing pattern. Washout data were collected from 50 adult CF patients. 
An additional patient with CF was enrolled but was unable to perform the test 
satisfactorily and declined to complete three washouts. Demographics and main 
outcome data for the two groups of subjects are given in Table 3.1.  
The proportion of male CF subjects was greater than that of adult male healthy 
volunteers (56% vs. 40%), though this was not statistically significant (Pearson Chi 
Squared test, p=0.115). The median age of the healthy volunteers was significantly 
higher than that of CF patients; 31.5 vs 24 yrs, p=0.0026 (Mann-Whitney U test). 
This reflects both the reduced age of the CF population generally, and also a 







Table 3.1: Demographics, spirometry and lung clearance index of adult healthy 
volunteers and cystic fibrosis patients.  
LCI = lung clearance index 
CV% = Coefficient of variation (%) for intra-visit repeats. 
* p=0.0026 compared to healthy controls (Mann-Whitney U test) 
** p<0.0001 compared to healthy controls (unpaired T-test) 
+
 p=0.047 compared to healthy controls (Mann-Whitney U test) 
 





Number 52 50  
Male / Female 21 / 31 28 / 22  







Mean (SD) FEV1  






(-42 to -29) 
Mean (SD) FEV1/FVC 






(-22 to -15) 
Mean (SD) FEF25-75  






(-95 to -71) 







(5.4 to 6.3) 








The mean (SD) FEV1 was significantly different between the two groups, 
being 102 (12) % predicted in healthy controls versus 68 (23) % predicted in CF 
patients, p<0.0001. 
Subjects with CF also had significantly lower FEF25-75 % predicted than 
healthy controls (34 versus 117 % predicted, p<0.0001). This is traditionally taken 
as a more sensitive measure of small airways disease than FEV1 alone. 
A single normal volunteer had an FEV1 of 73% predicted. This subject was a 29 yr 
old female, with no respiratory history or symptoms, who struggled to complete the 
spirometry assessment adequately on the occasion quoted. On a previous assessment 
she had achieved an FEV1 within the normal range.  
 
LCI in normal subjects 
There was a narrow normal range of LCI in adults of 5.95 – 7.43. This was 
independent of age, gender or height of the subjects.  
 
Change in LCI with age 
Data on LCI in subjects under 16 yrs, derived using identical apparatus and 
protocols, has been provided by Dr Kenny Macleod for this analysis. A summary of 
the additional subjects included in this analysis is given in Table 3.2. 
Figure 3.1 shows the relationship between LCI and age for the combined 
paediatric and adult cohorts (min 5 yrs, max 58 yrs). In those subjects over the age 
of 18 yrs there was no relationship between LCI and age. When the cohort of 
subjects under the age of 17 yrs was combined with these data, there was a weak but 
statistically significant correlation with age (Pearson r
2
=0.11, p=0.0026). The small 
dependence of LCI on age is best summarised by a normal range (95% limits of 
normality) in adults of 5.95-7.43 and in children (≤16 yrs) of 5.36-7.37. A weak 
relationship between height and LCI in the combined cohorts disappeared on 
multiple regression analysis. By contrast, FEV1 varied between 64 and 133% 
























Child healthy volunteers  
(age≤16 yrs) 
Number 30 
Male / Female 18 / 12 




Mean (SD) FEV1  
% predicted [Range] 
91 (12) 
[64-117] 
Mean LCI (SD) 
[Range] 
6.4 (0.5) 


































Figure 3.1: Effect of age on LCI. In adults (blue) there is no significant correlation 
between age and LCI, which remains stable over the age range of 17-58 yrs. The 
normal range is wider, and lower in children ≤16 yrs (green), which results in a 
weak but statistically significant correlation of LCI with age over the range 5 to 58 
yrs, shown by the solid black line (r
2
=0.11, p=0.0026). The means of the two 
populations (>17 yrs and ≤16 yrs) are represented by the blue and green horizontal 




LCI in patients with cystic fibrosis 
The group mean (SD) [range] for CF patients was 13.0 (3.5) [6.3-20.4], 
p<0.0001 compared to 6.7 (0.4) in healthy controls. Figure 3.2 shows the 
relationship between FEV1 % predicted and LCI for healthy control and CF adults. 
Unlike in healthy controls, where LCI was restricted to a narrow range, in CF 




There were 12 CF patients with FEV1≥80% predicted; all but one had LCI 
greater than the upper limit of normal. These subjects are represented in Figure 3.2 
by those CF subjects (red symbols) plotted on the right of the vertical dotted line. A 
summary of these subjects is presented in Table 3.3. Although for two of these 
subjects the LCI was only just above the upper limit of normal, it can be seen that 
even in those with FEV1 % predicted well within the normal range (>90% 
predicted), this does not exclude the presence of substantial gas mixing 
abnormalities. By contrast LCI was marginally elevated in only two healthy adults 
(measuring 7.7 and 7.8), consistent with the use of 95% confidence limits to define 
the normal range. The sensitivity of LCI for detecting CF was 98%, versus 76% for 
FEV1. 
LCI was also compared to FEF25-75 % predicted (Figure 3.3). There were fewer 
data points available for this assay (n=37 CF subjects and 25 healthy volunteers). 
There was only a single CF subject with FEF25-75 greater than 80% predicted and 
this subject had an elevated LCI (8.62), and an FEV1 of 98% predicted. There was a 
significant correlation between FEF25-75 percent predicted and LCI: Pearson r
2
=0.71, 
p<0.0001. Based on these data, the sensitivity of FEF25-75 for detecting CF was 96%, 
versus 100% for LCI in the same population. In healthy volunteers the range of 


































Figure 3.2: Lung clearance index (LCI) v FEV1 % predicted for adult healthy 
volunteers (blue) and patients with cystic fibrosis (red). The horizontal dotted lines 
represent the 95% limits of normality of LCI, calculated from the healthy adult 
population The vertical dotted line represents the lower limit of normal for % 
predicted FEV1. Linear regression of FEV1 % predicted versus LCI is shown for CF 
patients by the red dotted line; Pearson r
2











20 M ∆F508 / 4096-7AG IV 81.4 6.3 
26 F ∆F508 / 711+3AG IV 87.2 8.3 
39 F ∆F508 / D1152H IV 90.4 7.5 
30 M ∆F508 / G551D III 91.0 9.8 
41 F ∆F508 / A455E V 95.9 10.2 
23 M ∆F508 / ? ? 96.0 9.9 
18 F ∆F508 / ? ? 98.4 8.6 
27 F 1585-1GA / P67L IV 99.3 9.5 
20 M ∆F508 / ∆F508 II 99.4 12.5 
22 M G542X / A455E V 100.7 7.5 
33 M ∆F508 / ? ? 100.9 10.1 
49 M ∆F508 / 5T V 111.3 7.9 
 
Table 3.3:  Summary of the characteristics of the 12 cystic fibrosis patients with 
FEV1 % predicted within the normal range (≥80% predicted). Only a single subject 
had an LCI within the normal range (less than 7.4). 
Severity class of CF mutation is based upon the class of the non-∆F508 mutation, as 
described by Welsh et al. (Welsh and Smith 1993), and described in more detail in 
Chapter 1.  
“?” = mutation unidentified after extended testing. Diagnosis based upon a 
combination of clinical features and sweat testing. 
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Figure 3.3: Lung clearance index (LCI) v FEF25-75 % predicted for adult healthy 
volunteers (blue) and patients with cystic fibrosis (red). The horizontal dotted lines 
represent the 95% limits of normality of LCI, calculated from the healthy adult 
population. The vertical dotted line represents the lower limit of normal for % 
predicted FEF25-75. Linear regression of % predicted FEF25-75 and LCI is shown by 






Applicability of LCI technique in normal subjects and patients 
A washout test was excluded if the measured FRC differed by ≥10% from both 
of the other two washouts. This is in line with current recommendations on 
measurement of FRC by washout (Wanger, Clausen et al. 2005), and provides a 
built-in quality control of washout performance and analysis. In adult subjects, this 
resulted in the exclusion of a total of 6 tests (2 from controls, 4 from patients), 
representing less than 2% of the total number of repeats from both healthy 
volunteers and CF patients. All three washout repeats from an additional single adult 
healthy volunteer could not be analysed because the subject was unable to achieve a 
regular and reproducible breathing pattern. Two additional washout repeats, one 
from a healthy volunteer and one from a CF patient, were also excluded because of 
evidence of air-leak during wash-in that had only become apparent on formal data 
analysis. Finally, a single washout repeat from a CF patient was excluded because 
irregularities in breathing pattern made it impossible to analyse accurately.  
 
Repeatability of washout at same visit  
After exclusion of washout repeats that failed to meet quality control, the mean 
(SD) intra-subject coefficient of variation (CV) for FRC derived from repeat 
washout manoeuvres on the same visit was 3.2 (2.0) % for adult healthy volunteers, 
and 3.6 (2.3) % for CF patients. The mean (SD) CV for LCI was 3.6 (2.1) % for 
healthy adults, and 4.6 (2.5) % for CF patients. There was no significant correlation 
between the LCI CV and FEV1 % predicted. 
If the 6 washout repeats excluded on the grounds of reproducibility were 
included, mean CV for FRC increased to 3.5% for healthy volunteers and 4.1% for 
CF patients. Mean CV for LCI increased to 3.7% for healthy volunteers and 
increased to 5.1% for CF. 
Since three washout repeats were performed, it is not possible to perform a 
Bland-Altman analysis that contains all three repeats in a single analysis (Bland and 
Altman 1986). If a learning effect was significant however, this would be most 
pronounced between the first and final washouts. Bland-Altman analysis was 
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performed on all pairs of washouts for healthy controls and CF patients (i.e. washout 
1 vs 2, 2 vs 3 and 1 vs 3), but only the graphs of washout 1 vs 3 are presented here 
(Figure 3.4). Repeatability of washouts in healthy controls was acceptable, with no 
evidence of a learning effect. Inter-test reproducibility of LCI for individual 
washouts on the same day was between 0.68 and 0.88 (mean of 0.77), or around 
10%.   
Repeatability in CF patients was considerably poorer (mean inter-test 
reproducibility of 1.99), but this was skewed by some big differences between 
repeats in those with higher LCI (Figure 3.4b). Although there was no evidence of a 
learning effect, it is clear that LCI was less reproducible in subjects in whom it was 
very abnormal. This feature was consistent regardless of the pair of washout repeats 
selected for comparison. These are also the subjects in whom the test is most 




Inter-visit reproducibility of washout in healthy adults 
Repeat measurements of LCI were performed in triplicate on 16 healthy 
volunteers after an average (SD) of 36 (40) days. A Bland-Altman plot of the 
difference between repeat measures versus the mean of the measurements is shown 
for FRC in Figure 3.5 and for LCI in Figure 3.6.  
For FRC, the 95% limits of agreement between the two measurements were -
0.43 to 0.45 L. For LCI, the 95% limits of agreement for the two measurements 
were -0.78 to 0.46. Thus the inter-visit reproducibility of the FRC measurement was 
around 400 ml and that of the LCI measurement was 0.6. This is similar to, but 
slightly better than, the mean intra-visit reproducibility.   
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Figure 3.4: Bland-Altman plots of lung clearance index for first and third washout 
repeats for (a) healthy controls and (b) patients with cystic fibrosis. There is no 
evidence of a learning effect, and repeatability for healthy controls is both 
acceptable and consistent. However, repeatability for CF patients deteriorates in 
those with most severely abnormal gas mixing, and highest LCI. 
a: Healthy controls 


























































Figure 3.5: Bland-Altman plot of difference between functional residual capacity 
(FRC) measured on two separate occasions (quoted as mean of triplicate repeats), 
and mean of the two measurements of FRC. Horizontal dotted lines represent the 
mean and 95% limits of agreement of the difference between measurements on the 
two occasions. 
 













































Figure 3.6: Bland-Altman plot of difference between lung clearance index (LCI) 
measured on two separate occasions (quoted as mean of triplicate repeats), and 
mean of the two measurements of LCI. Horizontal dotted lines represent the mean 





It has been demonstrated in this chapter that clinical measurement of inert gas 
washout is practical using the modified Innocor device. It has also been shown for 
the first time that, in adults with CF, a simple measure of ventilation heterogeneity is 
more sensitive than spirometry in detecting lung function abnormalities. Finally, it 
has been shown that measurement of LCI is reproducible both within and between 
visits, and that there is little change over a wide range of subject age.  
Ventilation heterogeneity is thought to be altered by small airways dysfunction 
(Cosio, Ghezzo et al. 1978; Verbanck, Schuermans et al. 2004). Measurements of 
ventilation heterogeneity should therefore reflect the earliest pathology in CF - as 
has already been shown in children (Gustafsson, Aurora et al. 2003; Aurora, 
Gustafsson et al. 2004; Aurora, Bush et al. 2005). This is also the region of the lungs 
which is likely to be a key target for gene therapy. LCI therefore offers the ability to 
measure dysfunction in the airways of interest, and also to extend the range of 
patients suitable for these assessments.  
The preceding chapter concerned the technical characteristics of the Innocor 
device and a method of modifying it so that it was able to perform inert gas multiple 
breath washouts. In this chapter, the clinical application of the device has been 
demonstrated. In addition, a second modified Innocor device has been established at 
the Royal Hospital for Sick Children in Edinburgh, in order to perform MBW tests 
in children. Standardised procedures for the conduct of washout tests and for data 
analysis have also been developed (Appendix A & B). The data on LCI in subjects 
under 16 yrs were collected using this second device, and standardised protocols. In 
doing so, the feasibility of using this technique and equipment in a multi-centre 
setting has also been demonstrated. This is the first time that MBW measurements 
have been performed using the Innocor gas analyser, and the first time that LCI data 
have been collected simultaneously at two different sites. Although Paul Aurora and 
Per Gustafsson have been involved in paediatric studies in Gothenburg and London 
using identical mass spectrometer-based equipment, these studies were performed 




Furthermore, these are the first data on LCI in CF adults; previous studies have 
only reported measurements in subjects only up to 19 yrs. Even in adult patients 
with normal spirometry, the LCI may be markedly elevated, indicating significant 
“silent” lung damage. Some of the patients with normal FEV1 gave no symptoms 
and were on no treatment, the diagnosis of CF having been made incidentally. Yet 
despite this, there was abnormal gas mixing in almost all cases. There is a risk that 
the extent of lung disease in such patients may be underestimated and hence under-
treated.  
LCI has been reported in small numbers of adult subjects in several studies, 
but only a single study has been identified where large numbers of healthy non-
smokers have been assessed (Orzalesi, Hart et al. 1965). This study employed 
nitrogen washouts and reported a mean (SD) LCI in 26 adults (>15 yrs) of 7.1 (1.3). 
The mean LCI is very similar to that reported here (6.7) but the wider range of 
normal LCI in the earlier study may reflect both the smaller numbers and the 
presence of some smokers within the cohort. This study also found LCI to be 
unaffected by gender or age of subjects. An earlier study reported a more elevated 
LCI in 80 adult males, ranging from 9.0 to 10.0 depending on age (24-65 yrs) 
(Bouhuys 1963). This study did not control for smoking however and also reported a 
positive association between smoking history and LCI in older subjects. 
The mean (SD) LCI in normal subjects determined here is also very similar to 
that reported in the literature in children and adolescents (Table 3.5). In preschool 
children (mean age 4) this has been reported as 6.9 (0.4) (Aurora, Bush et al. 2005), 
and in school age children (mean age 11 yrs) as 6.5 (0.5) (Aurora, Gustafsson et al. 
2004) and 6.3 (0.4) (Gustafsson, Aurora et al. 2003) in two different populations 
from UK and Sweden respectively (Figure 1.8). The range for LCI reported here is 
almost identical to those reported previously in children of the same age. It can also 
be seen that LCI is remarkably consistent across different populations and 
technology.  
There was a weak, albeit statistically significant, rise in LCI with age. The 
clinical significance of this is unclear, since the magnitude of the difference (over a 
53 year age range) remains very small and is less than inter-visit reproducibility. 





Reference Age range (yrs) 
Number of 
subjects 
Mean LCI (SD) 
Current study, 
adult volunteers 
19-58 52 6.69 (0.38) 
(Orzalesi, Hart et 
al. 1965) 
15-45 26 7.1 (1.3) 
8-15 20 7.0 (1.0) 
Current study, 
paediatric controls 
5-16 30 6.37 (0.51) 
(Gustafsson, Aurora 
et al. 2003) 
4-18 28 6.33 (0.43) 
(Aurora, Gustafsson 
et al. 2004) 
6-16 33 6.45 (0.49) 
(Aurora, Bush et al. 
2005) 
2-6 37 6.89 (0.44) 
 
Table 3.5: Summary of previously published mean and standard deviation of lung 
clearance index (LCI) in healthy control populations. Data from this chapter are 





difference between mean LCI in children (8-15 yrs) and adults (Orzalesi, Hart et al. 
1965). Serial deadspace is known to affect LCI in infants and neonates (Schmalisch, 
Proquitte et al. 2006). However, the change in normal values of LCI was in the 
opposite direction to that which would be caused by a greater dead space/tidal 
volume ratio (as found in infants). It is possible therefore that this represents a true 
effect of age on lung elasticity and hence gas mixing. This is not unexpected, since 
it is known that mid-expiratory flows can be diminished in those over the age of 60 
yrs, even in healthy non-smokers (Fowler, Pluck et al. 1987), and it would not be 
unreasonable to expect some impairment of airways function prior to this. The age 
related change in LCI is small however, and this supports the use of LCI in long 
term follow-up studies. By contrast, there is a wide range of “normal” for FEV1 and 
FEF25-75 % predicted, which are influenced by the choice and accuracy of the normal 
range selected (Roca, Burgos et al. 1998). It has been shown that LCI may be 
affected by large changes in tidal volume, respiratory rate or FRC (Bouhuys, 
Lichtneckert et al. 1961; Gronkvist, Bergsten et al. 2002). In the present studies, 
tidal volume feedback was used to control tidal volume and respiratory rate within a 
range which should not affect the result. Since LCI is a ratio of cumulative expired 
volume and FRC, it is independent of small changes in FRC over the physiological 
range. This is supported by the reproducibility of LCI and the narrow range of LCI 
in healthy controls found in the current study. Furthermore because it is normalised 
for FRC, differences due to physical size are already accounted for. The normal 
range of LCI is therefore unaffected by age, height or gender of subject, leaving 
only the effects of gas mixing.  
This is especially important for longitudinal studies, particularly in children. Since 
spirometry changes with age, height and gender, it is normally expressed as a 
percent predicted. But this means accepting a wide range of FEV1 which would be 
considered “normal” for any individual, and the equations most commonly used to 
determine normal range change in late teens (Quanjer, Tammeling et al. 1993; 
Rosenthal, Bain et al. 1993). Use of different prediction equations for “normality” 
can have profound effects on the measured rate of decline in “percent predicted” 
values for spirometry (Merkus, Tiddens et al. 2002). Normal LCI however remains 
unchanged, allowing any deviation to be easily identified. This is a major advantage 
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of LCI over spirometry, particularly in adolescents. It is a significant challenge to 
accurately predict the “normal” FEV1 in CF patients during the adolescent growth 
spurt. This is often delayed in CF, and it is insufficient to base the choice of 
prediction equations on age alone. 
The entire assessment, comprising three washout repeats, typically took 
around 20-30 minutes for healthy volunteers, but 30-45 minutes for CF patients. 
This is considerably more burdensome than spirometry alone, and likely to place 
some limitation on the routine use of washout tests. Assessment time could be 
shortened by performing only two repeats, but this would require fast and accurate 
online data analysis to inspect the washout tracings and confirm acceptable 
reproducibility and quality. This is not possible with the current apparatus. 
Over 90% of adult subjects were able to complete all three washout 
manoeuvres without difficulty and generate reproducible measurements of FRC and 
LCI. Even for CF patients, the whole process (wash-in and wash-out) usually took 
little more than 10 minutes, and considerably less in children. Despite the relatively 
uncontrolled conditions, the mean CV for repeat FRC is similar to that described in 
the literature, which varies from 3.5-6.7% for plethysmography and 4.9-10.4% for 
helium dilution (Hankinson, Stocks et al. 1998). The mean CV for LCI is also better 
than that described in children (Aurora, Gustafsson et al. 2004). To a certain extent, 
this level of reproducibility represents a “best case scenario”, since washouts were 
excluded if they were poorly reproducible. In addition, some subjects attended on 
more than one occasion, and would therefore be more experienced with the 
technique than patients not previously exposed to it. There is a tendency for those 
with more severely affected lungs to tolerate the prolonged wash-in less well and 
generate less reproducible data, and this can be seen in Figure 3.4b. Reproducibility 
of LCI is affected by the magnitude of the abnormality. This may be intrinsic to the 
measurement error of the system, but it may also be a feature of the patients in 
whom LCI is highest. Dry air from the cylinder can cause discomfort and cough in 
some subjects with plentiful mucus. Those with the most severely affected lungs, 
and most elevated LCI, are more likely to shift mucus within and between washouts, 
which may change the distribution of ventilation (Mentore, Froh et al. 2005). The 
variability in repeat LCI measurements in these subjects could thus be a real effect 
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of changing ventilation distribution in severely damaged mucus-filled lungs, rather 
than an artefact of the measurement. In these patients, LCI is not an ideal measure of 
lung physiology, and its’ main advantage is in those with far less severely affected 
lungs. Nonetheless, the technique was found to be well tolerated and reproducible in 
the majority of subjects.  
Repeat measurements of LCI at a separate time point, in a cohort of the adult 
healthy volunteers, also demonstrate good inter-visit reproducibility of 0.6. This 
equates to less than 9% of the mean LCI, and is similar to the intra-visit 
reproducibility. Data on reproducibility of LCI in healthy volunteers have not been 
presented previously. Because of the nature of CF lung disease, and the difficulty in 
defining stability, it is beyond the scope of this thesis to assess long term 
reproducibility in patients with CF. Some data on short term reproducibility have 
been collected as part of a study looking at the short term effects of physiotherapy, 
and these are presented in Chapter 6. When assessing the significance of a change in 
LCI it is reasonable to take 0.6 as the level of a significant difference between two 
different measurements when LCI is within or close to the normal range. It is 
however likely that this will overestimate the significance of changes in those with 
more elevated LCI.  
From Figure 3.3, it would appear that FEF25-75 is almost as good a measure of 
airways dysfunction as LCI, with a similar sensitivity (96% vs. 100%). FEF25-75 is 
undoubtedly a quicker manoeuvre to perform than LCI, and can be performed on 
most standard spirometry equipment. However, it is known that these tests are 
dependent upon patient effort, and are poorly reproducible both within and between 
visits (Timonen, Randell et al. 1997). Data on the repeat measures of FEF25-75 were 
not collected in this study, but LCI was shown to have good within and between 
visit reproducibility. In addition, there is a narrow range of normal LCI, across a 
wide age range. The normal range of FEF25-75 in the same control subjects ranged 
from 83 to 174% predicted, and the normal ranges are poorly defined in different 
age groups (Timonen, Randell et al. 1997). LCI thus appears to be a potentially 
more sensitive measure than FEF25-75 with the added advantages of better 
reproducibility and more well defined normal range. Further work is required to 
more clearly define the advantages of each measurement in comparison to the other. 
  
147 
In summary, it has been demonstrated that a robust and compact gas analyser 
can be used to measure LCI and that this can be applied in a multi-centre setting. In 
adults with mild CF lung disease, LCI is a more sensitive indicator of lung 
pathology. This is likely to be particularly important as improved genotyping 
permits the identification of subjects with milder mutations. It also offers the 
possibility of measuring abnormality, and hence improvement, in subjects with 
milder CF lung disease in clinical trials of gene therapy. 
The following chapters include the longitudinal assessment of LCI over the 
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Chapter 4 - Change in physiological, functional and 
structural assessments of CF lung function over the 
course of an exacerbation. 
 
Introduction 
As has been discussed in Chapter 1, a major challenge of the cystic fibrosis (CF) 
gene therapy programme has been how to measure the clinical response to treatment. 
Ideally this would involve demonstrating an improvement in either lung function, survival 
or another clinically relevant outcome (e.g. exacerbation rate). With improvements in the 
standard medical management of CF have come great advances in patient wellbeing. The 
falling rate of decline in lung function and exacerbation rate, and improvements in 
survival, mean that these parameters are no longer appropriate end points for the majority 
of studies (Davis, Byard et al. 1997). This problem is exacerbated in the context of gene 
therapy studies, where there is a particular interest in delivering gene therapy to those 
with reasonably well preserved lung function in order to maximise transfection efficiency. 
Almost by definition, this subgroup of the CF population tends to have least in terms of 
symptoms and annual lung function decline. 
Surrogate clinical endpoints can be used to measure improvement in clinical status 
in trials, and the important features of any new trial endpoints are summarised in Table 
4.1. The preceding chapters have dealt with the practicalities of performing MBW 
measurements, and with the sensitivity and reproducibility of LCI. There are at least two 
further aspects of LCI measurements however that have not yet been addressed, and 
which are essential if the measurement is to find a role in the assessment of lung function 
after gene therapy. Firstly, LCI must respond in some way to an intervention known to 
improve the underlying pathology. For gene therapy, this ideally means that LCI would 
respond to an intervention, in a stable population, that is known to improve survival or 
quality of life. In CF, there are no such “gold standard” interventions that are not already 
widely adopted, and it would be unethical to withhold them for these 
 




Non-invasive and simple for the patient to perform 
Devoid of harmful or unpleasant side-effects 
Practical, with standardized equipment and interpretation 
Reproducible (with minimal error and variability) 
Sensitive 
Biologically relevant 
Stable, or behaves predictably, over time 
Changes with disease status 
 
Table 4.1: Features of biomarkers for use as endpoints in therapeutic trials in cystic 
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purposes. An alternative to this is to investigate how LCI, and other biomarkers, change in 
unwell patients as they are treated for an exacerbation. This is clearly not entirely 
analogous to the situation in which gene therapy is used, but provides an opportunity to 
investigate how biomarkers improve with therapy, how different assays correlate with 
other, and also provides data that can help to inform power calculations for the use of 
assays as trial endpoints. Biomarkers with relevance to disease status in CF would be 
expected to improve in the majority of patients. On the other hand, biomarkers that are 
poorly reproducible or do not change with treatment of an exacerbation, are less likely to 
be appropriate gene therapy trial endpoints.  
The second important aspect of this investigation is that it allows the UK CF Gene 
Therapy Consortium (UKCFGT) to assess the feasibility of performing MBW 
measurements in multiple trial centres. These are all important issues that have not been 
addressed previously for MBW tests.  
In this study a number of assays, including the best understood biomarkers from the 
literature, as well as novel markers developed in-house, have been brought together. The 
study was initiated by the UKCFGT consortium and involved recruitment and assessment 
of patients at three sites: the Western General Hospital and the Royal Hospital for Sick 
Children in Edinburgh, and the Royal Brompton Hospital in London. This chapter only 
includes the assessments performed in Edinburgh, and only includes established markers 
of function or inflammation. Although more samples were collected than those presented 
here, they are the subject of other researchers’ investigations. The assays that will be 
discussed in this chapter are summarised in Table 4.2. 
 
The aims of this chapter are to: 
1. Assess the change in LCI with treatment of an exacerbation 
2. Explore relevant correlations between the different markers of disease activity, 
including LCI, spirometry, symptoms, inflammation and HRCT appearances of the lung. 
 
Although not addressed specifically in this analysis, this study has also permitted 
assessment of the practicality of performing these assays in a multi-centre study. 
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• Sensitive  
• Reproducible 






• Provides information 
about  lung structure 
• Radiation exposure 
• Cost  
Haematology and 
biochemistry, incl. CRP 
• Simple 
• Widely available 





• Easy for patient if 
expectorating 
• Biological relevance 
(airway inflammation) 
• One of many sputum 
cytokines, with complex 
interactions 
• Reproducibility 
• Not all patients produce 
sputum easily 




Sputum differential and 
total cell counts 





Table 4.2: Assays selected for inclusion. 
1: Aurora, Gustafsson et al. 2004, Horsley, Gustafsson et al. 2008 3: Nasr, Gordon et al. 
2006. 4: Aziz, Davies et al. 2007. 5: Mayer-Hamblett, Aitken et al. 2007. 6: Sagel, Chmiel 
et al. 2007. 7: Downey, Brockbank et al. 2007. 




Twenty one patients were recruited in Edinburgh; 19 of these were from the Scottish 
Adult CF Service, based at the Western General Hospital, and 2 patients were recruited 
from the Edinburgh Paediatric CF Service, based at the Department for Respiratory and 
Sleep medicine at the Royal Hospital for Sick Children.  
Patients were recruited when they were started on intravenous (i.v.) antibiotic 
therapy for treatment of an exacerbation, as assessed by their usual clinical team and 
based upon a combination of symptoms and spirometry. Subjects over 10 yrs old, both 
inpatients and those receiving home i.v. therapy, were eligible. Patients were excluded if 
their FEV1 at the time of exacerbation was less than 30% predicted. Additional exclusions 
were patients who were on systemic corticosteroids at study entry or in the preceding 




Subjects completed a number of non-invasive assessments of disease activity in a 
fixed order at three separate time points (see Figure 4.1):  
 
1- Within 48 hours of commencing iv antibiotics for a pulmonary exacerbation. 
2 - Within 5 days of completion of antibiotic therapy  
3- On full recovery, originally intended to be between 2 and 8 weeks later, but requiring 
the patient to have been off treatment for at least 2 weeks.  
 




Figure 4.1: Summary of study flow 
CF patient with a clinically defined 























•As above but omitting 
HRCT chest 
Within 72hrs 
Standard clinical management with  
iv antibiotics for 14-28d 
Clinically stable for  
at least 2 more weeks 
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 In addition, high resolution CT scan of the chest was performed at visit 1 and 2, but 
not at visit 3. The order of the CT scan was not fixed, so some patients had this prior to 
LCI and some afterwards, though all on the same day. Details of the individual 
assessments are given below. 
This study was approved by the Lothian Research and Ethics Committee. All 
subjects provided informed consent. For the two subjects recruited from the Paediatric CF 
service, consent was obtained from parents, and the children provided assent. 
 
Clinical observations 
Pulse rate, blood pressure, respiratory rate, pulse oximetry, body temperature and 
weight were recorded at every visit. 
 
Lung Clearance Index 
Multiple breath washout was performed as previously described in Chapter 3, using 
the modified Innocor
 
gas analyser and 0.2% sulphur hexafluoride (SF6) as the tracer gas.  
 
Spirometry 
Spirometry was measured according to American Thoracic Society / European 
Respiratory Society guidelines (Miller, Hankinson et al. 2005) using an Easyone 
spirometer (ndd Medizintechnik AG, Zurich, Switzerland). Predicted values for FEV1 and 
mid-expiratory flows are those provided by the European Community for Coal and Steel 
(adults≥17 years) (Quanjer, Tammeling et al. 1993) and Rosenthal et al. (children≤16 
years) (Rosenthal, Bain et al. 1993). Three reproducible measures were required for a 
satisfactory result. The best of the three manoeuvres, defined as the result with the 
greatest sum of FEV1 and FVC, was recorded. Measurements were performed without a 
noseclip. 
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Sputum collection and processing 
Freshly expectorated sputum was stored on ice for a maximum of two hours and 
processed using a method modified from that described by Pavord et al. (Pavord, 
Pizzichini et al. 1997). Whole sputum was transferred to a sterile Petri dish and the 
sputum plugs separated out into a pre-weighed Falcon tube. The sputum plugs were 
treated with freshly
 
prepared 0.1% dithiotreitol (Sigma-Aldrich, Dorset, UK) in 
Dulbecco’s phosphate buffered saline (D-PBS), at a ratio of 4ml:1g. Each aliquot
 
was then 




 After dilution in an equal volume of 
D-PBS, the sample was filtered through pre-moistened 48µm nylon gauze (Seva, Bury, 
UK) to remove solid debris. The sputum sol phase was obtained by centrifugation 
(1200rpm for 10 minutes at 4
o




The cell pellet was re-suspended in 0.9% D-PBS. Total cell counts were obtained by 
counting cells in an improved Neubauer counting chamber. For differential cell counts, 
four spots (25, 50, 75 and 100µl) were pipetted onto glass slides for cytology. The slides 
were spun at 400 rpm for 5 minutes to draw the cells onto the slides. These were then 
fixed and stained using a commercially available kit based on May-Grünewald Giemsa 
stain (Surgipath Industries, Richmond, IL, USA). Cell differentials were obtained by 
inspecting the slide with the optimal cell density at a magnification of 100 times, under 
oil. 300-500 cells were identified and counted from each slide from two different regions, 
and the final percentage is the mean of these two measurements. 
The majority of patients were able to expectorate sputum spontaneously. However, 
when this was not possible, sputum was obtained by hypertonic-saline induction. Subjects 
were pre-treated with 2.5mg nebulised salbutamol. After a wait of 20 minutes, spirometry 
was checked, and the patient was then administered 3% saline via an ultrasonic nebuliser 
(Devilbiss, Sunrise Medical, CA, USA). After four minutes of nebulisation, subjects were 
asked to blow their nose and rinse their mouth with water before attempting to 
expectorate. This was repeated to a maximum of three saline nebulisations. Subjects 
repeated spirometry after every saline nebulisation to ensure no adverse effect of the 
procedure. Each sputum sample was collected in a fresh, pre-chilled tube, but all samples 
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were pooled for processing, which was identical to the procedure described for 
spontaneous sputum.  
 
Venous blood sampling 
Venous blood was collected in standard clinical blood collection tubes (Monovettes, 
Starstedt AG, Numbrecht, Germany) and analysed at the local clinical laboratories for full 
blood count and C-Reactive Protein (CRP). For data analysis, CRP samples where the 
level is below the lower limit of detection (3mg/ml) were given the value of 1mg/ml. 
 
Symptom score 
A symptom score sheet was developed to allow the patients to grade their symptoms 
in response to seven questions relating to different aspects of respiratory function (Figure 
4.2). Subjects were required to tick one of 5 boxes, scored from -2 (much worse than 
usual) to +2 (much better than usual). The possible range of scores is therefore from -14 
to +14, with no change from usual giving a score of 0.  
Two additional questions, on sputum colour and change in colour hue (question 
numbers 6 and 7), were subsequently excluded because of difficulty in scoring these 
objectively. 
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 Figure 4.2: Symptom score sheet. Responses were scored from -2 to +2, with a score of 
0 representing no change from usual. Questions 6 and 7 were not included in analysis due 
to difficulty in scoring objectively, so possible scores range from -14 to +14. 
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Computed Tomography 
Each CT examination consisted of two scans; a volumetric high resolution CT at 
inspiration and interspaced high resolution CT at expiration. These were performed on a 
Siemens 64 slice multi-detector scanner (Siemens AG, Erlangemn, Germany) or a 
Siemens Sensation 16 slice scanner (Royal Hospital for Sick Children and Western 
General Hospital respectively). The volumetric CT comprised contiguous thin-sections (1 
mm) through the entire volume of the lungs, 0.5s rotation time, 64 x 0.6mm collimation, 
pitch 1.4. The interspaced CT was obtained at end expiration with 1mm sections every 
10mm, 0.36s rotation time, 2 x 1mm collimation. In order to limit effective dose, 100 kVp 
was used for both scans. mAs values were varied according to the weight of each patient: 
1mAs per kg for patients up to 30kg, 30mAs for patients between 30 and 50 kg, 35 mAs 
for patients above 50 kg and 50 mAs for patients weighing more than 70 kg. No 
intravenous contrast was used.  
 
CT analysis 
Each set of CT images were saved onto a separate compact disc, with the only 
identifier on the disc being a four digit randomly generated number. A copy of the 
complete set of CTs was sent to the Royal Brompton Hospital where the images were read 
by two experienced radiologists blinded to the patient details. All the images were 
reviewed directly from workstations. The CTs were scored for eight independent features 
according to a scoring system devised at the Royal Brompton Hospital by Professor 
Hansell (Table 4.3). A semi-quantitative graded scoring system was used for extent and 
severity of bronchiectasis, bronchial wall thickness, small and large mucus plugging. Air 
trapping, consolidation and ground glass opacification were scored as a percentage to the 
nearest 5%. Each lobe of 6 was assessed: right upper, middle and lower lobes; left upper 
and lower lobes and lingula. The final score represents the sum of the individual lobe 
scores for that feature from both radiologists, i.e. 12 x the maximum score possible for an 
individual lobe. Unlike other scoring systems, the different features are only intended to 
be considered independently and there is no global CT score which summarises all the 
findings in a single number (Brody, Klein et al. 2004). 
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0 = none 
1 = <25% lobe involved 
2 = 25-50% lobe involved 
3 = 51-75% lobe involved 




0 = absent 
1 = trivial dilatation 
2 = >1 but <2 x diameter of accompanying vessel 
3 = 2-3 x vessel diameter 




0 = absent 
1 = trivial wall thickness 
2 = up to 0.5x diameter of adjacent vessel 
3 = > 0.5 to 1x  vessel diameter 
4 = > 1 to 2x vessel diameter 




0 = absent 
1 = mild 













Table 4.3: Summary of CT scoring protocol. Each lobe (of 6) was scored independently 
and the maximum possible score represents the sum of all the lobe scores from two 
radiologists (i.e. 12 x the maximum single lobe score). 
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Sputum IL-8 ELISA assay  
IL-8 assays were performed using a commercial kit (IL-8 Easia Kit, Biosource, 
Invitrogen, CA, USA). For sputum assays, a modification was made to the standard 
diluents to compensate for the constituents of diluted samples and standards and to 




Data were analysed using Prism (GraphPad Software Inc, CA, USA). Normal 
distribution was assessed using the D’Agostino and Pearson omnibus normality test. 
Results are quoted as mean (SD) or median (interquartile range) unless otherwise stated.  
For comparison of variables at different visits, paired t-test was used for parametric 
data and Wilcoxon matched pairs test was used for non-parametric data. Comparisons 
between multiple groups were performed using a one way ANOVA (parametric data) or 
Kruskal Wallis (non-parametric). Correlations were assessed using the Pearson correlation 
coefficient (parametric data) or Spearman R (non-parametric). 
A p value of below 0.05 was considered as statistically significant. 
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Results 
Twenty one patients were recruited in Edinburgh. Seventeen of these (81%) 
completed three visits, 2 (9%) completed 2 visits and 2 subjects only completed a single 
visit. Visit 2 data from one of the patients who only attended twice were subsequently 
excluded because of an excessive interval between the end of antibiotic therapy and the 
date of the second assessment (8 days). One patient was excluded because he was 
commenced on oral corticosteroids following visit 1. Paired pre- and post- antibiotic data 
are therefore available on 17 subjects, 16 of whom also completed a third assessment. 
Demographic data on these 17 subjects are summarised in Table 4.4. 
Visit 1 (start of exacerbation) was performed within 1 day of starting antibiotics for 
all but two subjects (range 0-3 days) (see Figure 4.3). Visit 2 (end of treatment) was 
performed a median of 1 days after the end of treatment (range -7 to 5). A single subject 
had the visit 2 assessment performed before her clinical review, at which time the 
decision was taken was to extend her treatment to a third week. These data were included 
however because the patient had already received two weeks of treatment and had 
completed the assessment, including CT, before the decision to extend treatment was 
made. Visit 3 (stable) was performed a median of 20 days after visit 2 (range 14-139). 
Mean duration of antibiotic treatment was 16 days. 12 subjects (71%) received 2 
weeks of treatment (13-16 days) and the other 5 subjects all received 3 weeks (19-22 
days). 
   
163 













Days from change in therapy
to assessment
















Figure 4.3: Time between assessment and start of antibiotics (red bars) or end of 
antibiotics (green). The dotted line represents day 0 (the day treatment was commenced or 
completed). A single subject had her visit 2 assessment prior to a clinical review which 
concluded that she required an additional 7 days of treatment to achieve a maximal 
response. These data have been included in the analysis. 
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Clinical characteristics of study population 
These data are summarised in Table 4.4. The majority of subjects (11/17; 65%) had 
an FEV1 at the first visit of between 40 and 60% predicted. The mean (SD) fall in FEV1 at 
visit 1 was 12.4% over baseline (defined as the best FEV1 in the last 6 months). Although 
the need for iv antibiotics was determined by the patient’s consulting clinician, all patients 
had a Fuchs score (Fuchs, Borowitz et al. 1994) for definition of pulmonary exacerbation 
of greater than or equal to 4 at visit 1, with the exception of a single subject who scored 
only 1. Median Fuchs score was 5 (range 1-8).  
Of the 17 subjects with paired visit data, 8 were known to have chronic colonisation 
with Pseudomonas aeruginosa, 5 with Burkholderia cepacia, and 5 with 
Stenotrophomonas maltophilia (see Table 4.4). 8 subjects were on DNase, 9 were on 
nebulised antibiotics (colomycin, tobramycin and gentamicin) and 8 were on regular 
azithromycin. 11 subjects were on inhaled corticosteroids or combined long-acting b-
agonists and inhaled corticosteroids.  
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 Subjects with paired 
assessments pre and post 
antibiotic therapy 
Subjects recruited into 
study but excluded or with 
a single assessment only 
n 17 4 
Mean age (SD) 
[range] 
21.8 (6.8) 
[11 - 40] 
22.3 (5.3) 
[18 – 29] 
Mean FEV1 % predicted at 
first visit [range] 
57.0 (10.9) 
[39.0 – 86.8] 
48.4 (10.6) 
[ 40.4 – 64.0] 
Mean best FEV1 % predicted 
in last 6 months [range] 
69.4 
[55.5 – 104.0] 
67.9 
[50.5 – 87.3] 
Male / Female 11 / 6 1 / 3 
Number (%) DF 
homozygotes 
14 (82) 0 
N (%) with pancreatic 
insufficiency 
15 (88) 3 (75) 
N (%) with diabetes mellitus 6 (35) 1 (25) 
N (%) with chronic airway 
colonisation by Ps. aeruginosa  
8 (47) 0 
N (%) with chronic colonisation 
by B. cepacia 
5 (29) 2 (50) 
 
Table 4.4: Clinical and demographic features of cystic fibrosis patients with and without 
paired assessments before and after antibiotic therapy for a pulmonary exacerbation. 
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Response of individual assays to treatment of an exacerbation 
1. Symptom score 
At the start of treatment, patients felt worse than normal with a mean (SD) symptom 
score of -4.9 (3.8) (Table 4.5). A single subject scored +5 on his symptom score, but this 
is likely to have been completed erroneously since he also indicated deterioration in the 
same symptoms when questioned for completion of Fuchs scoring. Since this was only 
recognised some time after the event, it has not been possible to retrospectively re-score 
the symptom score, and this value has been retained in the analysis. 
Mean symptom score improved to 3.3 (4.3) at the end of treatment (p<0.0001 
compared to visit 1, paired t-test) (Figure 4.4).  Mean symptom score at visit 3 fell to 1.1 
(5.3), this was still significantly greater than visit 1 (p=0.001). Visit 3 symptom score was 
not significantly different from a theoretical mean of 0 (p=0.41, one sample t test). Since a 
score of zero means no change over usual symptoms, this indicates that the patients were, 
on average, stable. The range of symptom scores however was greater than either of the 
preceding assessments. As might be expected, the mean score at visit 1 was significantly 
lower than usual baseline (score of zero) (p<0.0001), but the score at visit 2 was greater 
than baseline (p=0.006). This indicates that the patients’ symptoms had, on average, 
improved to a level that was better than their usual baseline after 2 weeks of antibiotics. 
 
2. Clinical observations 
The majority of clinical observations did not change significantly over the course of 
antibiotic treatment (see Table 4.5). Systolic BP was significantly higher at visit 3 
compared to visit 1 (124.7 vs 118.5 mmHg, p=0.004), and diastolic BP was significantly 
lower at visit 2 compared to visit 1 (71.4 vs 74.4 mmHg, p=0.033). The magnitude of 
changes was modest and the significance of these observations is unclear. There was a fall 
in respiratory rate between visits 1 and 2 which just failed to achieve statistical 
significance (22.1 breaths/min at visit 1 compare to 19.3 breaths/min at visit 2, p=0.052) 
(Figure 4.5). A single subject recorded a respiratory rate of 33 at visit 2. This was an 11 yr 
old male, whose other clinical observations had not deteriorated. There were no 
significant changes in weight, temperature, pulse rate, or oxygen saturations between 
visits. 
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 Visit 1 Visit 2 Visit 3 
n 17 17 16 
Symptom score  
[range] 
-4.9 (3.8) 
[-10 to 5] 
3.3 (4.3)*** 
[-5 to 9] 
1.1 (5.3)** 
















































Table 4.5: Change in clinical variables with antibiotic treatment (visit 1 to 2) and at 
stability (visit 3). Values are mean (SD). 
*p<0.05 compared to visit 1 
**p<0.005 compared to visit 1 
***p<0.0001 compared to visit 1 
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Figure 4.4: Change in symptom score with treatment of an exacerbation. Each set of 
points joined by a single grey line represents a single patient. A score of zero represents 
usual baseline symptoms. Horizontal red bars represent group mean. p values refer to 
significance of change in mean symptom score at the different time points (paired t-test).  
 
 





























Figure 4.5: Change in respiratory rate between visits. Each set of points joined by a 
single grey line represents a single patient. Horizontal red bars represent group mean. p 
values refer to significance of change in mean symptom score at the different time points 
(paired t-test). 
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3. Spirometry 
FEV1 improved in 12 (71%) subjects between visits 1 and 2 (Figure 4.6). In 4 
subjects, FEV1 increased by over 30% between the first two visits. Between the same two 
assessments, mean FEV1 increased significantly from 2.13 to 2.37 L/s (p=0.02, paired t-
test) (Table 4.6). There was a further increase in mean FEV1 at visit 3 to 2.40 L/s 
(p=0.003 vs visit 1, paired t-test). This represents a mean improvement of 240ml, or 
11.1%, with antibiotics. When expressed as percent predicted, FEV1 increased from 57.0 
to 63.0 % predicted between visits 1 and 2 (p=0.018).  
FVC also increased significantly between visits 1 and 2, from a mean (SD) of 3.21 
(0.97) L to 3.49 (1.12) L, p=0.027 (paired t-test) (Figure 4.7). There was a further small 
increase in mean FVC at visit 3 to 3.57 (1.11) L (p=0.007 vs visit 1, ns vs visit 2). The 
change between visits 1 and 2 was skewed by a single outlier, but remained statistically 
significant even if this subject was excluded. 
FEF25-75 percent predicted data were only analysed for flow volume loops from adult 
subjects, since the normal range data are only applicable above the age of 18 yrs (Quanjer, 
Tammeling et al. 1993). There was a non-significant improvement in mean FEF25-75 % 
predicted between visits 1 and 2, from 28.3 to 35.7% predicted, p=0.096 (paired t-test) 
(see Figure 4.8). 
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 Visit 1 Visit 2 Visit 3 
FEV1 (L) 
2.13 (0.58) 
[1.13 – 3.33] 
2.37 (0.73)* 
[0.90 - 3.99] 
2.40 (0.71)** 
[1.08 – 4.03] 
FEV1 % predicted 
57.0 (10.87) 
[39.0 – 86.8] 
63.0 (14.04)* 
[39.3 – 91.5] 
64.7 (12.57)** 
[47.2 – 92.9] 
FEF25-75 % predicted 
28.3 (10.20) 
[15.8 – 50.2] 
35.7 (16.6) 
[18.6 – 68.5] 
33.4 (14.08) 
[15.8 – 58.1] 
FVC (L) 
3.21 (0.966) 
[1.64 – 4.95) 
3.49 (1.118)* 
[1.56 – 6.49] 
3.57 (1.113)* 
[1.69 – 6.37] 
Lung Clearance Index 
14.0 (2.52) 
[11.2 – 19.6] 
13.1 (2.47)* 
[9.7 – 17.1] 
13.3 (2.83) 




[1.55 – 3.94] 
2.64 (0.67) 
[1.74 – 3.84] 
2.50 (0.70) 
[1.64 – 3.89] 
 
Table 4.6: Effect of antibiotic treatment on lung function parameters. Data are presented 
as mean (standard deviation) and [range]. 
*p<0.05 vs visit 1 
**p<0.005 vs visit 1 
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Figure 4.6: Change in FEV1 with treatment of an exacerbation. Each set of points joined 
by a single red line represents a single patient. p values refer to significance of change in 
mean FEV1 at the different time points (paired t-test). 
 






























Figure 4.7: Change in forced vital capacity (FVC) with treatment of an exacerbation. 
Each set of points joined by a single red line represents a single patient. p values refer to 
significance of change in mean FVC at the different time points (paired t-test). 
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Figure 4.8: Change in FEF25-75 with treatment of an exacerbation. 
Each set of points joined by a single red line represents a single patient. p values refer to 
significance of change in mean FEF25-75 at the different time points (paired t-test). 
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4. Lung Clearance Index 
LCI improved in 12 (71%) of subjects between visits 1 and 2, see Figure 4.9. Mean 
(SD) LCI improved from 14.0 (2.52) to 13.1 (2.47) between the same two visits, 
p=0.0401 (paired t-test). This represents a mean improvement in LCI of just over 0.8, or 
5.9% over visit 1. It can also be seen from Figure 4.9  that, even at visit 2 when the 
patients were symptomatically at their best, the LCI in all subjects was considerably 
greater than the upper limit of normal (7.45, see Chapter 3). This is in contrast with the 
FEV1, which was greater than 80% predicted in 3 subjects (18%) at visits 2 and 3.  
Between visits 2 and 3 there was less consistency in the change in LCI, with 
improvement in 9 of 16 subjects, and a greater spread of values. Mean LCI was greater 
(indicating a deterioration in lung gas mixing) at visit 3 than visit 2, although this 
difference was not statistically significant. This is similar to the change seen in FEF25-75 
but is in contrast to FEV1 and FVC, which continued to improve between visits 2 and 3. 
  
5. Functional Residual Capacity 
MBW measurements also generate a measure of FRC. This is the end tidal lung 
volume that is ventilated by quiet tidal breathing, and therefore does not include gas from 
regions of the lung that are not ventilated during tidal breathing. There was no significant 
change in mean FRC between any of the visits. Change in FRC was not correlated with 
disease severity, as assessed by either LCI or FEV1 percent predicted. Mean FRC was 86 
percent predicted at visit 1 and 91 percent predicted at visit 2, with a range over the three 
assessments of 60 to 117 percent predicted. 
The relationship between the FRC and LCI change over the course of antibiotic 
treatment is represented in Figure 4.11. This shows individual paired FRC and LCI 
measurements at visit 1 (red) and 2 (green) linked by a solid line. It can be seen that there 
is considerable heterogeneity of change in the individual markers, both in terms of 
magnitude and direction of change. In addition to this, there is heterogeneity of 
correlation between the two variables. If a consistent relationship existed between the two 
variables, then the lines would show a clear tendency to be linked in the same direction, 
e.g. if LCI improved (fell) as FRC increased the lines would point in the direction from 
top left to bottom right. The reasons why this might not be the case are covered in more 
detail in the discussion. 
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Figure 4.9: Change in LCI with treatment of an exacerbation. Each set of points joined by 
a single red line represents a single patient. p values refer to significance of change in 
mean LCI at the different time points (paired t-test). The upper limit of normal LCI for 
healthy controls is shown by the dotted line. 
 
















Figure 4.10: Change in FRC with treatment of an exacerbation. Each set of points joined 
by a single red line represents a single patient. p values refer to significance of change in 
mean FRC at the different time points (paired t-test) 
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Figure 4.11: Paired mean functional residual capacity (FRC) and mean lung clearance 
index (LCI), derived from multiple breath washouts, for cystic fibrosis patients treated for 
an exacerbation. Each pair of points represents a single patient, with paired measurements 
at visit 1 (pre treatment) represented by a red diamond, and visit 2 (post treatment) by a 
green diamond linked by a solid line. There is considerable heterogeneity of individual 
response in terms of both magnitude and direction of change in the individual variables, 
as well as correlation between the two. 
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Correlation between different measures of lung function 
In cross sectional analysis, there were significant correlations between LCI and both 
FEF25-75 percent predicted and FEV1 percent predicted at all three time points (Figure 
4.12). For FEV1, the Pearson r values ranged from -0.53 (p=0.028) at visit 1 to -0.59 
(p=0.013) at visit 2. For FEF25-75, the Pearson r values ranged from -0.62 (p=0.019) at 
visit 1 to -0.86 (p<0.0001) at visit 3. There was no correlation between LCI and FVC 
percent predicted at any time point.  
FEV1 percent predicted correlated strongly with both of the other two spirometric 
indices. Pearson r values for correlation between FEV1 % predicted and FVC % predicted 
ranged from 0.83 to 0.82, p=0.0003 to <0.0001. For correlation between FEV1 percent 
predicted and FEF25-75 percent predicted, Pearson r values ranged from 0.70 (p=0.0052) to 
0.86 (p<0.0001).  
There was a significant correlation between percent change in LCI and percent 
change in FEV1 (Figure 4.13), Pearson r=-0.59, p=0.012. There was also a correlation 
between percent change in LCI and percent change in FEF25-75 (Figure 4.14),  
Pearson r=-0.70, p=0.008. Despite these correlations, individual values showed wide 
discrepancy – some with large changes in LCI but no change in spirometry, and others 
with the opposite. There was no correlation between percent change in LCI and percent 
change in FVC (Figure 4.15). 
Overall there was a mean improvement in LCI of 5.6%, compared to a mean 
improvement in FEV1 of 11.1%, in FVC of 9.4%, and in FEF25-75 of 26.0%.   
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Visit 1

















































Figure 4.12: Cross sectional correlations between LCI and spirometry at the 3 visits. 
FEV1 (red diamonds), FVC (green open diamonds) and FEF25-75 (blue circles) are all 
expressed as % predicted. Significant correlations are represented by solid lines in the 
corresponding colour. 
  Visit 1: start of exacerbation 




















   
178 





























Figure 4.13: Correlation between percent change in FEV1 and percent change in LCI. An 
improvement in LCI is represented as a negative change in LCI. Each point represents a 
single subject with paired LCI and spirometry before and after antibiotic therapy for an 

















Figure 4.14: Correlation between percent change in FEF25-75 and percent change in LCI. 
Each point represents a single subject with paired LCI and spirometry before and after 
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Figure 4.15: Correlation between percent change in FVC and percent change in LCI. 
Each point represents a single subject with paired LCI and spirometry before and after 
antibiotic therapy for an exacerbation. There was no significant correlation between 
percent change in the two variables. 
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6. Computed Tomography 
Of the 21 patients recruited, 16 (76%) had HRCT performed at visit 1. 12 of these 
also had a CT performed after antibiotic treatment; two subjects only attended for a single 
visit, one subject missed his CT appointment but completed the remaining assessments, 
and one subject was excluded because he was commenced on oral steroids. Because the 
CT data are intended to be paired, these four CT scans have not been scored, and have 
therefore not been included in this analysis. Subjects who did not receive a CT at visit 1 
also did not receive a CT at visit 2, since the value of the assessment was felt to be 
principally in obtaining paired measurements. Three subjects did not undergo CT 
scanning at visit 1 because they were recruited before the radiology department had 
confirmed the protocols, and two subjects did not undergo CT scanning because of time 
constraints. A single subject with paired CT scans did not receive an expiratory CT scan 
at visit 2, so air trapping scores for this visit are not available. Lung function assessments 
were completed on all 12 subjects with paired CTs. 
Table 4.7 and Figure 4.16 summarise the individual CT scores at both visits for the 
12 subjects with paired CT scans. There was a fall in all 8 score components after 
antibiotics. Statistically significant improvements were seen in the scores for: extent of 
bronchiectasis (38.3 after treatment vs 40.8 at visit 1, p=0.044); small mucus plugs (15.8 
vs 18.3, p=0.004); and large mucus plugs (14.5 vs 16.8, p=0.022). There was no change in 
the severity of bronchiectasis score. Consolidated lung and ground glass appearances were 
present in only a minority of subjects overall. There was a trend to improvements in the 
wall thickness and air trapping scores.  
The changes seen at CT are illustrated in Figures 4.17-4.19 using representative CT 
images from a single subject, EdTr013. This subject was an 18 year old female who was 
significantly unwell at the start of treatment, with an elevated CRP (249mg/ml) and a fall 
in FEV1 of 37% from her best recorded value in the last 6 months. With treatment, she 
showed improvement in all of these variables (FEV1 improved by 25% from 1.52 to 1.90) 
and in LCI (improvement of 12% from 11.6 to 10.2). This patient showed improvement in 
all CT scores except extent and severity of bronchiectasis. Large mucus plugging the left 
lower lobe is shown on HRCT in Figure 4.17. Following over two weeks of antibiotics 
and physiotherapy, this has largely cleared from the airway. Small mucus plugs, seen as 
nodular irregularities in small airways made visible by inflammation and mucus, are 
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illustrated in Figure 4.18. Finally, gas trapping is illustrated in Figure 4.19. This occurs 
when inflamed small airways collapse on expiration, leading to hyperinflation and 
decreased attenuation of the distal lung. It is seen as a mosaic attenuation pattern on 
expiratory CT (Hansell 2001). 
 







Visit 1 Visit 2 
Difference 
(95% CI) 





[31 – 48] 
38.3 (8.2) 
[21 – 48] 
2.0 






[21 – 45] 
30.9 (8.3) 
[14 – 42] 
0.1 
(-2.4 – 2.6) 
0.942 
Wall thickness 60 
31.1 (7.2) 
[21 – 43] 
27.5 (6.5) 
[19 – 38] 
3.6 






[12 – 24] 
15.8 (3.9) 
[10 – 24] 
2.5 






[8 – 24] 
14.5 (5.3) 
[5 – 21] 
2.3 
(0.4 – 4.3) 
0.0217 
Air trapping 1200 
492.3 (230.7) 
[50 – 745] 
436.8 (186.7) 
[210 – 725] 
55.5 




Median (IQ range) 
1200 
12.5  
 (5 – 15) 
0 
 (0 - 7.5) 
-12.5 0.129* 
Ground glass 
Median (IQ range) 
1200 
0 
 (0 – 12.5) 
0 
 (0 – 2.5) 
0 0.375* 
 
Table 4.7: Effect of antibiotic treatment on scores for eight different abnormalities seen 
on HRCT. The details of the score are described in the text. Values are expressed as mean 
(SD) [range] unless otherwise stated. p values refer to comparison of group means from 
before and after treatment (visits 1 and 2 respectively), calculated using paired t-tests or 
Wilcoxon signed rank pairs (indicated with an asterisk: * ). p values less than 0.05 are 
highlighted in bold. 
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Figure 4.16: Effect of antibiotic therapy on lung CT scores. Each set of points represents 
a single CF patient with paired assessments before (red circle) and after (blue circle) 
antibiotic therapy for an exacerbation. Group means are shown by the horizontal red line 
and p values refer to comparison of group means before and after treatment (p >0.05 are 
not shown). Horizontal dotted grey lines in upper panel indicate maximum possible score 
for that feature. The scores for consolidation and ground glass appearances (lower panel) 
were zero at both visits in the majority of subjects. Maximum possible score for all 
features in lower panel was 1200. 
 

























Figure 4.17: Large mucus plugs seen on HRCT in a bronchus in the left lower lobe 
(circled) of an 18 year old female with CF at the start of an exacerbation (top) and after 19 
days of intravenous antibiotics. Following treatment, the airway has been largely cleared 
of the obstructing mucus. For this subject, overall mucus plug score improved from 20 to 
11. 
Before treatment 
After 19d antibiotics 


























Figure 4.18: Small mucus plugs seen on HRCT in the lung of the same subject described 
in Figure 4.17. Small plugs are seen as nodular irregularities in the left upper lobe 
(circled); these represent small airways made visible by plugging with mucus and 
inflammatory secretions. In this subject, the small mucus plugs score improved from 22 to 
18. 
After 19d antibiotics 
Before treatment 



























Figure 4.19: Expiratory CT scan showing air trapping in the lungs of the same CF patient 
as shown in Figures 4.17 and 4.18. A mosaic attenuation pattern is seen before treatment, 
with the dark areas representing regions of gas trapping (two of these have been 
highlighted, but there is additional gas trapping anteriorly bilaterally). After treatment, the 
dark areas are no longer visible. In this subject the air trapping score improved from 680 
to 430.  
Before treatment 
After 19d antibiotics 
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 Correlation of functional and structural assessment 
Correlations between the structural measurements derived from CT scores and the 
physiological assessments can be assessed in two ways. The first method is to look at 
cross sectional comparisons, with each of the two visits considered separately, and the 
second method is to look at how the changes in different variables over the course of 
treatment correlate with each other. Both of these will be reviewed. 
Table 4.8 shows the cross sectional correlations between the different CT features 
and both LCI and FEV1, for both visits. At visit 1, LCI only showed a weak correlation 
with a single feature - extent of bronchiectasis (Pearson r=0.62, p=0.03). At visit 2 
however, there were significant correlations between LCI and wall thickness score 
(r=0.73, p=0.008), large mucus plugs (r=0.64, p=0.02) and air trapping (r=0.68, p=0.02). 
These are illustrated in Figure 4.20. 
FEV1 percent predicted showed significant correlations at visit 1 with three features: 
extent of bronchiectasis (Pearson r=-0.65, p=0.02), small mucus plugs (r=-0.70, p=0.01) 
and large mucus plugs (r=-0.60, p=0.04). At visit 2, FEV1 percent predicted showed 
significant correlations with 5 of the CT features: extent of bronchiectasis (r=-0.85, 
p=0.0005), severity of bronchiectasis (r=-0.70, p=0.01), wall thickness (r=-0.68, p=0.02), 
small mucus plugs (r=-0.61, p=0.03), and large mucus plugs (r=-0.75, p=0.005). See 
Figure 4.21. 
Neither LCI nor FEV1 showed any correlation with the scores for percent 
consolidated lung or ground glass shadowing.  
When the absolute and percent changes in lung physiology were compared to the 
absolute and percent changes in the CT scores, there were almost no significant 
correlations. The single exception was a correlation between percent change in FEV1 and 
percent change in air trapping score (Pearson r=-0.61, p=0.045). FEV1 did not correlate 
with air trapping in cross sectional analysis, and this positive correlation was distorted by 
a single outlier with a 400% increase in air trapping score at visit 2 (Figure 4.24). Graphs 
of percent change in the CT variables which showed change with antibiotic therapy, 
versus LCI and FEV1, are presented in Figures 4.22 to 4.24.  
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 Visit Lung clearance index FEV1 % predicted 
Extent of 
bronchiectasis  
1 0.62 (0.03) -0.65 (0.02) 
2 0.58 (0.05) -0.85 (0.0005) 
Severity of 
bronchiectasis  
1 0.03 (0.92) -0.10 (0.75) 
2 0.46 (0.14) -0.70 (0.01) 
Wall thickness  
1 0.17 (0.59) -0.46 (0.13) 
2 0.73 (0.008) -0.68 (0.02) 
Small mucus plugs 
1 0.40 (0.20) -0.70 (0.01) 
2 0.47 (0.12) -0.61 (0.03) 
Large mucus plugs 
1 0.33 (0.30) -0.60 (0.04) 
2 0.64 (0.02) -0.75 (0.005) 
Air trapping 
1 0.42 (0.20) -0.27 (0.42) 
2 0.68 (0.02) -0.34 (0.31) 
Consolidated lung* 
1 -0.46 (0.13) -0.32 (0.31) 
2 -0.13 (0.68) 0.15 (0.63) 
Ground glass* 
1 0.33 (0.29) -0.54 (0.07) 
2 0.48 (0.18) 0.18 (0.56) 
 
 Table 4.8:  Correlations between individual CT score components and LCI or FEV1. 
Both visits are presented; visit 2 (post treatment) are shown in grey. Correlations are 
shown as the Pearson correlation coefficient with the p value in brackets. Non-parametric 
(Spearman) correlations were used for non-normally distributed data (indicated by an 
asterisk: *). Significant correlations (p<0.05) are highlighted in bold. 
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Figure 4.20: Correlation between LCI and CT score for extent of bronchiectasis (top left), 
airway wall thickness (top right), large mucus plugs (bottom left) and percent gas trapping 
(bottom right). Visit 1 data are shown in red, visit 2 in blue. Statistically significant 
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Figure 4.21: Correlation between FEV1 % predicted and CT score for extent of 
bronchiectasis (top left), severity of bronchiectasis (top right) and airway wall thickness 
(middle left), large mucus plugs (middle right) and small mucus plugs (bottom).Visit 1 
data are shown in red, visit 2 in blue. Statistically significant correlations are represented 
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% Change in wall thickness
 
Figure 4.22: Percent change in severity of bronchiectasis score (top panel) and airway 
wall thickness score (bottom panel) after antibiotics, against percent improvement in LCI 
(blue circles) and FEV1 (red diamonds). Improvements in FEV1 and LCI are both 
positive, improvement in CT score is negative (i.e. a fall in the score). 
Airway Wall Thickness 
Bronchiectasis 
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Figure 4.23: Percent change in small mucus plugs score (top panel) or large mucus plugs 
score (bottom panel) after antibiotics, against percent improvement in LCI (blue circles) 
and FEV1 (red diamonds). 
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Figure 4.24: Percent change in percent air trapping score after antibiotics, against percent 
improvement in LCI (blue circles) and FEV1 (red diamonds). 
Air Trapping 
   
194 
7. Response of sputum markers of inflammation. 
Sputum was obtained by spontaneous expectoration from all 17 patients at visit 1. 
Two patients were unable to produce sputum at visit 2, and required induction of sputum 
by saline nebulisation. At visit 3, all 16 of the subjects who attended for this assessment 
were able to expectorate spontaneously. 
Sputum cell differentials were performed on all subjects, but adequate total cell 
counts were incomplete due to a lab error. Cell counts were therefore only obtained from 
7 samples at visits 1 and 2, and from 9 samples at visit 3. Summary cell differential and 
cell count data are presented in Table 4.9. There was no significant change in any of the 
cell differentials with treatment (Kruskal-Wallis 1 way ANOVA). There was significant 
change in the total cell count between the visits, from a median of 3.4 x10
6
/ml at visit 1, 
to 0.9 x10
6
/ml at visit 2 (p=0.03 versus visit 1), and 2.6 x 10
6
/ml at visit 3 (p=0.03 versus 
visit 1). Therefore, despite there being no change in the percentage of neutrophils, there 
was a fall in the absolute neutrophil count after antibiotics (p=0.039), see Figure 4.25. 
There was no change in the absolute numbers of the other cell types. Given the small 
numbers of subjects involved, the cell count data should be interpreted cautiously. 
Sputum IL-8 is a recognised marker of inflammation, and has been previously 
shown to be elevated in patients with CF, and correlates with lung function and other 
sputum inflammatory markers (Mayer-Hamblett, Aitken et al. 2007). In this cohort there 
was no significant change in sputum IL-8 with antibiotics (Figure 4.25). Mean (SD) 
sputum IL-8 at the start of the exacerbation was 15.4 (10.7) ng/ml. At visit 2, sputum IL-8 
was 19.8 (15.2) ng/ml, and at visit 3 it was 15.2 (12.4) ng/ml (p=0.62, 1 way ANOVA). 
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91.7 [83-99] 6 [0.9-14] 0.7 [0-5.3] 0.5 [0-5.3] 
2 
n=17 
91.9 [67-99] 6 [0.4-16] 0 [0-4.7] 1 [0-17.2] 
3 
n=16 






































Table 4.9: Median [range] cell differentials and total cell counts for sputum obtained 
before and after antibiotics from CF patients.  
* p=0.03 versus visit 1 
+ 
p=0.03 versus visit 2 






























































Figure 4.25: Change in total sputum neutrophil count (top panel) and sputum IL-8 
concentration (bottom panel) with treatment of a CF exacerbation. Each set of points 
joined by a line represents a single patient. Red bars represent group medians (top) and 
group means (bottom). 
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Correlation between change in clinical and physiological measures of CF 
The following parameters, selected on the basis of significant change and clinical 
relevance, were assessed for correlations between each other: 
Change (between visits 1 and 2) in:- 
• LCI (percent change) 
• FEV1 (percent change) 
• Sputum IL-8 
• Total sputum neutrophil count 
• Peripheral blood white cell count 
• Serum CRP 
• Symptom score 
 
As previously described, there was a significant correlation between the percent 
change in LCI and the percent change in FEV1 between visits 1 and 2 (Pearson r=-0.59, 
p=0.01). LCI was not however significantly correlated with any of the other variables 
described above. FEV1 percent change was also correlated weakly with change in 
symptom score (Pearson r=0.49, p=0.046), but not with any of the other variables. Change 
in sputum IL-8 was correlated with change in symptom score (Spearman r=-0.60, 
p=0.02), but this was due to the effects of a single outlier. There were no other significant 
correlations between any other of the variables. 
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Time to next exacerbation 
It was hypothesised that low responders, in terms of magnitude of change in LCI or 
improvement in symptoms, might have improved only poorly and would exacerbate again 
quickly. The date of the next course of antibiotics, either oral or intravenous, was 
therefore retrieved from the patients’ notes after the end of the study. This was compared 
to the percent change in LCI and to the change in symptom score between the preceding 
two visits. A single subject (EdTr012) has two entries because he was prescribed 
antibiotics both between visits 2 and 3 and after visit 3. These data are summarised in 
Table 4.10. 
There was no consistent relationship between either change in LCI or change in 
symptoms, and time to next exacerbation (Figure 4.26). EdTr010 showed a significant 
elevation in LCI at visit 2. Despite an improvement in his symptom score at this time, he 
was sufficiently unwell to restart intravenous antibiotics 5 days later. However, when 
EdTr011 restarted antibiotics on the day of his third assessment, his symptom score had 
fallen by 18 points from visit 2, to -10, yet his LCI and FEV1 were both better than at the 
post-antibiotic assessment. Apart from these two subjects, no other antibiotics were 
prescribed within 2 weeks of an assessment. 
Overall, there was an average improvement in LCI of 0.8 between visits 1 and 2. 
When the data in Table 4.10 were divided on the basis of a rise (deterioration) in LCI 
between visits of greater than 0.8 (n=7) and a fall (improvement) of greater than 0.8 
(n=6), there was no difference between the two groups in terms of median time to next 
exacerbation (59 days for those with an improvement in LCI, vs 62 days for those whose 
LCI deteriorated). The median change in symptom score was a fall of 3 points for subjects 
with an improvement in LCI and a rise of 5 points for those with a fall in LCI.  
Time to next exacerbation was actually longer in those who had reported more 
symptoms at the preceding visit. When subjects were divided on the basis of an 
improvement or deterioration in symptom score of +/- 4 or more, there was a median time 
to next antibiotics of 72 days in those whose symptom score had deteriorated (n=5), and 
only 61 days in those whose score had improved (n=6) (p=0.44).  
 
 









visit and start 
antibiotics (d) 
% Change in 





EdTr001 3 35 -0.5 1 
EdTr003 3 93 5.0 -8 
EdTr004 3 184 -25.7 -3 
EdTr005 3 61 4.3 5 
EdTr007 3 92 -15.4 0 
EdTr008 3 72 -24.1 -6 
EdTr009 3 80 -12.8 0 
EdTr010 2 5 13.0 7 
EdTr011 3 0 -1.1 -18 
EdTr012 2 16 -14.1 10 
EdTr012 3 70 -12.0 5 
EdTr013 3 51 -12.0 -10 
EdTr014 2 62 6.5 13 
EdTr015 3 231 -10.1 -10 
EdTr016 3 74 0.1 3 
EdTr017 3 104 -4.6 5 
EdTr051 3 46 -0.3 2 
EdTr052 3 57 -9.9 0 
 
Table 4.10: Time to next exacerbation in days, and change in LCI and symptom score at 
the last visit prior to starting antibiotics. There are two entries for EdTr012, corresponding 
to two different courses of antibiotics (between visits 2 and 3, and after visit 3). Percent 
change in LCI and change in symptom score refers to the difference between the 
preceding two assessments. 
   
200 
 









Percent change in LCI





250 Time to next
antibiotics (d)
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Figure 4.26: Time between last assessment and next course of antibiotics for a pulmonary 
exacerbation (days) plotted against the percent change in LCI (left, blue diamonds) or 
change in symptom score (right, red diamonds) between the preceding two visits. There 
was no consistent relationship between either the direction or magnitude of change in 
either of these variables and the timing of the next antibiotic course. 
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Discussion 
This study represents the first time that LCI has been measured in CF before and 
after an intervention that is known to improve lung function. Previous investigators have 
only shown improvement in LCI in response to short term interventions, such as inhaled 
β-agonists in asthmatics (Gustafsson 2007). The improvement of LCI with antibiotics in 
CF is an important finding, since the ability of LCI to change in accordance with clinical 
status is vital if it is to be considered as an endpoint for therapeutic trials. 
There are however a number of important differences between this study and the 
proposed gene therapy studies. The most obvious difference is that in this study the 
patients were unwell at the start, and have undergone assessment of LCI before and after 
treatment. This is a different scenario to that proposed for gene therapy studies. Patients 
with an exacerbation are known to have suffered a deterioration in lung function, and we 
anticipate that this will be reversible with treatment. FEV1 in the subjects described here 
was 12% lower than their best measurement in the last 6 months. With gene therapy 
however, we will be treating stable patients and hoping to detect an improvement above 
their usual baseline. How easy that will be depends upon how much of the abnormality in 
gas mixing is reversible.  
LCI is a measure of overall ventilation heterogeneity, which is in turn affected by a 
number of different processes in the CF lung. These include fixed abnormalities in airway 
and parenchymal structure due to fibrotic and destructive processes, as well as modifiable 
abnormalities due to regional differences in inflammation and mucus retention. This can 
be seen clearly in the CT images in Figures 4.17-4.19. Antibiotics have resulted in an 
improvement in the inflammatory processes, such as mucus retention (Figure 4.17) and 
small airway plugging (Figure 4.18), but the appearances of the underlying bronchiectasis 
are unchanged. Neither severity nor extent of bronchiectasis scores changed in this 
subject, and nor would we necessarily expect them to. Thus there is an “offset” in 
ventilation heterogeneity due to fixed abnormalities in lung architecture that are not 
amenable to improvement with antibiotics, and are unlikely to be improved even with 
reversal of the genetic defect. 
In gene therapy studies there is particular interest in delivering treatments to subjects 
with the mildest disease. This is because the presence of mucus and pus filled airways in 
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those with more severely affected lungs may reduce transfection efficiency. Also, a long 
term aim of gene therapy would be to deliver to younger subjects, before disease becomes 
established. Adults with mild disease are the best available model of these patients. LCI is 
particularly useful in subjects with mild airways disease, and in Chapter 3 it has been 
shown to be a sensitive marker of airways disease in these adults. However, it is not 
known how much of the ventilation heterogeneity that causes this elevation in LCI is due 
to the effects of airway remodelling, and how much is due to the reversible effects of 
inflammation.  
Subjects with mild airways disease are not well represented in the current cohort 
because they tend to suffer fewer exacerbations. Three patients had FEV1 within the 
normal range at the end of treatment, and all had considerable elevation in LCI. All 
subjects also had measurable bronchiectasis, mucus plugging and air trapping at visit 2, 
although the lack of a matched healthy control population means that it is not possible to 
make judgements about how significant these findings are. However, it is encouraging 
that improvements in LCI were also seen in subjects with milder disease, not simply in 
those with the most severely affected lungs. Indeed if the cohort is divided into two 
groups, based upon the LCI at visit 2, the mean LCI improves by 9.2% in the half with the 
best (lowest) LCI at visit 2, but only improves by 2.2% in those with the highest LCI.  
An improvement in LCI with treatment suggests that lung gas mixing is becoming 
more homogenous. Given that the mean FRC is unchanged, this suggests that ventilation 
is being improved to regions of the lung poorly ventilated at the start of the exacerbation. 
This is an important observation, since it is also possible that LCI could increase in 
treated patients if the treatment served to open up regions of the lung previously 
unventilated, though it is not known what volume of lung would be sufficient to cause a 
measurable change in LCI. As shown in Figure 4.11 however, there is considerable 
heterogeneity of response, with some subjects showing an increase in FRC and in LCI. 
This suggests that some less well ventilated lung regions are indeed being opened up, 
causing overall inhomogeneity to increase, and thus leading to a rise in LCI as a result of 
successful treatment (see Figure 4.27C). Indeed an increase in CT score for 
inhomogeneity was seen in CF patients treated with inhaled tobramycin solution, despite 
an improvement in the overall CT score (Nasr, Gordon et al. 2006). Figure 4.27 represents 
this diagrammatically. Although clearly an oversimplification, it represents two possible 
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outcomes of therapy, both increasing the volume of lung ventilated by tidal breathing (i.e. 
the FRC measured by washout) but one reducing and the other increasing ventilation 
heterogeneity. In vivo, the interactions between different lung units are not independent 
(Venegas, Winkler et al. 2005), and the effects on LCI and FRC of mucus clearance likely 
to be complex and unpredictable (Mentore, Froh et al. 2005). 
 
 
Changes in other markers 
LCI is the only endpoint that has not been assessed previously in CF patients over 
the course of treatment for an exacerbation. Previous studies have shown improvements in 
spirometry and CRP with treatment of an exacerbation, similar to the data presented here 
(Bell, Bowerman et al. 2000; Cunningham, McColm et al. 2003; Downey, Brockbank et 
al. 2007). These markers provide useful confirmation that the patients in this study were 
similar to previously reported studies, were unwell at the start of therapy,  and improved 
with treatment. 
IL-8 was included in this study because it is considered to be an important chemo-
attractant in the CF airways, and is known to be induced by both elastase and Tumour 
Necrosis Factor-α (TNFα) (Konstan and Berger 1997). IL-8 has been shown to correlate 
with FEV1 in a large cross sectional analysis, combining 269 patients from 4 different 
studies (Mayer-Hamblett, Aitken et al. 2007). IL-8 has also recently been listed as a 
candidate biomarker of CF airways inflammation (Sagel, Chmiel et al. 2007).  However, 
despite being elevated in CF, IL-8 has not previously been shown to fall significantly with 
treatment. Cunningham et al. reported a non-significant decrease in sputum IL-8 in 14 
children undergoing parenteral treatment for a pulmonary exacerbation (Cunningham, 
McColm et al. 2003). More recently, Downey et al. could find no change in a number of 
sputum sol mediators, including IL-8 , in 16 adult patients after 2 weeks of treatment for 
an exacerbation (Downey, Brockbank et al. 2007). A different kit was used to assess IL-8 
in the current study, which may explain why the levels of IL-8 were so much lower than 
in the study by Downey et al.. Nonetheless, the failure of IL-8 to improve with therapy is 
in agreement with previously published observations, and casts a shadow over its 
potential as a useful biomarker in interventional studies. 









Figure 4.27: Possible effects of mucus clearance in the lungs on ventilation heterogeneity 
(LCI) and ventilated lung volume (FRC). 
The figure represents three lung units of the same size. Figure 4.27A shows the units pre-
treatment; 1: partially obstructed and poorly ventilated, 2: completely obstructed and 
unventilated, 3: unobstructed. 
Figure 4.27B represents one possible outcome of treatment on the same three lung units: 
the partially obstructed unit has been cleared and is now normally ventilated. This should 
reduce ventilation heterogeneity (and hence LCI) and increase FRC. 
Figure 4.27C represents another possible outcome. The unventilated unit has now been 
partially opened up and is poorly ventilated. This will therefore also increase FRC but will 
increase ventilation heterogeneity, leading to an increase in LCI. 
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Downey et al. also reported a fall in absolute neutrophil count, although this did not 
achieve statistical significance. Similar to this study, they reported no change in percent 
cell counts or absolute counts of the other cell types (Downey, Brockbank et al. 2007). 
Over the last few years HRCT has attracted interest in the evaluation of CF lung 
disease, including as an endpoint in interventional studies. It is known to be more 
sensitive than traditional measures of lung function, and a number of scoring systems 
have been developed and been shown to have good inter-observer reproducibility (Aziz, 
Davies et al. 2007). Changes on CT have been shown to correlate with important clinical 
outcomes, such as pulmonary exacerbations (Brody, Sucharew et al. 2005), and to 
correlate with regional inflammation, assessed by percentage neutrophils and IL-8 levels 
on bronchoalveolar lavage (Davis, Fordham et al. 2007). Global HRCT scores have also 
been shown to improve in 16 CF patients treated with inhaled tobramycin solution, 
whereas in the placebo group there was no change (Nasr, Gordon et al. 2006). The CT 
scans included in this study were analysed by some of the leaders in this field, and their 
analysis has also shown good reproducibility (Aziz, Wells et al. 2007). The scoring 
system used however is one that they have developed themselves. Although this contains 
very similar components to those of previously described systems, this does not permit 
direct comparison with previous studies nor with previously reported healthy controls. CT 
appearances before and after antibiotics have been reported in 19 CF subjects by Shah et 
al. (Shah, Sexauer et al. 1997). They observed a reduction in airway wall thickness in 2 
subjects, and in mucus plugging in 6, but no change in severity and extent of 
bronchiectasis, or air trapping. These observations are similar to those reported here, 
where the most significant changes were in scores for mucus plugging. Unlike Shah et al., 
air trapping and wall thickness did improve in an appreciable percentage of subjects, 
which may reflect the sensitivity or the scoring system, the resolution of the scans, or the 
experience of the observers.  
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Visit 3 and time to next exacerbation 
The inclusion of a third visit was intended as an assessment of the patients at 
stability, and this assessment was intentionally deferred if the patient did not feel well. 
This was actually quite difficult to achieve in a number of patients, as evidenced by the 
extended delay between visit 2 and visit 3 in several cases. This is also illustrated in the 
spread of symptom scores at visit 3, far greater than at visit 2 when the majority of 
subjects actually felt better than “normal”. Although severity of symptoms is subjective, 
and influenced by a range of psychological and sociological factors (Riekert, Bartlett et al. 
2007), it is clear that an assessment of what is “normal” or stable is hard to achieve in 
some patients with CF. There is also a discordance between symptoms and other 
measures of well being, including measures of lung function. Despite the symptom score 
being focussed on respiratory symptoms, mean FEV1 actually improved between visits 2 
and 3, yet symptom score fell.  
The change in LCI at visit 3 is also important. If LCI is to prove useful in long term 
monitoring of subjects, then it needs to be relatively stable when the subjects are well. At 
visit 3, the mean LCI was not significantly different from that at visit 2, but there was 
considerable individual variation in this. In healthy subjects, LCI has good reproducibility 
between two visits, and the intra-visit coefficient of variation for repeat assessments is 
less than 5% in both controls and CF patients (Chapter 3). In CF however, the 
reproducibility may be poorer between visits on different days due to changes in 
inflammation or mucus distribution. The question of how reproducible LCI is when 
subjects are stable, or as near to this as is realistically possible, is important because the 
level of variability affects the statistical power of LCI to detect real changes in lung 
physiology in response to treatment. This question cannot be addressed by this study, 
which involves relatively small numbers of subjects, between only 2 visits, at a time of 
changes in therapy and clinical status. A longitudinal study of many subjects, over a 
several months, is required to address these questions, and is currently in progress. 
The other important feature of the third assessment was whether deterioration in LCI 
would be able to predict clinical deterioration. Clinical deterioration was measured as the 
time to the next course of antibiotics prescribed for a pulmonary exacerbation. No 
consistent relationship was seen between the change in LCI, the change in symptom score 
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or time to next exacerbation. The time to next exacerbation data should be interpreted 
with caution however, since only two subjects received antibiotics within 2 weeks of the 
assessment – one of these showed a significant deterioration in LCI and the other did not. 
It would be unreasonable to expect any assessment to predict how well or otherwise a CF 
patient would feel more than 2 weeks later. Also, presentation of respiratory symptoms in 
CF patients is complex, and the request for antibiotics is influenced by a variety of 
external factors. Thus, some subjects may have qualified for treatment earlier than that 
actually prescribed, but deferred or failed to present. These factors were not assessed in 
the present study.  
 
Lung physiology and structural lung disease 
Cross sectional comparisons of lung function assessments, including LCI, and 
HRCT chest have already been described. Gustafsson et al. reported on retrospective data 
collected on 44 CF patients aged up to 20 yrs (Gustafsson, de Jong et al. 2007). They used 
the Brody score, which evaluates 8 features of CF airways disease, and expresses the sum 
of the extent and severity of these as a percentage of the maximum possible score. 
Overall, LCI was more sensitive than either FEV1 or FEF75 at predicting an abnormal CT 
score, and was particularly sensitive to an abnormal gas trapping score (>30%), with a 
sensitivity of 94%. These were patients with well preserved lung function, the majority 
having FEV1 within the normal range, and almost a third having LCI within the normal 
range. In the subjects described here, all subjects had elevated LCI, and only three had 
FEV1 within the normal range. There was still a significant correlation with the gas 
trapping score at visit 2 however, of a similar magnitude to that described by Gustafsson 
et al. (Gustafsson, de Jong et al. 2007). There were also significant correlations with the 
scores for airway wall thickness and large mucus plugs, again similar to the findings 
reported by Gustafsson et al.. Unlike the earlier study however, in this study there were 
more, and stronger, correlations between CT score and FEV1, which probably at least 
partially reflects the greater number of abnormal FEV1 measurements. FEV1 showed 
strongest correlations with CT features of large airways disease, including extent and 
severity of bronchiectasis, airway wall thickening and large mucus plugs. There was no 
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correlation between air trapping, believed to be a feature of small airways obstruction, and 
FEV1, though there was a weak correlation between the small mucus plugs score and 
FEV1.  
No convincing associations were seen between changes in CT score and changes in 
conventional lung function measurements. This may be related to the nature of the CT 
scoring system used, which considers each feature as independent and does not produce 
an overall CT score. The lack of correlation between CT and lung function changes may 
therefore be due to the fact that there is no single structural feature that is 
disproportionately responsible for the deterioration in lung function seen at the start of an 
exacerbation. Instead there is a combination of abnormalities that all contribute. It is 
possible that these associations would become more apparent, and statistically significant, 
if greater numbers of subjects were included in the analysis. 
 
Relationship between LCI and FEV1 
In Chapter 3, LCI was shown to be a more sensitive indicator of airways 
dysfunction in CF patients than FEV1. In this study, on the face of it, LCI has performed 
less well than FEV1, with a mean precentage change of only around half that seen in 
FEV1, and far less than that seen in FEF25-75. To a certain extent this is to be expected.  
Deterioration in FEV1 is one of the few objective criteria routinely employed in the 
decision to start antibiotics. The mean percent fall in FEV1 (from best baseline) at the start 
of the study was almost exactly the same as the percent improvement in FEV1 after 
treatment (12.4% versus 11.1% respectively). An improvement in FEV1 therefore 
confirms the success of the antibiotic treatment. Furthermore, since FEV1 falls with 
worsening lung function, any improvement is measured against the initial (lowest value). 
LCI on the other hand rises with deterioration in gas mixing, and improvement is 
measured against the higher value (LCI improves by 7.3% if measured against the visit 2 
value). In addition, there is an offset to LCI, equivalent at least to the lower limit of the 
normal range (5.95, see Chapter 3), below which LCI cannot fall, no matter how well the 
patient. Although FEV1 also possesses a lower limit, this is considerably lower, relative to 
normal range, than that of LCI. This must be borne in mind when considering the percent 
change in LCI. Finally, FEV1 is technique and effort dependent (Krowka, Enright et al. 
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1987), and unwell patients often struggle to complete the manoeuvre, with maximal 
effort, to obtain three reproducible repeats. LCI however is independent of effort, and is 
not affected by how systemically well the patient feels. These factors may all contribute to 
the smaller percent improvement seen with LCI as opposed to FEV1.  
However, it is important to note that LCI is not proposed as a replacement for FEV1. 
The two measures are quite distinct, and measure different, and complementary, aspects 
of lung physiology. FEV1 is a less physiological manoeuvre than multiple breath washout, 
and is insensitive to early airways disease. This has been recognised for some time (as 
discussed in Chapter 1). That does not mean however that spirometry is not a valid 
assessment of airways function, particularly in those with more marked airways disease 
and measurable impairment in FEV1. In these subjects, LCI is less useful since, from a 
practical point of view, it takes longer to perform, and there is a trend towards less 
reproducibility. Certainly, in subjects with an FEV1 below 40% predicted it becomes 
considerably more difficult to perform accurately and may not be an appropriate 
physiological measurement in this population.  
There is a significant correlation between FEV1 and LCI, and between the change in 
these two measurements. Since both measure aspects of lung physiology, correlation 
between them is to be expected. However, they are affected to differing extents by disease 
of different regions of the bronchial tree, and this is emphasised by the features on CT that 
they show strongest correlations with. If a strong correlation existed between FEV1 and 
LCI, this would be both surprising and would make the newer and more complex 
measurement less useful. 
 
Multi-centre use of Innocor to measure LCI 
From the point of view of the CF Gene Therapy Consortium, the establishment of 
equipment and expertise to measure LCI on multiple sites was an important objective of 
this study. Although this thesis only includes data collected in Edinburgh, it is nonetheless 
worthwhile considering some of the lessons learnt. Despite being used in three centres by 
three different operators, the system was largely trouble-free. This was in no small part 
due to the robustness of the equipment, which meant that there were no major technical 
challenges during the eight months that this study was recruiting. The only minor 
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technical problem occurred with the machine used at the Royal Brompton Hospital. There 
was evidence of occasional interference in the SF6 signal in a handful of washouts (not 
more than three), that looks much like an electronic pulse, such as that generated by a 
mobile phone. This was resolved by excluding the affected portions of the breaths from 
analysis, but cannot be done without some impact on accuracy. 
It was also apparent that there was a learning curve associated with the performance 
of washout tests, and a degree of operator-dependency. In addition, unwell CF patients 
may be less receptive to being taught new techniques, especially when they are protracted. 
The process is made more difficult because Innocor does not offer an effective real time 
feedback. The operator is not provided with a last-breath expiratory volume display, and 
the SF6 signal display is a rolling average, delayed 1.5 seconds by the flow-gas delay, 
rather than a real time feedback of the actual SF6 concentration. Furthermore the readout 
available to view washouts whilst they are progressing is too small to do much more than 
look for leak and to grossly confirm adequacy of wash-in and washout. With experience, 
these limitations can be managed, but occasionally problems with washout quality are 
only apparent after the test is complete and the data are exported for analysis. 
In order to confirm the integrity of the washout procedures, a Standard Operating 
Procedure was written both for the conduct of the washout tests and for the analysis of 
data (Appendix A & B). Accuracy of data analysis amongst the three operators was 
confirmed by a reciprocal sharing and analysis of data from each of the three sites 
(Macleod, Horsley et al. 2007). 
 
Limitations of this study 
The limitations of the use of time to next course of antibiotics as an outcome have 
already been discussed. The major limitation of the data presented in this chapter are the 
small numbers involved. This makes it difficult to generate statistically meaningful 
correlations, particularly in the case of the CT data where there are only 12 subjects with 
paired data. It also means that the data are particularly susceptible to the effects of 
outliers. Despite this, the correlations between CT score and lung physiology at visit 2 are 
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similar to those previously reported in a much larger cross sectional study, which supports 
the validity of the findings (Gustafsson, De Jong et al. 2008).  
The data presented here are only those from the Edinburgh patients, although 
another 25 subjects were recruited at the Royal Brompton Hospital (of whom 21 have at 
least 2 visits). These data have not been included in the analysis presented here, for a 




Lung clearance index improves with antibiotic treatment in CF patients with a 
pulmonary exacerbation. This is despite no significant change in the ventilated lung 
volume, suggesting that treatment improves the ventilation of regions of the lung poorly 
ventilated during an exacerbation. LCI is complementary to spirometry as a measure of 
lung function, and is more closely correlated with measures of small airway function (CT 
score for air trapping) than FEV1.  
This confirms that LCI is able to change appropriately in response to an intervention 
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Chapter 5 - Effects of cystic fibrosis lung disease on gas 
mixing indices derived from alveolar slope analysis 
 
Introduction 
The preceding two chapters have involved the use of lung clearance index (LCI) as 
the primary outcome measure of the multiple breath washout tests. The washout curves 
however contain more information than is necessarily summarised by a single figure 
derived from the cumulative expired volume required to wash out the tracer. Over the 
years a number of attempts have been made to refine washout analysis in order to extract 
more of the information. Phase III slope analysis was first described in a clinical study by 
Verbanck et al. over 10 years ago (Verbanck, Schuermans et al. 1997). This analysis is 
particularly significant because it proposes that the ventilation heterogeneity can be 
divided into two components, reflecting processes in different parts of the bronchial tree.  
The analysis is explained in more detail in the following section but, in summary, 
involves plotting the concentration normalized phase III slope of the individual breaths of 
the washout against the lung volume turnover (obtained by dividing the cumulative 
expired volume by the FRC) (see Figures 5.1 and 5.2). This profile is then divided into 
two separate components, each reflecting a different aspect of gas mixing. The first 
component is called Scond, since it is considered to be determined purely by convective gas 
mixing in the conducting airways. The second component is considered to originate from 
interaction between diffusion and convection in the acinar zone in healthy lungs, and is 
labelled Sacin.  
In children with well controlled asthma, LCI was significantly higher than controls, 
despite no difference between the cohorts in baseline FEV1 or FeNO, and remained higher 
after nebulised salbutamol (Macleod, Horsley et al. 2008). Scond correlated with LCI, 
though the difference between controls and asthmatics was not statistically significant. In 
adult asthmatics, Scond is a predictor of airways hyper-responsiveness and responds to 
treatment with bronchodilators, whilst in smokers Scond shows a persistent improvement 
with smoking cessation (Verbanck, Schuermans et al. 1999; Verbanck, Schuermans et al. 
2006; Downie, Salome et al. 2007). In these studies, abnormalities in Sacin appear to be 
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less reversible than those of Scond. In COPD, Sacin correlates with gas transfer, a marker of 
alveolar integrity (Verbanck, Schuermans et al. 1998; Verbanck, Schuermans et al. 2004).  
 Phase III slope analysis has become increasingly prominent over the last few years, 
and has recently been the subject of editorials in major respiratory journals (Cosio 2006; 
Venegas 2007). It promises to offer a method of assessing effects of treatment on 
conducting airway function, an appealing proposition for CF gene therapy studies. 
However, the analysis has so far largely remained restricted to a single unit and their 
collaborators. More importantly, it has not been performed previously in adults with CF. 
Because the derivation of Scond and Sacin was based upon experimental observations and 
modelling of gas mixing processes in the distal airways of healthy adults (Paiva and Engel 
1984; Crawford, Makowska et al. 1985), it is not known how the very different 
pathologies present in the CF lung would affect it. 
Alveolar function is known to be preserved in CF until late in the disease. The 
original hypothesis behind this study was thus that CF would primarily affect the 
conducting airways, and therefore Scond, and that this would correlate with LCI as a 
measure of overall ventilation heterogeneity, and with lung function measurements that 
reflect conducting airway function (e.g. FEV1 and Raw).  
 
Aims: 
The aims of this study were to explore how ventilation distribution is affected by CF lung 
disease across a range of severities.  
1. To characterise how Scond and Sacin change with increasing severity of CF lung 
disease, as defined by worsening FEV1 and LCI.  
2. To correlate Scond and Sacin with other markers of lung function, specifically 
transfer factor (as a marker of alveolar function), airways resistance (Raw), and 
RV/TLC (a measure of gas trapping). 
 
In addition, data collected by Dr Kenny Macleod on Scond and Sacin in children have also 
been included in order to better explore the relationship between disease severity and 
phase III slope indices. 
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Figure 5.1a (top): Washout of a healthy subject (FEV1 103% predicted, FRC 1.9L, LCI 
7.0). SF6 concentration is shown with phase III portion highlighted in red. Expiratory 
volume is shown by the dotted tracing in the upper part of the graph. 
Figure 5.1b (bottom): Washout of a subject with moderate CF (FEV1 58% predicted, 
FRC 2.3L, LCI 14.3). The phase III slope is much steeper, both at the first breath and over 
subsequent breaths. A volume-concentration plot of an individual breath from this same 
washout, illustrating how the phase III slope is calculated, is shown in Figure 5.2. 

































  Phase I
 
 
Figure 5.2: Identification of phase III slope. A single breath of the washout in Figure 5.1b 
is shown. Phase I of the washout represents anatomic deadspace, with little or no tracer 
gas concentration. Phase II represents the mixed alveolar and bronchial tracer gas, as the 
concentration of tracer rises rapidly to the sloping phase III (“alveolar”) plateau. In some 
subjects an additional phase IV slope is seen as a steep upturn in the slope at the end of 
the breath. This represents the closing volume and the expiration of tracer from the least 
well ventilated regions of the lung. Linear regression of the SF6 concentration over the 
final third of the breath volume (65-95% expired volume) is used to calculate the phase III 
slope, shown by the dotted line. 
In addition, airway dead space can be calculated from analysis of phase I and II slopes, 
according to the method described by Fowler (1948). This is covered in more detail later 
in the chapter. 
 















































Figure 5.3a (top): SnIII is plotted against lung turnover (TO) for the whole of the washout 
for a patient with cystic fibrosis (red circles) and for a healthy volunteer (blue diamonds). 
There are clear differences between the two subjects, relating both to the slope of the plot 
and the offset. Scond is derived by linear regression of the portion of the slope between 
lung TO =1.5 to 6.  
Figure 5.3b (bottom): This refers to further analysis of the CF data in Figure 5.3a. The 
convection dependent contribution to the total SnIII is derived by multiplying Scond by the 
lung turnover. This is then subtracted from the total SnIII to give a measure of diffusion-
convection dependent inhomogeneity (SnIIIDCDI, plotted as grey circles). The value of 
SnIIIDCDI for the first breath is Sacin. 
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Phase III slope analysis  
Using the single breath washout (SBW) test, ventilation heterogeneity is determined 
from the slope of the alveolar plateau, also referred to as the phase III slope (see Figure 
5.2). Although SBW tests are useful clinical tools (Estenne, Van Muylem et al. 2000), 
they are not able to inform us about the mechanisms responsible for the observed 
inhomogeneity. Both diffusive and convective ventilation heterogeneity are present in the 
normal lung (e.g. gravity dependent variations in ventilation distribution (Milic-Emili, 
Henderson et al. 1966)) but are affected to varying extents by different disease processes. 
Within the normal human airways, diffusive gas mixing is the major contributor to 
ventilation distribution in the acinus (Dutrieue, Vanholsbeeck et al. 2000). Since diffusion 
is related to the molecular mass of the gas molecule, SBW tests can be refined by using 
helium and sulphur hexafluoride (SF6) together. This allows inferences to be made about 
the ventilation of the most peripheral air spaces (Gronkvist, Emery et al. 2002).  
Phase III slope analysis of multiple breath washout is an alternative analysis that 
aims to separate the contribution of the convection and diffusion to overall gas mixing 
(Verbanck, Schuermans et al. 1997; Aurora, Kozlowska et al. 2005). The technique of 
phase III slope analysis used in this study is similar to that originally described by 
Verbanck et al. (Verbanck, Schuermans et al. 1997). The alveolar slope of each breath of 
the washout is determined by linear regression of the alveolar plateau. This is initially 
identified from the final third of the expired volume, but can also be manually adjusted to 
allow for closing volume and physiological variability (see Figure 5.2). The phase III 
slope is then divided by the mean expired SF6 concentration over the corresponding 
portion of the expiration, in order to account for the dilution of the marker gas, to give a 
concentration-normalised phase III slope (SnIII) for SF6. When plotted against lung 
turnover (TO) (i.e. cumulative expired volume divided by FRC), there is a progressive 
rise in SnIII in those with abnormal gas mixing. The two different measures of ventilation 
heterogeneity are calculated from this plot of lung TO vs SnIII (Figure 5.3).  
When washouts are performed with gases of differing diffusivity, the difference in 
SnIII values (∆Sn) between the two gases increase over approximately the first five 
breaths, but remain constant thereafter (Crawford, Makowska et al. 1985). According to 
this model, this indicates that the change in SnIII over the middle portion of the washout 
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(TO 1.5 to 6) is independent of diffusive gas mixing - this is known as Scond. 
Multiplication of Scond by the TO number of a breath generates a measure of the 
convection dependent inhomogeneity (SCDI) contribution to the total (measured) SnIII for 
that breath. This can be subtracted from the total SnIII of the breath to generate a measure 
of the diffusion-convection dependent inhomogeneity (SDCDI), i.e. that occurring in the 
zone of the diffusion front, where convective and diffusive processes interact to produce a 
phase III slope (see Figure 5.3). 
The two measures of ventilation heterogeneity have been given designations based 
upon the supposed anatomical location of the gas mixing process (Verbanck, Schuermans 
et al. 1997). Hence, the slope of SnIII versus lung TO (between TO 1.5 and 6) is labelled 
Scond, because it is believed to reflect convective gas mixing, which is considered to occur 
in the conducting airways. The SDCDI value for the first breath is labelled Sacin, because 
this is considered to best represent diffusion-convection interaction. In healthy adults, 
modelling suggests that this occurs around division 20-21 of the bronchial tree for SF6, 




Seventeen healthy non-smokers (less than 10 pack years smoking history) with no 
known lung disease and on no regular respiratory medications were recruited as normal 
volunteers. Twenty nine healthy child controls, with no history of wheeze, asthma or 
prematurity (<34 weeks), were recruited from amongst those attending follow-up of stable 
upper-limb fractures as well as children of hospital staff. Twenty two CF adults were 
recruited from the Scottish Adult CF Service, and eighteen children with CF were 
recruited from the paediatric respiratory service at the Royal Hospital for Sick Children in 
Edinburgh. The diagnosis of CF was based upon a combination of clinical presentation 
and sweat testing and confirmed by genotyping. All volunteers and patients or guardians 
provided informed consent. Children too young to provide formal consent provided 
assent. This study was approved by the Lothian Research and Ethics Committee. 
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Multiple Breath Washout  
LCI was measured by multiple breath inert gas washout, using the modified Innocor 
gas analyser and 0.2% SF6 as the tracer gas, as described in Chapter 3. Unlike the studies 
by Verbanck et al. (Verbanck, Schuermans et al. 1997), subjects were not restricted to an 
expired volume of 1L. In children, the requirement for 1L breaths is impractical. When 
this was tried in adults, it was found that patients with CF experienced difficulty 
maintaining this artificial breathing pattern, which was also prone to induce coughing. 
Exhaled volume was displayed to the adult subjects on a separate screen, so that tidal 
volume could be targeted to between 500-1000 ml, but this was not used for children.  
Figure 5.1 shows raw data illustrating the washout and the difference in phase III 
slopes between controls and patients. 
 
Data analysis 
The custom-built software described in Chapter 2 that is used for calculation of FRC 
and LCI is also able to analyse phase III slopes by linear regression of the concentration-
volume plot of each breath of the washout. The software also calculates the mean expired 
SF6 concentration over the same portion of the breath, and generates values for SnIII. The 
default setting is for the alveolar slope to be identified as lying between 65 and 95% of the 
exhaled breath volume. Each breath is visually inspected to ensure that the linear portion 
of the phase III slope is selected and to achieve an accurate rendition of the phase III 
slope. In particular, in cases where a phase IV slope was visible on the tracing, this was 
not included in the calculation.  
The software is only able to generate values for SnIII for each breath, and does not 
calculate Scond. Derivation of Scond and Sacin from breath volume and SnIII data was 
therefore performed in Excel (Microsoft, Redmond, WA, USA) on a table generated by 
the MBW analysis software, containing breath number, breath volume and SnIII. Plots of 
SnIII versus lung volume turnover were inspected to ensure that there were no extreme 
outliers (e.g. from very small or rapid breaths), before linear regression between lung TO 
1.5 and 6 to generate a value for Scond.  
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Breath volume correction 
Before calculation of Scond, SnIII values were transformed by multiplying by the 
corresponding breath volume in litres. This method was described by Aurora et al. 
(Aurora, Kozlowska et al. 2005) as a method of reducing the dependence of SnIII on 
expired volume. In a study of phase III slopes in 63 children, aged 2-17 yrs, the authors 
recognised that a strong hyperbolic relationship existed between first breath SnIII and 
expired volume, and furthermore that a large proportion of SnIII variability was explained 
by subject variables such as age, height and gender. By multiplying SnIII by expired 
volume for that breath (in litres), this relationship was abolished, and the association 
between Scond and age disappeared.  
Volume correction is a mathematical device which reduces the variability associated 
with breaths of different sizes, and also allows comparison between individuals of 
different ages and with previous studies. The approach is appropriate in the studies 
presented here because of the wide age range of subjects included. For assessments in 
adults alone, it would be much harder to justify the use of this correction. In the studies 
presented here however, the relationship between uncorrected and volume-corrected 
variables is strong, and the conclusions are unchanged if the uncorrected values are used 
in adults (see Results). To make it clear when the transformed data have been used, phase 
III slope indices derived by this method have been designated ScondVTc and SacinVTc (VTc = 
tidal volume corrected).  
 
Tests were performed in triplicate and LCI is quoted as the mean of at least two 
reproducible washouts. As a quality control measure, tests where the measured FRC 
differed by more than 10% from both of the other two repeats were excluded (Wanger, 
Clausen et al. 2005). 
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Lung function 
All other lung physiology parameters were performed on standard lung function 
laboratory equipment according to ATS/ERS standards (Macintyre, Crapo et al. 2005; 
Miller, Hankinson et al. 2005; Wanger, Clausen et al. 2005). Plethysmography was 
performed on a Zan 500 USB plethysmograph (Ferraris Respiratory, Hertford, UK)  or a 
Jaeger Masterlab plethysmography (Erich-Jaeger, Hoechberg, Germany). Lung volumes 
are quoted as the mean of three reproducible repeats (within 5%). Airways resistance was 
calculated as the specific resistance at 0.5L/s, Raw (0.5), and is quoted as the mean of at 
least two reproducible repeats (within 10%). Diffusing capacity was assessed on a Collins 
Pulmolab (Ferraris Respiratory, Hertford, UK) using the single breath technique 
(Macintyre, Crapo et al. 2005). Measurements of KCO are quoted as the mean of two 
repeats. Reference ranges were taken from Quanjer et al. (Quanjer, Tammeling et al. 
1993). 
FEV1 and FVC are quoted as the highest of three repeat manoeuvres (Miller, 
Hankinson et al. 2005). FEV1 data are expressed as z-scores, as described by Stanojevic et 
al. (Stanojevic, Wade et al. 2008). For reference, percent predicted values for FEV1 are 
also presented (Quanjer, Tammeling et al. 1993). In this regard, the presentation of 
spirometry differs from the other chapters in this thesis, which have employed the 
conventional percent predicted notation for FEV1. The Stanojevic reference ranges were 
published after all these studies contained within this thesis had been completed, and after 
the studies in Chapters 3 had been published. The studies presented in the current chapter 
however were published after the new reference ranges. Since the published and peer 
reviewed manuscript derived from these data contains the Stanojevic z-score notation for 
FEV1, this has been maintained in the current chapter, but the percent predicted values are 
also quoted for comparison with other chapters and published studies. The advantages of 
the Stanojevic reference ranges are that they provide more accurate reference ranges, 
particularly in adolescence, and improved definition of the lower limits of normality. 
They are particularly for useful for studies involving a wide age range of subjects 
(Stanojevic, Wade et al. 2008). 
Lung function testing was performed within 3 hours of LCI measurement, and 
though the order of the tests was not fixed there was at least a 30 minute interval between 
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the completion of lung function testing and start of MBW. Exhaled gas volumes were 
converted to body temperature, ambient pressure, and saturated water vapour (BTPS) 
conditions. 
Paediatric volunteers completed triplicate washouts followed by spirometry only, 
using an Easyone spirometer (Ndd Medizintechnik, Bern, Switzerland), according to 
ARTP guidelines (1994). Full lung function was not performed in these patients. FEV1 
data have been presented and analysed as z-scores (Stanojevic, Wade et al. 2008), but 




Data were analysed using Prism (GraphPad Software Inc, CA, USA). Parametric 
data are quoted as mean (SD), unless otherwise stated, and were compared using t-tests. 
Non-parametric data, and small datasets, are quoted as median (inter-quartile range), and 
compared using the Mann-Whitney U test. Correlations were analysed using Spearman’s 
rank correlation. A p value of 0.05 was considered significant. A Bonferroni correction 
for multiple comparisons of independent variables was applied to the correlations in Table 
5.3, and for this analysis a p value of below 0.01 was considered statistically significant. 
The upper limit of normality for Sacin, Scond and LCI was defined at the mean + 1.96 x 
standard deviation of the control population. 
 
 
   
224 
Results 
Twenty two CF adults completed MBW, spirometry and diffusing capacity 
assessments. Plethysmography was not completed in one adult patient because of 
technical problems with the apparatus. Seventeen adult healthy volunteers completed inert 
gas washout, and diffusing capacity. Plethysmography was not completed in 5 controls. A 
single CF adult was excluded from SnIII analysis because she was only able to produce 
two reproducible washouts, which due to variability in breathing pattern could not be 
analysed accurately for SnIII analysis.  
Eighteen children with CF and 29 healthy child volunteers completed MBW and 
spirometry. No other lung function assessments were performed in children.  
Demographics and lung function data for all 39 adult subjects are presented in Table 
5.1 and for all 47 paediatric subjects in Table 5.2. Based upon the combined control 
populations, the upper limit of normality for LCI was calculated as 7.50, for SacinVTc was 
0.230 and for ScondVTc was 0.048. 
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 Healthy Adults CF adults 
Difference 
(95% CI) 
Number 17 22  







(-8.0 to 3.2) 






(-49.5 to -30.2) 
FEV1 z-score 
0.04 (0.76) 
[-1.26 – 1.77] 
-3.03 (1.62) 
[-6.33 – 0.79] 
-3.1* 







(-24.2 to -9.9) 
LCI 
6.7 (0.6) 




(4.46 to 7.84) 
Mean expired volume (ml) 822 (154) 836 (140) 
14 
(-82 to 111) 
Mean (SD) FRC (L) 






(-0.76 to 0.49) 














(10.9 to 22.8) 
Mean (SD) DLCO 






(-2.82 to 0.23) 
Mean (SD) DLCO/VA 






(-0.29 to 20.30) 
SacinVTc  
0.112 (0.055) 
[0.012 – 0.271] 
0.366 (0.208) 
[0.052 – 0.742] 
0.254* 
ScondVTc   
0.010 (0.015) 
[-0.028 – 0.032] 
0.086 (0.030) 
[0.044 – 0.148] 
0.076* 
 
Table 5.1: Demographics and lung function of patients and controls. Values are means 
(standard deviation) and [range of values], unless otherwise stated.  
Raw (0.5) = Airways resistance; RV/TLC = Residual volume / total lung capacity; DLCO = 
Diffusing capacity, DLCO/VA = diffusing capacity adjusted for alveolar volume. 
*p<0.0001, 
+
p=0.0001, **p=0.03 (t-tests) compared to controls 
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 Healthy Children 
CF Children Difference 
(95% CI) 
Number 29 18  
Male / Female 18 / 11 12 / 6  
Age (yrs) 
11.1 (3.3) 




(-0.7 to 3.4) 
FEV1 percent predicted 
90.6 (11.9) 
[64.1 – 116.6] 
89.9 (32.0) 
[47.7 – 164.8] 
0.9 
(-14.1 to 12.3) 
FEV1 z-score 
-0.81 (0.97) 
[-3.32 – 1.23] 
-1.32 (2.38) 
[-5.04 – 4.75] 
-0.51 
(-1.50 to 0.49) 
LCI 
6.2 (0.5) 




[4.8 – 14.0] 
1.0
+ 
(1.9 to 0.2) 
Mean expired volume (ml) 538 (253) 487 (149) 
-51 
(-184 to 82) 
Mean (SD) FRC (L) 






(-0.73 to 0.45) 
SacinVTc  
0.117 (0.062) 
[0.019 – 0.286] 
0.192 (0.123) 
[0.038 – 0.497] 
0.076* 
(0.021 to 0.130) 
ScondVTc   
0.015 (0.019) 
[-0.031 – 0.058] 
0.068 (0.029) 
[0.022 – 0.124] 
0.053** 
(0.039 to 0.067) 
 
Table 5.2: Demographics and lung function of paediatric patients and controls. Values are 
means (standard deviation) and [range of values], unless otherwise stated.  
+
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Comparison between CF adults and healthy controls 
CF adults had lower mean FEV1 z-scores than healthy controls (-3.03 vs 0.04, 
p<0.0001), and higher mean LCI (12.8 vs 6.7, p<0.0001).  
CF patients also had higher mean SacinVTc (0.366 vs 0.112, p<0.0001) and higher 
mean ScondVTc (0.086 vs 0.010, p<0.0001) than healthy controls. There was no statistically 
significant difference in mean KCO % between the two groups. 
 
Comparison between CF children and healthy controls 
There were no statistically significant differences in spirometry between the patients 
with CF and healthy controls. As with the adult subjects, children with CF had higher 
mean LCI (7.3 vs 6.2 in controls, p=0.022), and higher mean SacinVTc (0.192 vs 0.117, 
p=0.007) and mean ScondVTc (0.068 vs 0.015, p<0.0001).  
 
Comparison between CF children and adults 
There was no significant difference between mean ScondVTc in CF children and in CF 
adults (p=0.06), but mean LCI and mean SacinVTc were both significantly lower in CF 
children than CF adults (p<0.0001 and p=0.0036 respectively). 
 
Association between LCI and phase III slope indices 
The relationships between LCI and ScondVTc and SacinVTc are presented in Figures 5.4 
and 5.5 respectively. Elevation of ScondVTc appears to be an early event in CF, occurring in 
both adults and children with normal LCI (Figure 5.4). However, ScondVTc did not increase 
further with increasing disease severity, and appeared to reach an asymptote with a 
maximum value of 0.15. SacinVTc on the other hand, was within the normal range in the 
majority of children (Figure 5.5). In CF adults, SacinVTc showed a significant correlation 
with LCI (Spearman r=0.86 (p<0.0001)) but remained within the normal range until LCI 
was greater than 10.  
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Figure 5.4: Relationship between ScondVTc and LCI for healthy subjects and cystic fibrosis 
patients. 
Healthy adults are represented as pale red circles and healthy children as pale blue circles. 
CF adults are represented as red diamonds and CF children as blue diamonds. The 
horizontal and vertical dotted lines represent the upper limits of normal ScondVTc  and LCI 
respectively.  
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Figure 5.5: Relationship between SacinVTc and LCI for healthy subjects and cystic fibrosis 
patients. 
Healthy adults are represented as pale red circles and healthy children as pale blue circles. 
CF adults are represented as red diamonds and CF children as blue diamonds. The 
horizontal and vertical dotted lines represent the upper limits of normal SacinVTc and LCI 
respectively. Linear regression of SacinVTc versus LCI for CF patients is represented by the 
diagonal line.  
   
230 
Association between Scond, Sacin and other markers of lung function 
In CF adults, SacinVTc showed significant correlations with RV/TLC (r=0.72, 
p=0.0003), a measure of gas trapping, and with FEV1 z-scores  
 (r=-0.73, p=0.0002). SacinVTc was also correlated with Raw (r=0.56, p=0.01) but there was 
no association between SacinVTc and diffusing capacity in either CF adults or controls. In 
CF adults, ScondVTc was not significantly correlated with any other measures of lung 
function. Table 5.3 shows how the main outcome measures correlate with each other for 
CF adults.  
DLCO/VA percent predicted is the quoted measure of diffusing capacity since this 
takes into account the often abnormal alveolar volume (VA) in CF patients. The predicted 
DLCO/VA was derived from predicted DLCO and predicted VA equations in the reference 
data of Quanjer et al. (Quanjer, Tammeling et al. 1993). When the correlations were 
performed against DLCO, DLCO percent predicted, or DLCO/VA, the findings were 




Relationship between age and phase III slope analysis 
There was no relationship between age and either SacinVTc (p=0.98) or ScondVTc 
(p=0.22) for all healthy control subjects. These data are presented in Figures 5.6 and 5.7.
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Table 5.3: Summary of correlations between different markers of lung function in 
patients with cystic fibrosis. Correlations were assessed using Spearman’s rank 
correlation coefficient. p values of greater than 0.05 are recorded as ns (not significant). 
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Figure 5.6: Age versus ScondVTc for all subjects. Patients with cystic fibrosis are shown in 
red and control subjects in blue. The blue dotted line represents linear regression of the 
control data (p=0.22). 
 





















Figure 5.7: Age versus SacinVTc for all subjects. Patients with cystic fibrosis are shown in 
red and control subjects in blue. The blue dotted line represents linear regression of the 
control data (p=0.98). 
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Reproducibility and reliability of Phase III slope indices 
In healthy controls the phase III slope was often essentially horizontal with each 
breath, and changed little over the course of a washout. This made the calculation of a 
“slope” of Scond difficult, since all the individual phase III slopes showed essentially minor 
variation around zero. It also meant that negative values for Scond could be obtained, 
something that has also been previously described in the calculation of phase III slopes in 
children using 4% SF6 as the tracer gas (Aurora, Kozlowska et al. 2005). In contrast, with 
CF patients the anticipated progression of the phase III slope was clearly seen, and 
allowed calculation of a slope with reasonable certainty. This is illustrated by calculating 
the r
2
 value of the slope. For healthy adult controls (n=12 with complete full lung function 
tests), overall median (IQ range) r
2
 value was 0.14 (0.07 to 0.18). For CF patients on the 
other hand, median r squared was significantly greater at 0.64 (0.51 to 0.75), p<0.0001 
(Mann Whitney U test). 
Coefficient of variation (CoV) of intra-subject repeats is an alternative measure of 
reproducibility, that has already been reported for LCI (see Chapter 3). For healthy adult 
volunteers, the median (IQ range) CoV of ScondVTc was 59.5 % (32.0 – 87.4), and for 
SacinVTc was 18.9% (10.0 – 30.0). The large CoV of ScondVTc in healthy subjects reflects the 
poor reproducibility of the technique in this population; the very low values of Scond mean 
that small variations in slope have a large impact on measures of reproducibility. For CF 
adults, median CoV of ScondVTc was 32.7 % (14.0 – 41.4), and for SacinVTc was 22.4 (10.6 – 
22.1).  
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Effects of altering the Phase III slope analysis 
All data presented here are for ScondVTc and SacinVTc, the breath volume corrected 
derivations of Scond and Sacin described by Aurora et al. (Aurora, Kozlowska et al. 2005). 
When the uncorrected data were analysed, a similar pattern of associations and 
correlations was seen. This is because both ScondVTc and SacinVTc correlate strongly with 
their uncorrected values (r=0.80 and r=0.91, p<0.0001 respectively for adults). 
There are however a number of differences between the analysis presented here and 
that performed in previous studies on phase III slopes. The first, and most obvious, is the 
lack of tight expiratory volume control. The reasons for this have already been covered, 
but in order to establish the effect of this on the calculation of Scond, washouts were 
reanalysed according to a number of different criteria. The effects of these alterations 
were primarily assessed on Scond, since this variable is also used to derive Sacin. 
 
Association between Phase III slope indices and mean tidal volume 
Previous studies have indicated that in normal subjects, LCI is affected by extremes 
of breath volume (Gronkvist, Bergsten et al. 2002). In order to investigate whether this 
could influence the results, measures of ventilation heterogeneity were compared to mean 
tidal volume (VT), normalised for mean FRC or for body surface area (BSA, calculated 
using the Mosteller formula (Mosteller 1987)).  Neither LCI, Scond nor Sacin correlate with 
VT, VT/FRC or VT/BSA. Because of the multiple comparisons involved, the level of 
significance for this analysis was set at 0.01. This is illustrated in Figure 5.8. The lack of 
correlation between measures of ventilation heterogeneity and breath volume, suggest that 
these data are not adversely affected by breath volume. 
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Figure 5.8: Relationship between the individual subject’s mean tidal volume (VT) to FRC 
ratio (averaged over 3 washout repeats) and phase III slope analysis, for all adult subjects. 
There was no statistically significant correlation between VT/FRC and either SacinVTc or 
ScondVTc. 
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Re-analysis of Phase III slope indices based on breath volume 
The effect of small tidal volumes on Scond was assessed in two ways for the 
washouts performed in adult subjects. Firstly, in order to address the criticism that phase 
III slopes cannot be calculated from smaller breaths, phase III slopes were re-calculated 
only for breaths of greater than 850ml. No upper limit on breath volume was set, but the 
tidal volume correction was applied to these calculations to allow for this. If there were 
fewer than 4 breaths of greater than 850ml within the TO range 1.5 to 6, no attempt was 
made to calculate Scond. Only subjects with 2 or more washouts where Scond could be 
calculated were included in this analysis. This led to the exclusion of 5 of 12 healthy 
volunteers and 10 of the 21 CF patients. Mean (SD) VT of all subjects was 854 (139) ml, 
whereas for the washouts reanalysed with a minimum volume of 850ml, mean VT was 
955 (85) ml. The effect of this on ScondVTc is shown in Figure 5.9. This also shows the 
standard ScondVTc values, as already shown in Figure 5.4, where a minimum breath volume 
of 400ml was accepted, here denoted as ScondVTc (400). For CF patients, mean ScondVTc 
(850) was 0.078, significantly lower than mean ScondVTc (400) for the same subjects 
(0.108), p=0.0012 (paired t-test). The inclusion of more and smaller breaths into the phase 
III slope analysis therefore led to an increase in the calculated Scond, and is thus not 
sufficient to explain the failure of Scond to increase with increasing ventilation 
heterogeneity. 
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Figure 5.9: ScondVTc calculated only from those breaths of the washout greater than 850ml 
in volume: ScondVTc (850). This is plotted against LCI for healthy volunteers (HV) (blue 
circles) and CF patients (red circles). In addition, for the same subjects ScondVTc calculated 
from all breaths greater than 400ml, as described in the Methods and previously illustrated 
in Figure 5.4, is also shown as black crosses: ScondVTc (400). 
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An alternative analysis was also performed to calculate Scond using only the most 
robust SnIII values. Firstly, all washouts with a mean tidal volume over the TO range 1.5 - 
6 of less than 850ml were excluded. Secondly, all washouts where the expiratory volume 
variability (measured as the within-washout CoV of expiratory volume) was greater than 
20% were excluded. Finally, only the two washout repeats with the closest values for 
ScondVTc were included, and a mean ScondVTc generated from these. ScondVTc values for 9 CF 
patients and 6 healthy controls met these inclusion criteria. Mean (SD) tidal volume was 
953 (66) ml, and mean intra-washout coefficient of variation of tidal volume was 9.6% 
(range 1.9 – 18.7%). Despite this selection, the graph in Figure 5.10 remains very similar 
to that in Figure 5.4. There is a progression of SacinVTc with deteriorating LCI, but no 
further progression of ScondVTc. 
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Figure 5.10: ScondVTc and SacinVTc from selected washouts plotted against LCI. Washouts 
were only included if they conformed to strict criteria on mean and standard deviation of 
washout breath volume, as described in the text. 
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Effect of altering the TO range on Scond. 
It was apparent during data analysis that in some washouts from CF patients there 
was a levelling off of the SnIII values within the TO range 1.5 to 6. This is illustrated in 
Figure 5.11, a plot of SnIII vs TO for a washout from a 19 year old male with CF, FEV1 
61% predicted and LCI of 15.8. Because the curve flattens off before TO=6, calculation 
of linear regression up to TO=6 is erroneously diminished. A solution to this is to use a 
lower TO range. The lower limit (TO=1.5) is set by the behaviour of diffusive gas mixing, 
and therefore remains unaltered. The upper limit of the range however has been reduced 
to 4 for calculation of Scond. Any further reduction risks leaving too few data points in the 
range of interest for accurate calculation. 
All 99 washout repeats from the 21 adult CF patients and 12 adult healthy controls 
were reanalysed and Scond re-calculated from TO range 1.5 to 4, Scond (TO4). A Bland-
Altman plot of Scond (TO4) and the standard method of calculating Scond between TO 1.5 
and 6, Scond (TO6), is presented in Figure 5.12. With increasing Scond, there is a tendency 
for Scond (TO6) to be lower than Scond (TO4), as would be expected from looking at plots 
such as that in Figure 5.11.  
A plot of the adjusted ScondVTc data (utilising the TO range 1.5 to 4) versus LCI is 
shown in Figure 5.13. The original data (to TO=6) are also shown as black crosses. This 
adjustment to the calculation of Scond had little effect on Sacin, which is therefore not 
shown separately. In a single CF patient, flattening occurred before TO=4 and this 
subject’s data were therefore excluded.  
Mean ScondVTc was higher when the reduced TO range was employed (0.102 vs 
0.088), but this difference was not statistically significant (p=0.25, paired t-test). Overall, 
this adjustment had little effect on the overall shape of the LCI vs Scond graph, which 
continued to show restriction of progression of Scond with worsening LCI. 
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Figure 5.11: SnIII vs lung volume turnover for a single washout of a patient with 
moderately severe CF lung disease. Although there is a clear progression of SnIII with 
sequential breaths, this flattens out within the range of lung volume turnover (TO) used to 
calculate Scond – shown as the red linear regression line. If a lower upper limit for TO 
range is used, plot appears to be more linear and the regression line (blue) is steeper. 
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Figure 5.12: Bland-Altman plot of Scond generated from a lung volume turnover range of 
1.5 to 4, Scond (TO4), and the standard range of 1.5 to 6, Scond (TO6).  
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Figure 5.13: ScondVTc (blue circles) and SacinVTc (red diamonds), restricted to the lung 
volume turnover range 1.5 to 4 for calculation of Scond. This is plotted against lung 
clearance index. For reference, the original ScondVTc values are shown as black crosses.  
For patients with CF, there was no significant correlation between LCI and either ScondVTC 
calculated to TO=4 (r
2
=0.12, p=0.14) or to TO=6 (r
2
=0.006, p=0.75). 
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Airway dead space and LCI 
Airway dead space was calculated according to the method described by Fowler for 
the first three breaths of each washout (Fowler 1948). A custom software application 
written using Igor Pro 6.1 (Wavemetrics Inc, USA) was prepared by Dr Nick Bell and 
used to calculate the expired volume at which the area under the SF6 expirogram (area A 
in Figure 5.14) equalled that between the SF6 expirogram and the line extrapolated from 
the phase III slope (area B in Figure 5.14), for each of the first three breaths of each 
washout. 
Predicted values for Fowler dead space were calculated using the height and gender-
dependent equations described by Hart et al. (Hart, Orzalesi et al. 1963). These data are 
summarised in Table 5.4. 
Although airway dead space was significantly higher in the healthy subjects (179 vs 
159 ml, p=0.033), there was no significant difference between the percent predicted 
values or the dead space: tidal volume ratios (VD/VT). Moreover, the values of VD/VT 
were lower than those previously shown to have an effect on LCI (Schmalisch, Proquitte 
et al. 2006).There was no correlation between airway dead space or percent predicted 
dead space and LCI or ScondVTc. There was no correlation between LCI and VD/VT, but a 
weak correlation between ScondVTc and VD/VT was statistically significant (Pearson r=-
0.42, p=0.016). Inspection of the graph however did not reveal a convincing association 
between the two variables (Figure 5.15). In addition, this was in the opposite direction to 
that which would be expected if this was a true effect, i.e. one would expect an increase in 
VD/VT to cause an increase in ScondVTc. 























Figure 5.14: Calculation of airway dead space as described by Fowler (1948). The phase 
III slope is extrapolated back to meet the rising SF6 concentration on the SF6 expirogram. 
The expired volume at the point that (area A) = (area B) is the airway dead space. This 
was calculated for each of the first three breaths of each washout. 








Fowler dead space (ml) 
179 (29) 
[132 - 247] 
159 (23)* 
[109 - 186] 
Percent predicted Fowler 
dead space 
119 (13.8) 
[99.1 – 146.2] 
111.2 (16.1) 
[84.4 – 150.0] 
VD/VT 
0.222 (0.038) 
[0.160 – 0.269] 
0.203 (0.025) 
[0.172 – 0.268] 
 
Table 5.4: Comparison of airway dead space, calculated from the first three breaths of 
each washout, for CF patients and healthy controls. Percent predicted dead space is taken 
from the equations derived by Hart et al. (Hart, Orzalesi et al. 1963).  
*p=0.033 
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Figure 5.15: Correlation between ScondVTc and dead space to tidal volume ratio (VD/VT). 
There is a statistically significant correlation between ScondVTc and VD/VT (Pearson r=-
0.42, p=0.016). 
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Curv analysis 
An additional analysis of washout curves has also been proposed. This involves 
plotting lung TO against log mean expired tracer gas concentration for the first 6 lung 
volume turnovers. The ratio of the slopes of these points between TO 3 to 6 over TO 0 to 
3 has been termed the curvilinearity, or Curv, of the washout (Verbanck, Schuermans et 
al. 2008). While Curv is a measure of specific ventilation heterogeneity, irrespective of 
the sequential emptying of these heterogeneously ventilated lung units, Scond is dictated 
both by specific ventilation heterogeneity and sequential emptying (Verbanck, 
Schuermans et al. 2008). Hence, it would be expected that Curv and Scond correlate to 
some extent. 
Curv was calculated for all the washouts. Overall mean (SD) Curv was lower in CF 
than in controls; 0.632 (0.161) vs 0.879 (0.061), p<0.0001. ScondVTc showed a significant 
correlation with Curv when all the data were combined (Pearson r=-0.69, p<0.0001), 
Figure 16. Curv also showed significant correlations with LCI (r=-0.88, p<0.0001) and 
FEV1 z-score (r=0.69, p<0.0001). 
The literature on Curv is less exhaustive than that on LCI or phase III slope analysis. 
If the assertion that Curv exclusively reflects specific ventilation heterogeneity is correct 
(Verbanck, Schuermans et al. 2008), then this would appear to account for a significant 
proportion of the early rise in Scond. However, Scond levels off whilst Curv continues to 
fall. This supports the proposal that Scond is limited intrinsically by the nature of its 
derivation, rather than by the degree of conducting airway abnormality in CF (see 
discussion of main manuscript).  
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Figure 5.16: Curvilinearity (Curv) plotted against ScondVTc for all CF patients (red) and 
controls (blue). The graph includes data from both children and adults. The dotted line 
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Discussion 
From first principles it might be expected that CF patients with more severe lung 
disease would have more inhomogeneous convective gas mixing. However, this is not 
what has been demonstrated using a method based upon phase III slope analysis. 
Although the convection dependent component (Scond) was elevated in almost all CF 
subjects, including children with mild disease and normal LCI, Scond did not continue to 
rise with increasing disease severity (as expressed by deteriorating FEV1 or LCI) and 
appeared to reach an early asymptote. In contrast, the contribution to the normalised phase 
III slope of diffusion-convection interaction (Sacin) was correlated with severity of lung 
disease and hyperinflation (RV/TLC). Furthermore, increases in heterogeneity of gas 
mixing appeared to occur largely in the Sacin component. These findings were seen even 
after eliminating potential methodological differences between this and previously 
published studies. 
In addition, whilst Verbanck et al. found a relationship between Sacin and diffusing 
capacity in COPD patients (Verbanck, Schuermans et al. 1998; Verbanck, Schuermans et 
al. 2004), this was not evident in this study of CF patients. It is likely that this reflects 
differences in the pathology. Verbanck looked at asthmatics and smokers, in whom 
diffusing capacity is a valid marker of alveolar integrity (McLean, Warren et al. 1992). In 
CF however, alveolar structure and diffusing capacity are well preserved until late in the 
disease (Sobonya and Taussig 1986; Espiritu, Ruppel et al. 2003), and this is reflected in 
the large number of normal diffusing capacity measurements reported here. Another 
important difference between the multiple breath washout analysis and the assessment of 
diffusing capacity is that the latter requires a vital capacity breath, which may serve to 
open up additional regions of the lung poorly ventilated at tidal volume. If the two tests 
were assessing different regions of the lung, they would not be expected to exhibit close 
correlations. 
Sacin does however show a convincing correlation with RV/TLC, measured at 
plethysmography. This is a measure of hyperinflation which, particularly in those with 
normal alveolar function, one would expect to be caused by disease of the small 
conducting airways (measured by Scond) (Macklem, Thurlbeck et al. 1971; Cosio, Ghezzo 
et al. 1978). This was demonstrated recently by King et al., who looked at the effect of 
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methacholine challenge on airways resistance (measured by forced oscillation technique) 
and SnIII (King, Downie et al. 2005). They confirmed that in healthy controls, Scond was 
related to the volume of gas trapping at FRC, whereas Sacin was not.  
The very earliest effects on gas mixing appear to occur in the conducting airways, 
and Scond was elevated in almost all children with CF, including those with LCI well 
within the normal range. This corresponds with our understanding about the site of 
earliest pathology in CF (Brownlee 2006).  Increasing ventilation heterogeneity however 
is not reflected as a worsening of Scond, even though convective flow differences between 
larger lung units might be anticipated. Indeed, it has been shown by Brown et al. that 
aerosol bolus dispersion, a phenomenon of convective gas mixing, continues to 
deteriorate in CF with increasing overall ventilation heterogeneity measured by 
133
Xe 
washout (Brown, Gerrity et al. 1998). Furthermore, Curv analysis, also considered a 
measure of convective gas mixing (Verbanck, Schuermans et al. 2008), continued to 
increase with LCI (see Figure 5.16). It appears unlikely therefore that convective flow 
heterogeneity reaches an early maximum and shows so little progression in those with far 
more severe lung involvement. The failure of Scond to increase in this study may partly be 
related to the low tidal flows employed. Faster breathing, or greater breath volumes, might 
reveal dynamic differences in flow-resistance between lung units that would increase 
measurements of convective gas mixing heterogeneity beyond those seen at tidal 
breathing. However, this would still fail to explain why Sacin, rather than Scond, is so 
strongly correlated with gas trapping. 
Although the principles of phase III slope analysis were first described over 10 years 
ago, the analysis has largely remained restricted to a single group and their collaborators. 
Only recently have other investigators begun to apply this analysis, most notably in 
children with CF (Gustafsson 2007). Phase III slope analysis is based upon persuasive 
experimental data and modelling, and now supported by a growing number of clinical 
studies (Verbanck, Schuermans et al. 1997; Verbanck, Schuermans et al. 1998; Verbanck, 
Schuermans et al. 1999; Verbanck, Schuermans et al. 2003; King, Downie et al. 2005; 
Verbanck, Schuermans et al. 2006; Downie, Salome et al. 2007). However, these 
assumptions and modelling were derived from histological data on normal lungs (Paiva 
and Engel 1984; Crawford, Makowska et al. 1985). Furthermore, all the studies that have 
reported the use of Scond and Sacin have been in those with mild airways disease; either 
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normal subjects (Crawford, Makowska et al. 1985), smokers (Verbanck, Schuermans et 
al. 2004; Verbanck, Schuermans et al. 2006), those with asthma or bronchial 
hyperreactivity (Verbanck, Schuermans et al. 1997; Verbanck, Schuermans et al. 1999; 
Verbanck, Schuermans et al. 2003; King, Downie et al. 2005; Downie, Salome et al. 
2007), and those with mild-moderate COPD (Verbanck, Schuermans et al. 1998).  
The pathology in CF however is quite different from any of these groups. Adult CF 
patients in particular may have marked suppurative lung disease, with radiological 
evidence of bronchiectasis, regional lung collapse, bullous lung disease, and small 
airways obstruction (Helbich, Heinz-Peer et al. 1999). Even in early disease, 
bronchiectasis, mucus plugging and gas trapping are commonly described features 
(Helbich, Heinz-Peer et al. 1999). It is not clear what effect these fundamental differences 
will have on the assumptions behind the phase III slope analysis but it is of note that Scond 
shows no correlation in CF patients with any other measures of lung function, including 
those such as Raw that might have been anticipated to reflect similar processes (King, 
Downie et al. 2005).  
It is possible that a combination of increasing airway dead space and falling tidal 
volume in CF patients with more severe lung disease might affect gas mixing. This has 
been investigated and shown not to be the case. There was no significant difference 
between dead space: tidal volume ratios in CF and controls, and the values were lower 
than those previously shown to have an effect on LCI (Schmalisch, Proquitte et al. 2006). 
Although there was a statistically significant correlation between ScondVTc and VD/VT, this 
was weak (r=-0.42, p=0.016), unconvincing, and in the opposite direction to that which 
would be expected if this was a true effect. 
There are two possible interpretations of these findings. The first is that, compared 
to other airways diseases (including COPD and asthma), CF represents the severe end of a 
spectrum. The limitations seen on Scond are thus applicable in all diseases, but are apparent 
much earlier in disease progression in CF. This also would explain why other authors 
have so far failed to describe Scond values greater than 0.150. Indeed such a limitation was 
described by Paiva (Paiva 1975) more than 30 years ago in a two-compartment lung 
model. He showed that SnIII would increase sequentially during a washout, and that this 
increase would be steeper with increasing difference in ventilation distribution. However, 
he also showed that this increase in SnIII would reach an asymptote, and that this would 
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occur earlier in the washout with more pronounced ventilation heterogeneity. This is 
precisely what has been described here in patients with CF. It might be possible to make 
inferences about convective ventilation from the level of this asymptote. Unfortunately 
however real life data do not perform as neatly as lung models and the reality is that the 
progression of SnIII tails off rather than coming to an abrupt end, making it hard to 
determine with precision the level of the asymptote or more particularly the breath at 
which it is reached. 
As an adjunct to this, rather than necessarily an alternative, the derivation of Scond 
may be particularly susceptible to the nature of airways disease in CF. The effects on 
ventilation of small airway obstruction due to mucus plugging may be what makes LCI 
such a sensitive measure of early disease in CF. It is also possible that, as disease 
progresses, these same pathological processes invalidate some of the assumptions behind 
phase III slope analysis. Complete obliteration or obstruction of small airways means that 
they will not contribute to convective ventilation (Scond). Furthermore, as larger airways 
become obstructed the diffusion front is moved proximally (i.e. towards the mouth). The 
resulting regional differences in gas distribution therefore occur at very low or zero gas 
flows and are present at the start of the washout. They would thus be measured by the Sacin 
component of phase III slope analysis. This would also explain the association between 
hyper-inflation (a result of small airways obstruction), Sacin, and LCI. This would also 
explain why Sacin correlates with measures of conducting airway obstruction, such as Raw 
and FEV1. This hypothetical model is illustrated in Figure 5.17. More information could 
be obtained about the contributions of the different gas mixing processes by performing 
washouts of two different gas species simultaneously, as has been done with SF6 and 
helium for single breath washouts. Unfortunately, this is beyond the scope of the current 
study. 
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Figure 5.17: Hypothetical model of effects of deteriorating lung function in CF on Scond 
and Sacin. In the healthy lung (top) Scond measures inhomogeneity of gas mixing in the 
conducting airways and Sacin measures diffusion-conduction inhomogeneity in the acinus. 
In early airways disease (middle) there is inflammation of the small airways which causes 
increased convection dependent ventilation inhomogeneity (Scond) but acinar function and 
gas diffusion (measured by Sacin) are unaffected. In patients with significant CF related 
lung disease (bottom) there is inflammation of the small airways which become blocked 
with mucus. This causes gas trapping on expiration but also results in a proximal 
movement of the diffusion front. Thus Sacin is elevated, whilst the region measure by Scond 
is diminished since the small airways are no longer a site of bulk convective flow. This 
also explains the correlation of Sacin with gas trapping. The preserved alveolar integrity 
means that measures of gas transfer are not altered. 
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Methodological differences between this and previous studies 
Since the original description of phase III slope analysis, and the majority of the 
published clinical observations, come from the group headed by Sylvia Verbanck, it is 
necessary to consider how this study differs from her work. In Verbanck’s studies, very 
precise expiratory volume targeting of one litre has been employed (Crawford, Makowska 
et al. 1985; Verbanck, Schuermans et al. 1997). CF patients however, especially those 
with poorer lung function, found it hard to maintain such large tidal volumes. Even in 
healthy controls it can be uncomfortable to breathe large volumes of dry gas for long 
periods, and this is exacerbated in CF patients in whom this can induce the sensation of 
wanting to cough. In this study, therefore, patients were encouraged to maintain a tidal 
volume between 500-1000ml, and expiratory volume feedback was used to assist rather 
than tightly control this. Used in this way, expiratory volume feedback is very effective in 
ensuring uniformity of breathing pattern and volume. Since the strict 1L breath volume 
control is an important feature of the work by Verbanck et al., expiratory volume 
correction has been applied to SnIII, as described by Aurora et al. (Aurora, Kozlowska et 
al. 2005), in order to allow comparison with these studies.  However, the data from the 
two analysis protocols show strong correlation with each other and conclusions from the 
uncorrected data were the same as those presented here. 
Because of the wider range of VT permitted in this study, and the heterogeneity of 
subjects, the range of VT/FRC ratios (see Figure 5.8) are much higher than those that can 
be inferred from previous studies (Verbanck, Schuermans et al. 2004). This could 
influence the relationship between Sacin and LCI if one or the other were more susceptible 
to changes in VT. However, no statistically significant correlation is seen between any 
measure of tidal volume and any measure of ventilation heterogeneity. 
For Scond, the picture is more complex. A tidal volume that is too small may be 
insufficient to generate a true alveolar slope - for this reason breaths of less than 400ml 
were not included in the calculation of Scond. On the other had, particularly in CF patients, 
a phase IV slope may be seen with larger breaths. In order to address the objection that 
insufficient breath volumes were included, a number of further analyses were completed. 
Recalculation of Scond using a minimum breath volume of 850ml actually reduced Scond, 
   
256 
and made no substantial change to the shape of the Scond versus LCI graph (Figure 5.9). 
Secondly, when washouts were selected based upon strict criteria (with a mean tidal 
volume, and within-washout coefficient of variation of breath volume, very similar to that 
described by Verbanck (Verbanck, Schuermans et al. 1998)), the conclusions remained 
unchanged (Figure 5.10). It would therefore appear that, regardless of analysis protocol, 
Scond does not increase with increasing disease severity, but Sacin does.  
 
Effect of tracer gas 
Most previously published studies of phase III slope analysis have been performed 
on nitrogen washouts. SF6 is denser than nitrogen, and its diffusivity is considerably less. 
SF6 may therefore accentuate the diffusive differences in the lungs and lead to differences 
in Scond and particularly in Sacin compared to other, lighter, gases. Gronkvist et al. showed 
a significant increase in Sacin of 30% when measured with SF6 compared to He 
(Gronkvist, Bergsten et al. 2002). The difference between SF6 and nitrogen however is 
likely to be less than this and cannot explain the findings entirely. The values of Sacin 
obtained in CF are higher than those in patients with asthma (mean values range from 
0.113 to 0.264) (Verbanck, Schuermans et al. 1997; Verbanck, Schuermans et al. 1999; 
Verbanck, Schuermans et al. 2003) but they are similar to Sacin values derived from 
nitrogen washouts in CF patients (0.307) (Gustafsson 2007) and COPD patients (0.48) 
(Verbanck, Schuermans et al. 1998). Furthermore, Sacin in healthy controls reported here is 
similar to that previously reported in control groups (Verbanck, Schuermans et al. 1997). 
Finally, Gustafsson reported on nitrogen washouts in children with asthma and CF, and a 
similar degree of impairment in FEV1 (Gustafsson 2007). He showed that despite LCI and 
Sacin being significantly greater in the CF patients, there was no statistically significant 
difference in Scond.  
The values for Scond in controls presented here were lower than those reported in 
nitrogen washouts in healthy adults (Verbanck, Schuermans et al. 2004) and are similar to 
values reported by Aurora et al. in healthy children up to 18 yrs (Aurora, Kozlowska et al. 
2005). In a cohort of 4 subjects, Prisk et al. measured Scond from both nitrogen washout 
and SF6 wash-in simultaneously, and found a non-significant reduction in mean Scond 
calculated from SF6 as opposed to nitrogen (Prisk, Elliott et al. 1998).  They also showed 
a steadily rising plot of SnIII vs lung TO in three of the four subjects. In one subject 
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however, SnIII appeared not to change with increasing breath number for both SF6 and He 
wash-ins (raw data of nitrogen washout not shown). Although these were trained subjects, 
performing SF6 wash-ins, with large tidal volumes (1250ml), the data are consistent with 
the current study. The phase III slope of healthy subjects reported here was usually around 
zero (i.e. near horizontal) and changed very little during the course of a washout. This 
made Scond difficult to calculate in healthy subjects, and more susceptible to the effects of 
outlier values of SnIII. It also partly explains the poor repeatability of the measurement in 
control subjects, since small absolute changes in Scond between washouts translate into 
substantial percent changes. Reproducibility of ScondVTc in CF patients is far better than 
that seen in healthy volunteers, but it is clear that, even in those subjects where Scond can 
be generated with reasonable certainty, reproducibility is poor compared to LCI. No data 
on these variables have been published by previous researchers to allow comparison with 
phase III slope indices derived from nitrogen washouts. 
Another criticism of the data presented here relates to the calculation of Scond in 
controls. When these data were reviewed, the graph of SnIII vs lung TO for the healthy 
volunteer shown in Figure 3a was not felt to show a neat slope. This graph is 
representative of those obtained from healthy volunteers, but there are differences in 
washout analysis that may explain these findings. When washouts are analysed by 
Verbanck’s method, the SnIII data are first averaged for the washout repeats, a method that 
is made possible by the stricter breath volume control (such that every breath of the 
washout has the same TO number). The same method is more complicated with the 
washouts performed for this study, and when this was attempted did not produce 
smoother plots. Another factor that may partially explain the differences is the 
contribution of nitrogen in the blood coming out of solution during a nitrogen washout. 
Although this would only involve very small amounts of nitrogen, this may be enough to 
affect the slope of the alveolar plateau, and is a phenomenon that does not occur with the 
use of an exogenous insoluble marker gas. 
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Summary 
This chapter presents novel data on phase III slope analysis in both children and in 
adults with CF. Although Scond is sensitive to early changes in airway physiology, it does 
not correlate with other measures of gas mixing or airway function due to an early ceiling 
value that is reached even in those with apparently mild disease. Since Scond changes little 
with increasing disease severity, it may not be a useful physiological measurement in CF 
adults. Phase III slope analysis is complex to perform, and is reliant on compliant 
subjects. It thus suffers from being difficult to carry out in patients with CF, and in adults 
with moderate to severe disease the underlying modelling assumptions may be incorrect. 
In these patients the analysis appears to offer few advantages over LCI. Despite 
differences between this study and those of Verbanck et al. in the performance of the 
washout test and analysis, the present findings appear to be robust and are not merely an 
artefact of less rigorous tidal volume control. 
There are a number of questions posed by this work. In particular the validity of 
volume correction of phase III slope analysis is not universally accepted, although no 
effect of this on the final conclusions of this study has been shown. In addition, other 
studies have shown convincing progression of SnIII in healthy controls, and have not 
reported negative values of Scond in adults. Whether this is an artefact of less intense 
breath volume control, or an effect of using SF6 as the tracer gas, remains unclear. It 
would require a mass spectrometer to simultaneously perform nitrogen and SF6 washouts, 
something that is beyond the scope of the present work. 
None of this negates the use of this phase III slope analysis in subjects with mild 
non-CF airways disease. However, fundamental differences in airway pathology exist 
between asthma and CF and caution should be applied in extending observations from 
patients with mild airways disease into patients with more severely disordered regional 
ventilation. 
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Chapter 6 - Short term effects of physiotherapy on 
spirometry and multiple breath washout in the CF lung 
 
Introduction 
Physiotherapy is a recognised treatment in cystic fibrosis, and is widely used to aid 
clearance of secretions. Despite having been an accepted therapy for many years, there is 
actually little hard evidence of benefit in terms of effect on lung function (Bradley, Moran 
et al. 2006). Although there are numerous small studies looking at the effects of different 
physiotherapy techniques, previous attempts to assess the effects of physiotherapy on 
routine lung function measurements have failed to show an improvement over no 
physiotherapy (van der Schans, Prasad et al. 2000). Since LCI appears to be more 
sensitive to airway physiology than spirometry, it was hypothesised that it may be more 
sensitive to the effects of physiotherapy as a short term intervention. In particular, it was 
hypothesised that improved clearance of secretions, such as have been demonstrated 
following chest physiotherapy (van der Schans, Prasad et al. 2000), would improve lung 
gas mixing and lead to a reduction in LCI.  
Highly heterogeneous gas mixing would also lead to uneven distribution of 
nebulised therapies, including gene therapy. It was therefore recognised that this study 
would also provide important information about the best methods of preparing the lungs 
of CF patients for nebulised therapies. If a benefit, in terms of LCI, could be shown with 
physiotherapy, this would support its use prior to gene therapy as a method of reducing 
the amount of mucus in the lungs and reducing unevenness of distribution of therapy. The 
original hypothesis was that successful airway clearance would improve gas mixing and 
lead to a reduction in LCI. 
 
The aims of this study were to: 
 
 1. To assess the effect on LCI of 30 minutes of active cycle breathing 
physiotherapy compared to a control group who receive no physiotherapy. 
 2. To compare this to the effect on spirometry. 




This was an open-label cohort study, which involved 14 patients with cystic fibrosis, 
recruited from the Scottish Adult CF Service. Patients underwent assessment of lung 
clearance index (LCI) with three washout manoeuvres, according to the standard protocol 
(as described in Chapter 3), followed by spirometry. Subjects were then assigned to 
receive either no physiotherapy or 30 minutes of active cycle of breathing technique 
(ACBT) (described below), administered by a senior respiratory physiotherapist. Subjects 
were assigned on the basis of availability of the physiotherapist to perform this. Subjects 
who were not assigned to physio remained seated for 30 minutes, and were allowed, but 
not encouraged, to expectorate. All sputum expectorated between LCI measurements was 
collected in a pre-weighed pot. Immediately after the physiotherapy or rest period, 
subjects repeated three LCI measurements, again followed by spirometry. Patients in the 
control (no physiotherapy) group were then offered the same 30 minute period of 
physiotherapist-assisted ACBT chest physiotherapy.  Figure 6.1 shows a summary of the 
study design. 
The original study design had an additional 10 minutes for description of ACBT 
built into the physiotherapy period. This turned out to be unnecessary, since all subjects 
were familiar with the technique, and a much briefer practical summary was provided by 
the physiotherapist instead, with the treatment period reduced to a total of 30 minutes. 
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Inclusion criteria 
1. Cystic Fibrosis patients under the care of the Scottish Adult CF Service  
2. Chronic sputum producers 
3. Usual FEV1≥40% predicted 
4. Whether carrying out regular physiotherapy or not.  
 
Exclusion criteria 
1. Usual FEV1<40% predicted. 
2. Regular / pre-physio short acting bronchodilators. 
3. Patients whose airways were colonised by Burkholderia sp. or MRSA. 
 
Patients were not excluded if they were prescribed and taking “as required” short 
acting bronchodilators, regular long acting bronchodilators or inhaled corticosteroids. 
Patients were also not excluded if they were on nebulised antibiotics or DNase. 
All subjects provided written, informed consent, and this study was approved by the 
Lothian Research and Ethics Committee. 





Figure 6.1: Study protocol design. Subjects completed triplicate MBW measurements, 
followed by spirometry, followed by 30 minutes of active cycle breathing (ACB) 
physiotherapy or a rest of 30 minutes. MBW and spirometry were then repeated 
immediately after this. 






Approximate time taken: 
45mins                             30mins                        45mins 
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Lung function assessments 
Lung clearance index 
Lung clearance index (LCI) was measured by multiple breath inert gas washout, 
using the modified Innocor gas analyser (Innovision, Odense, Denmark) and 0.2% SF6 as 
the tracer gas, as described in Chapter 3.  
 
Spirometry 
FEV1 and FVC are quoted as the highest of three repeat manoeuvres (Miller, 
Hankinson et al. 2005). Predicted values for FEV1 are those provided by the European 
Community for Coal and Steel (adults≥17 yrs) (Quanjer, Tammeling et al. 1993). Lung 




Active cycle of breathing physiotherapy was selected as the physiotherapy 
intervention. This technique is familiar to the majority of patients, and consists of a series 
of forced expirations (huffs), interspersed with thoracic expansion exercises, relaxation 
and breathing control (Prasad 1993). Huffs performed from mid to low lung volumes are 
considered to allow mobilisation of more peripheral secretions. Although chest 
percussion, positive expiratory pressure devices, or autogenic drainage can be used as 
adjuncts to this technique, they were not employed in this study and subjects performed 
physiotherapy sitting in a chair. All expectorated sputum was collected in a pre-weighed 
container. 
Patients were asked to withhold their usual physio on the day of assessment. 
 




Data were analysed using Prism (GraphPad Software Inc, CA, USA). Normal 
distribution was assessed using the D’Agostino and Pearson omnibus normality test. 
Parametric data are quoted as mean (SD), unless otherwise stated, and were compared 
using t-tests. Non-parametric data are quoted as median (inter-quartile range), and 
compared using the Mann-Whitney U test. Correlations were analysed using Spearman’s 
rank correlation.  
 
Results 
Fourteen patients were recruited and completed the study. Nine subjects underwent 
physiotherapy and five subjects completed the control arm. Summary demographics are 
presented in Table 6.1 and a summary of the individual subjects, including potential 
confounding factors, is presented in Table 6.2. Although subjects with a usual baseline 
FEV1 of less than 40% were not approached, three subjects failed to achieve an FEV1 of 
≥40% on the day of assessment, including one subject with an FEV1 of 21% predicted. 
These subjects nonetheless completed the study. The reason for not approaching those 
with FEV1<40% was that these subjects tend to take longer to complete washouts, and it 
was felt that the study would be excessively prolonged in those with the most severe lung 
disease. There were no differences between groups in age or baseline percent predicted 
FEV1. Baseline LCI was significantly higher in the control group (p=0.046). However this 
difference only just achieved statistical significance and should be interpreted with 
caution given the small numbers of patients involved. 
From Table 6.2, it can be seen that some patients attended for assessment having 
already completed their physiotherapy that day. In addition, three subjects had taken short 
acting bronchodilators within the preceding four hours. It was impractical to delay the 
study for those who had already completed chest physiotherapy or taken bronchodilators. 
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n 9 5   
M:F 7 : 2 3 : 2   







(-16.9 to 4.0) 
0.20 
Median baseline 













[10.6 – 14.6] 
17.0 
[10.2 – 17.8] 
-2.7 
(-5.3 to -0.1) 
0.05 
 
Table 6.1: Summary demographics of patients.  
 
































Physio 3 27 M 38.6 150 AD & flutter 3hrs 
DNase 
Colomycin 
Completed physio  
< 3hrs previously 
Physio 4 44 F 49.7 0 to 30 
ACB & 
percussion 
3d nil  
Physio 5 17 M 53.6 30 to 50 ACB 12hrs DNase  





days-wks nil  
Physio 7 21 M 52.6 10 AD weeks nil  
Physio 8 20 M 99.4 10 Accapella >12hrs nil  
Physio 9 19 M 70.3 15 ACB 12hrs Colomycin  




Control 2 24 M 33.5 15 to 30 AD >12hrs nil  
Control 3 34 M 41.5 0 to 100ml 
Mix of ACB, 
Flutter, PEP 
>12hrs nil  
Control 4 18 M 47.0 up to 50 AD 1.5hrs DNase 
Took Bricanyl   
< 1hr before 
Control 5 41 F 97.6 up to 60 ACB + AD 18hrs Colomycin  
 
Table 6.2: Individual patient summary. 
ACB = Active cycle of breathing, AD = Autogenic drainage, PEP = positive expiratory 
pressure device 
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Effects of physiotherapy on LCI and Spirometry 
There were no significant changes in group mean FEV1, FVC, LCI or FRC after 
either intervention (physio or control).  Mean % change in FRC and LCI in the physio 
group was non-significantly higher than in controls (5.73 vs 1.92%, p=0.06, and 4.07 vs 
2.55%, p=0.15, respectively). There was a wider variability in % change in both of the 
MBW variables after physiotherapy than in spirometry or in the control group (see 
Figures 6.2 to 6.4). Maximum change in LCI in controls was 7%. In contrast 4/9 of the 
physiotherapy group had a change in LCI of greater than +/- 7%, and overall maximum 
change was 15%. Similarly maximum change in FRC after physiotherapy was 21% vs 7% 
in controls. There was no consistent pattern of response, and no correlation between 
change in the individual markers of lung function (FEV1, FRC and LCI). 
Median wet weight of sputum expectorated after physiotherapy was 3.33g. This was 
not significantly different to that expectorated in control subjects (3.29g), though once 
again there was a greater range of values in the physio group (Figure 6.5). 
When sputum weight was plotted against lung function, the only significant 
correlation was with absolute percent change in LCI (Spearman r=0.62, p=0.018) (see 
Figure 6.6). 
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  Physio Control 
 FEV1 (L) 
Start 2.45  
(2.28-3.00) 
1.75  
(1.14 – 2.31) 
End 2.48  
(2.17 – 2.88) 
1.70 
(1.12 – 2.37) 
Median % change 
(range) 
2.36 
(-9.14 – 11.01) 
0 
(-4.57 – 4.64) 
FVC (L) 
Start 4.06 
(3.16 – 4.12) 
3.53 
(2.16 – 3.83) 
End 3.92  
(3.66 – 4.51) 
3.56 
(2.27 – 3.85) 
Median % change 
(range) 
-3.62 
(-6.61 – 22.11) 
0.54 
(-4.17 – 8.68) 
LCI 
Start 13.2 
(11.4 – 14.3) 
17.0 
(12.8 – 17.6) 
End 13.6 
(11.5 – 15.1) 
17.0  
(12.9 – 18.5) 
Median % change 
(range) 
4.07  
(-7.65 – 14.8) 
2.99 
(-1.29 – 7.04) 
FRC (L) 
Start 2.89 (2.26 – 3.21) 3.34 (1.67 – 4.52) 
End 2.92 (2.41 – 3.36) 3.41 (1.69 – 4.61) 
Median % change 
(range) 
5.18  
(-2.23 – 20.54) 
1.90 
(-3.98 – 7.03) 
Sputum wet weight (g)  3.33 (1.39 – 5.43) 3.29 (0.45 – 6.36) 
 
Table 6.3: Summary of lung function, pre and post intervention, in physio and control 
groups. Data are presented as median (interquartile range), except the data on median % 
change, where the entire range is given. “Median % change” refers to the intra-subject 
percentage change in the parameter described, rather than change in group median.





































Figure 6.2: Change in spirometric indices pre and post-intervention for the physiotherapy 
and control groups. Each pair of points joined by a single line represents paired 
measurements on a single subject. 
 





















































Figure 6.3: Change in MBW indices pre and post-intervention for the physiotherapy and 
control groups. Each pair of points joined by a single line represents paired measurements 
on a single subject. 














































Figure 6.4: Summary of percent change in the different lung function variable in the two 
groups before and after intervention. Each point represents the percent change in a single 
individual. Horizontal bars represent group mean. 
Increase in LCI indicates increased ventilation heterogeneity. Increase in FRC suggests 
opening up of previously unventilated lung. 
worse LCI 































Figure 6.5: Comparison of wet weight of sputum expectorated in each group between the 
two MBW assessments. Each point represents a single individual, horizontal bars 
represent group mean. 
 




























Figure 6.6: Correlation between wet weight of sputum expectorated, for all subjects, 
during intervention period and absolute percent change in LCI. The non-parametric 
regression line is shown as a dotted line. 
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Discussion 
When this study was originally conceived, it was anticipated that physiotherapy, by 
aiding the clearance of mucus from the lungs, would improve gas mixing and lead to a 
reduction in LCI. This is not what was found. Although none of the lung function 
parameters achieved a statistically significant change after physiotherapy, the trend was 
for an increase in LCI, and in FRC.  
There are a number of methodological issues with this study that need to be 
considered (see below), not least the small numbers involved, which make it hard to arrive 
at any firm conclusions. However, it would appear from Figures 6.2 to 6.4, that 
physiotherapy has complex effects on MBW measurements. Whilst the paired spirometry 
measurements, and the paired control group MBW measurements, changed relatively 
little, there was a wide spread of % change in LCI and FRC in the physiotherapy group. 
However, there was no consistent pattern of change, and no correlation between the 
change in the different lung function variables.  
Since this study was commenced, other evidence has come to light which supports 
and helps to explain this observation. The first concerns two abstracts from the paediatric 
physiology  research group at Great Ormond Street Hospital, who have been using LCI to 
follow longitudinal changes in two groups of children assigned to different physiotherapy 
positive expiratory pressure (PEP) devices (Main, Tannenbaum et al. 2004; Main, 
Tannenbaum et al. 2006). In the first of these abstracts, Main et al. reported on a cross-
sectional analysis of 11 children (median age 12.9 yrs) before and after physiotherapy 
with either the PEP mask or the Cornet device (an oscillatory expiratory pressure device). 
There was no control group for this study, but they showed a non-significant elevation in 
mean LCI, and 4 of the subjects showed a significant elevation in LCI after physiotherapy 
(Main, Tannenbaum et al. 2004). This is concordant with the conclusions from this study, 
that physiotherapy can cause an elevation in LCI. 
The second piece of work, which helps to explain some of these observations, 
relates to hyperpolarised helium MRI scanning in CF patients before and after chest 
physiotherapy. Hyperpolarised helium MRI scanning involves the subject inspiring a 
single vital capacity breath containing helium 3. This is first hyperpolarized to align the 
spins of the helium nuclei, which improves resolution of MRI and allows an image to be 
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obtained of the distribution of that breath in the lungs (van Beek and Wild 2005). Mentore 
et al. reported on the changes in ventilation distribution images in 15 CF adults (Mentore, 
Froh et al. 2005). In eight of the patients they also recorded MRI before and after 
salbutamol, and then again after nebulised DNase followed by 30 minutes of chest 
physiotherapy. There was evidence of ventilation heterogeneity in CF patients with 
normal FEV1 using MRI, a finding which is consistent with those described in this thesis 
with LCI (Chapter 3). In the eight subjects who underwent further investigation, there was 
a significant improvement in ventilation heterogeneity after salbutamol, despite no change 
in FEV1. After physiotherapy, there was an increase in ventilation heterogeneity in 6 of 
the 8 subjects. More importantly, this increase in ventilation heterogeneity was 
unpredictable, with some areas becoming ventilated that were not previously ventilated, 
and some becoming less well ventilated that were previously well ventilated. An image 
taken from this paper is reproduced in Figure 6.7. These observations were repeated by 
Woodhouse et al., who reported on 9 children with CF before and after physiotherapy, 
and showed a similar unpredictable change in ventilation distribution (Woodhouse, Wild 
et al. 2007). 
Both of these reports support the findings of this study, namely that physiotherapy 
causes alterations in lung gas mixing which appear to be greater than those of control 
subjects who have not undergone physiotherapy. It does not appear to be possible to 
predict which factors determine how LCI will change, certainly not from the small 
numbers involved in this study. It is likely that similar processes to those discussed in 
Figure 4.33 are occurring with physiotherapy. 
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Figure 6.7: Taken from Mentore et al. (Mentore, Froh et al. 2005). Coronal 
hyperpolarised helium MRI images of a representative subject with CF at baseline, after 
nebulised salbutamol (albuterol) and following treatment with nebulised DNase and chest 
physiotherapy. Ventilation is shown in light grey, with dark areas representing areas of 
regional hypoventilation. The number of ventilation defects decreased after salbutamol 
(middle image), and then increased again after DNase and physiotherapy (e.g. area 
indicated by arrowhead).  
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Limitations of the study 
 
There are a number of methodological limitations with this study that require further 
consideration. The study design was compromised by practical and logistical limitations, 
and it would have been preferable to have repeated measurements at least once more, after 
a short rest period (e.g. 1 hour after physiotherapy). It is known that sputum loosened at 
physiotherapy is often not expectorated until 1-2 hours later (Van Ginderdeuren, 
Verbanck et al. 2007), and it may be that any beneficial effect of physiotherapy on LCI 
would not be seen until this time. However, the two assessments and intervention already 
took around 2 hours for the majority of patients, and even this was an unpalatably long 
study for many. For the same reason, it was not possible to use a crossover study design, 
in what is already a heavily studied CF population. Patients with more severe lung disease 
(i.e. FEV1<40% predicted) were not approached, as they were likely to require even 
longer to complete the study, but it is possible that greatest change in gas mixing would 
have been seen in those with the most abnormal gas mixing, and most copious sputum 
production, at the start. 
It is unfortunate that some patients arrived having already recently completed 
physiotherapy or taken bronchodilators. Because of the small numbers, no subgroup 
analysis is possible on these subjects, but this may have reduced the effects of further 
treatment in the two patients who were in the physiotherapy group but had already 
performed physiotherapy on themselves that morning. Patients had been asked to forego 
morning physiotherapy if possible, but it was recognised that if patients felt that they 
required physiotherapy they should not withhold it for the purposes of this investigation. 
Although there were no statistically significant differences between the two cohorts 
in terms of baseline variables, this also reflects the small numbers involved. It can be seen 
from Figure 6.2 and 6.3 that the subjects in the physio group tended to be less unwell than 
those in the control group, with higher mean FEV1 and lower mean LCI. In addition, from 
Table 6.2 it would appear that those in the physio group were less heavy producers of 
sputum than those in the control group, although this can be difficult to quantify from 
subjective recall. With hindsight, it would have been useful to have provided the patients 
with a sputum pot to collect all sputum expectorated in the preceding 24 hours. 
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The final, and possibly most important, limitation of this study concerns the 
adequacy of the control group. All subjects, including those in the control group, 
completed spirometry after the first set of LCI measurements. Unfortunately spirometry - 
being a forced expiratory manoeuvre - is very similar to the manoeuvres used in 
physiotherapy, and often induces coughing and expectoration in patients. This can be seen 
from the weight of sputum expectorated by the control group during the 30 minute period 
of resting, which was very similar to the amount expectorated by the physiotherapy group. 
If these subjects expectorated at this rate all day, they would produce considerably more 
sputum than they described. This may help to explain some of the variability seen in LCI 
and FRC in the control group, and makes comparisons between the control and active 
intervention groups less reliable. 
 
Implications for future research 
This study highlights some of the difficulties with clinical studies, particularly in 
cystic fibrosis patients. Patients with CF are very heterogeneous in terms of disease 
severity, have an already considerable treatment burden and, particularly in Edinburgh, 
are a heavily studied group. In order to study patients in whom change was likely, the 
requirement for this study was that patients be sufficiently affected by CF to be chronic 
producers of sputum, whilst avoiding those with the most severely affected lungs. This 
places significant restrictions on the numbers of subjects available to be recruited to the 
study.  
The study also highlights the need for balanced groups. Although there were no 
statistically significant differences between the control and intervention groups in terms of 
baseline physiology and demographics, this is likely to be an artefact of the small 
numbers involved. Inspection of the raw data, summarised in Table 6.1, reveals 
convincing evidence that the control group were less well than the intervention group, 
with lower median FEV1 and higher median LCI. If the groups are not comparable, 
particularly likely when small numbers of participants are involved, this can distort the 
conclusions. Strategies for balancing the groups include stratifying the group allocation 
based upon key clinical indicators, such as baseline FEV1 or sputum production.  
Another learning point from this study is the importance of controlling conditions. 
This is particularly relevant in terms of those subjects who completed physiotherapy, or 
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who took bronchodilators shortly before attending for the study. It was impractical to 
require them to attend on a later occasion, but this may have affected the amount of 
sputum they were able to expectorate.  
Finally, there is the issue of the spirometry, one of comparative measurements, 
affecting the primary outcome, LCI. This was a failing of study design, and was one of 
the key learning points of this study – a lesson that has been incorporated into subsequent 
study design. It had been appreciated prior to this that spirometry might interfere with 
LCI, and this is why spirometry has always been performed after LCI. The extent of the 
effect was however underestimated. 
If this study were to be repeated, the design would be amended to a randomised 
crossover study, notwithstanding the difficulties this might present in terms of 
recruitment. The restrictions on patient eligibility would be relaxed to include those who 
produced any sputum (at one end of the spectrum) to those with FEV1>30% predicted (at 
the other end). The difficulty of assessing LCI in those with the most severe lung disease 
remain, and it would be inappropriate to approach those with FEV1 below 30% predicted. 
Tests would only be performed in the morning, in those able to withhold morning 
physiotherapy, and inability to do this would be an exclusion criterion for the study. This 
should maximise the volume of sputum produced and hence the chance of detecting a 
measurable change in LCI. All short-acting bronchodilators and other nebulised therapies 
would be omitted pre-physiotherapy, and patients unable to complete physiotherapy 
without these would not be included. Patients would also be asked to provide a 24 hour 
sputum collection for the preceding 24 hours, on each study day.  
The protocol would be amended to include “baseline” spirometry on day 1, followed 
by 24 hour sputum collection, followed by assessment 1 on day 2, and assessment 2 on 
day 3. Each assessment would consist of LCI, followed by intervention, followed by LCI 
immediately, and again at 90 minutes post intervention (see Figure 6.7 for amended study 
proposal). All sputum would be collected. Spirometry would only be performed after the 
third LCI assessment (i.e. at the end of the assessment), so as not to interfere with sputum 
production or LCI. This design would mean that FEV1 could not be used as a comparative 
outcome measure since it is not measured immediately pre-physiotherapy, but this is an 
acceptable limitation in order to assess the effects on LCI properly. 








Figure 6.8: Proposed amended study protocol, based upon experience gained from the 
study described in this chapter. The study is now a randomised crossover design, and 
requires subjects to attend on three occasions. Subjects are randomised at day 2, and 
receive the alternative intervention at day 3. Each of the two LCI assessment days is now 
longer, with a third assessment at 90 minutes post intervention. The merits and difficulties 
with this study design are discussed in the text. 
Wait 
30mins 
LCI & spirometry 
Day 1 
1. Consent 
2. Baseline spirometry 
3. Provide sputum pot and instruction 














LCI & spirometry 
Wait 
(Total 90mins  
post physio) 
Day 3 
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The use of a crossover study design avoids the need for complex group stratification 
protocols. This would considerably increase the burden of the study on subjects, and is 
likely to affect recruitment negatively. However, it would offer the best chance of 
detecting a consistent change in LCI with physiotherapy, something that has not been 
possible with the current study design. At the moment, such a study is unfortunately not 
possible in Edinburgh because the ongoing CF research precludes additional recruitment 
of subjects to such a demanding schedule.  
 
Summary 
Despite the limitations of this study, chest physiotherapy does appear to cause 
changes in LCI and FRC in patients with CF, despite unpredictable direction of change 
and little effect on spirometry. This contradicts the original hypothesis – that 
physiotherapy would improve lung gas mixing – and may stem from the movement of 
secretions in the small and medium sized airways.  
It is not known what happens subsequently though, and it may that, if assayed a few 
hours later, LCI would improve or return to baseline. That LCI changes at all with 
physiotherapy however, supports its role as a sensitive marker of airways function in 
these patients. It is less clear what this means for gene therapy delivery. It would appear to 
make sense to precede therapy with physiotherapy in order to encourage expectoration of 
secretions. However, this may actually worsen ventilation heterogeneity in the short term, 
and perhaps nebulised therapies should be delayed for an hour or so afterwards in order to 
let this settle, though there is a lack of hard evidence to support this suggestion. 
Important lessons have been learned from this study about the sensitivity of LCI to 
respiratory interventions, and the importance of controlling timing of these. A proposal 
for an improved study design is included, which would address the majority of these 
issues, albeit at the expense of a more demanding study schedule. 
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Chapter 7: Discussion 
Both within the CF Gene Therapy Consortium and in the larger CF research 
community, there is a need for sensitive, repeatable, and practical measures of airways 
disease (Rosenfeld 2007). Neonatal screening offers the opportunity to detect those with 
milder mutations early on, before lung disease becomes well established. Longitudinal 
assessment of these subjects will therefore require better physiological tests than are 
routinely available. From a gene therapy perspective, sensitive measures that reflect 
disease in the airways of interest are necessary if any physiological change in response to 
therapy is to be demonstrated without requiring very large numbers of subjects (Que, 
Cullinan et al. 2006). 
In all of these respects MBW tests, and in particular LCI, offer distinct advantages 
over conventional lung function assessments. Prior to the studies presented here, LCI was 
already recognised to be a more sensitive measure of airways dysfunction in children, 
with a normal range that was stable throughout childhood (Gustafsson, Aurora et al. 2003; 
Aurora, Gustafsson et al. 2004; Aurora, Bush et al. 2005). These assessments were 
performed using a mass spectrometer, which is impractical for the multi-centre studies 
planned by the CF Gene Therapy Consortium.  
The first part of this thesis deals with the technical capabilities of an alternative gas 
analyser, one that was originally developed and marketed for an entirely different role. On 
paper the Innocor device presents an attractive option for use in multiple breath washouts, 
as it is both compact and robust, and already contains the two important elements of a 
MBW apparatus – a gas analyser and a pressure transducer for a flow meter. However, the 
device has not been designed for the purpose of MBW assessment, and requires both 
physical modification and the use of custom-prepared software to interpret the data.  
The result of the modifications described in Chapter 2 is a system that is practical 
for use in multi-centre studies with a high patient throughput. In order to achieve this, 
compromises have been necessary. For example, the calculation of flow-gas delay used is 
that generated by the Innocor device from a series of fast inspirations. Although the 
reproducibility of this is good, the calculations are not open to close inspection by the 
operator, and also require the inclusion of the on-board oxygen analyser. This is in series 
with the photoacoustic gas analyser and is known to adversely affect rise time. Alternative 
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methods of assessing flow-gas delay are possible, which could reduce variability in how 
the manoeuvre is performed, but would require additional hardware and software and are 
outwith the scope of the work presented in this thesis. 
The second part of this thesis deals with the use of the modified Innocor device in 
clinical assessments of healthy subjects and patients with cystic fibrosis. It has been 
shown that washouts can be performed in the majority of controls and patients, and that 
this assessment can usually be completed within 10 minutes in patients with CF. The 
number of washouts that failed to meet quality control criteria was small, consisting of 
less than 2% of all washout repeats in adults. In healthy volunteers and those with mild 
CF, intra-visit reproducibility of LCI was good. In those with more severe disease 
however, the reproducibility of repeat measurements was seen to deteriorate, and this 
reflects the clinical experience that these subjects tend to find the washout harder to 
complete and often have less comfortable and relaxed breathing patterns. The reasons for 
this may include the effects of dry gas mix on the mouth and lungs, mouthpiece 
discomfort and accumulation of saliva around the mouthpiece. In these subjects, with very 
abnormal gas mixing, LCI is a less useful physiological assessment. 
In healthy subjects, the normal range of LCI is remarkably stable over a wide age 
range, in contrast to standard measures of lung function. Normal LCI is also reproducible 
between different centres, and the normal ranges reported in this thesis are almost 
identical to those previously published in paediatric populations (Gustafsson, Aurora et al. 
2003; Aurora, Gustafsson et al. 2004). This is a major advantage of LCI over spirometry, 
and makes it particularly suitable for longitudinal assessments and in adolescents. In 
adults, the sensitivity of LCI to disease status means that it is elevated even in CF subjects 
with normal spirometry and no symptoms. Since an abnormality can be measured, the 
effect of therapeutic interventions on lung physiology can now be assessed in these 
subjects. They form an ideal cohort in which to assess the effects of gene therapy, not 
least since the condition of their lungs most closely mimics that of children, in whom it is 
not currently possible to trial gene therapy.  
In patients, as might be expected, there is a significant correlation between FEV1 
percent predicted and LCI. Although the relationship between disease severity and 
genotype is complex, LCI is more abnormal in those with pancreatic insufficiency and 
   
283 
shows a trend to greater abnormality in those with chronic colonisation of the lungs with 
Pseudomonas aeruginosa.. 
The third part of this thesis concerns the effects of interventions on LCI. Two 
interventions have been reported on: intravenous antibiotics in CF patients undergoing an 
exacerbation, and lung physiotherapy in chronic sputum producers. In the first of these 
studies, there was a small fall in LCI in those treated with antibiotics. Although this fall, 
relative to baseline, was no greater than that in FEV1, there was considerable 
heterogeneity in the response to antibiotics with some subjects showing an elevation in 
LCI. This may reflect the opening up of previously poorly ventilated lung regions by 
treatment. In some of these subjects, with already very abnormal gas mixing and 
significant structural lung disease, LCI may not be ideal as a clinical outcome. This was 
also seen when the effects of physiotherapy on LCI were investigated. Although formal 
physiotherapy appeared to have a greater effect on LCI and FRC than spirometry alone, 
the effect was neither consistent nor predictable, and was as likely to lead to a 
deterioration in LCI as an improvement. However, the fact that an improvement in LCI 
with antibiotic therapy could be shown, even in those with the lowest initial LCI, is 
reassuring for the use of LCI as an outcome measure.  
Neither of the two interventions described is an ideal surrogate to predict the 
usefulness of LCI in measuring the effects of gene therapy. Both preferentially involve 
patients with more marked lung disease, either because these are more likely to 
experience exacerbations or to be chronic sputum producers, and these are not the ideal 
candidates for nebulised gene therapy. The CT data described in Chapter 4 show clearly 
that the majority of the patients had substantial structural lung disease that did not 
improve with antibiotics, and would result in impaired gas mixing efficiency even if the 
acute inflammation was entirely resolved. Furthermore, in both cases there is likely to be 
widespread disease of both small and large airways, as confirmed by the CT scans 
performed after antibiotics. Since the advantages of LCI lie in measuring early airways 
disease, assumed to be occurring largely in the small airways, it may not be the best 
outcome measure for the studies described here.  Alternative studies that LCI may be a 
more appropriate and sensitive outcome measure for include the effects of nebulised 
hypertonic saline, DNase or azithromycin. The effect of these interventions on LCI in 
subjects with mild disease and normal spirometry could be the subject of future research. 
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The experience of assessing LCI before and after physiotherapy, although difficult to 
interpret, has provided important insights into the effects of spirometry on lung gas 
mixing which would assist in the design of future short-term interventional studies.   
Although LCI is the most commonly reported MBW analysis, there has been 
increasing interest in the use of phase III slope analysis of MBW in order to separate the 
effects of ventilation heterogeneity in the conducting airways and at the diffusion front 
(Cosio 2006). In CF however, this does not appear to be a useful analysis perform. Scond, 
proposed as a measure of convective ventilation heterogeneity in normal subjects and 
those with mild airways disease (Verbanck, Schuermans et al. 1997), is elevated very 
early in the course of CF, including in children and those with normal LCI. However, it 
fails to reflect worsening convective gas mixing with increased disease severity. This 
appears to be due to theoretical and practical limitations of the analysis, rather than to 
convective gas mixing reaching a true maximum. Phase III slope analysis therefore adds 
little to MBW analysis in patients with CF, and it is not proposed that it be used in future 
analyses in this patient group. 
 
Proposals for future research 
Much of the impetus to develop MBW techniques has come from paediatricians, 
driven by the requirement for simple non-invasive and sensitive measures of early airways 
disease (Gustafsson 2005). Most notably this has been in the field of CF research, but the 
benefits of MBW analysis in other disease groups in children has recently also been 
recognised (Macleod, Horsley et al. 2008). Although the Innocor gas analyzer has been 
used in children down to the age of 5 yrs, it would not, in its’ current format, be suitable 
for use in children and infants younger than this. The two aspects of its’ function that are 
likely to restrict use in younger subjects are the gas analyzer response time (160 ms) and 
the gas sample flow rate (120 ml/min). In order to permit use in pre-school children, these 
would either have to be substantially altered to fit with current recommendations 
(Beydon, Davis et al. 2007), or further validation would be required, using appropriate in 
vitro models, to demonstrate that the system was accurate at high respiratory rates and 
low tidal volumes. The technical demands of performing MBW tests in infants mean that 
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both current response time and gas sample flow rate are excessive for use in these 
subjects.  
There are a number of techniques by which the Innocor performance could be 
improved. Firstly, removing the oxygen analyser affords some improvement in analyser 
response time. Alterations to the gas sample line and gas sample flow rate could also 
affect gas signal rise time (Schena, Thompson et al. 1984). In order to make the Innocor 
device a more straightforward system for MBW tests, the on-board software would need 
to be altered to allow better display of real time flow and gas signals, as well as breath 
volume feedback. Both of these aspects can only be pursued with the assistance of the 
manufacturers. 
In CF, there is a need for more work on the longitudinal changes in LCI. As 
discussed in the previous section, there is also a need for intervention studies in subjects 
with milder disease both to assess the short term effects of interventions on airways 
function, as well as the longer term effects. LCI would appear to be an ideal tool for these 
sorts of studies. 
In adults, much of the previously published work on washouts has focussed on Scond 
and Sacin, products of phase III slope analysis. These studies have largely focussed on how 
Scond and Sacin relate to the underlying diseases, but have also shown the value of washouts 
in adults with mild disease. In particular, there is increased ventilation heterogeneity in 
smokers with no other evidence of lung function impairment (Verbanck, Schuermans et 
al. 2004), and in ventilation heterogeneity in response to inhaled corticosteroids (Downie, 
Salome et al. 2007). In adult studies, despite the availability of a range of proposed small 
airway assays (Cohen, Douma et al. 2008), there remains a need for sensitive and 
repeatable measures that can reliably reflect small airways function. Areas where there is 
a particular need for these include the early, non-invasive, identification of bronchiolitis 
obliterans in lung transplant patients. At present, this is identified initially by changes in 
the mid expiratory flows, but these tests are poorly reproducible and not reliable in those 
with airflow obstruction due to narrowing around the anastomosis. Changes in single 
breath washout tests have been shown to predate those of FEF25-75 (Estenne, Van Muylem 
et al. 2000), and there is good reason to expect LCI to do the same . 
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MBW analyses may also be able to identify early airways disease in healthy 
smokers with normal spirometry, or to detect response to treatment in asthmatics. At 
present, the use of MBW tests remain under-exploited in adult studies. 
The washout curves contain considerably more data than that represented by LCI 
alone, and a number of alternative analyses are possible. Data presented in this thesis, as 
well as additional analyses not described here, have failed to identify a superior measure 
of ventilation heterogeneity in terms of sensitivity or robustness. However, it is possible 
that different measures may be more suited to different patient groups. It is also possible 
that wash-in curves could provide much of the same information, whilst halving the time 
required for the investigation, and therefore greatly improving patient acceptability. 
 
In summary, the following future studies are proposed: 
1. Improving Innocor performance to facilitate use in younger subjects* 
2. Improving Innocor operating system 
3. Longitudinal assessments of gas mixing in CF* 
4. Long term response to interventions likely to affect small airways in CF, e.g. 
DNase, hypertonic saline, azithromycin. 
5. Use in bronchiolitis obliterans* 
6. Use as an endpoint in asthma intervention studies 
7. Detection of early airways disease in smokers* 
8. Analysis of wash-in curves* 
 
* Currently under investigation with the assistance of other researchers. 
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Appendix A – Standard operating procedure for use of 





Part 1: Background 
  • Innocor 
  • Lung Clearance Index 
 
Part 2:  Hardware Adaptations 
 
Part 3:   Software Settings 
 
Part 4:   Daily Checks 
 
Part 5:  Performing a Test  
 
Part 6:  Special Considerations in subjects under 16 yrs 
 
Part 7:  Data Export 
 
Part 8:  Infection Control  
 
Part 9:  Innocor Usage Log 
 
Part 10:  Data analysis 
 
This manual is for the use of Innocor to lung clearance by inert gas washout. The entire process from setting 
up the machine to exporting data is covered. The principles of data analysis are also covered in a separate 
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Part 1: Background 
 
Lung Clearance Index 
Inert gas washout is a technique for assessing the efficiency of gas mixing in the lungs. It 
involves measuring the elimination of a non-absorbed gas as it is exhaled during tidal 
breathing. The gas can either be resident nitrogen washed out by breathing 100% oxygen, 
or an exogenous tracer gas which has first been breathed in to equilibrium. As gas mixing 
becomes more uneven (or more inhomogenous) the washout is prolonged. Inhomogeneity 
of ventilation is a sensitive marker of airways dysfunction in early CF particularly. The 
reasons for this are complex, but it is likely that disease of the small airways produces 
regional differences in ventilation before it is sufficient to affect overall airways resistance 
(and hence FEV1). 
Lung clearance index (LCI) is a simple marker of deranged ventilation that can be 
calculated from the washout curves. Past studies using a variety of methods have 
demonstrated that LCI is reproducible and more sensitive than FEV1 at identifying early 
lung disease in children. In addition, LCI has been shown to be further raised in children 
infected with Pseudomonas aeruginosa to be an early predictor of deteriorating lung 
function in children.  
An additional advantage in children is that there are no techniques to learn (e.g. as with 
forced expiratory manoeuvres) and only tidal breathing is required. Successful tests 
should therefore be possible in the majority of children down to the age of five. 
 
 
Figure 1: Example of a washout graph 
 
In order to measure inert gas washout, a sensitive and rapid gas analyser is required. We 
have adapted a piece of equipment originally designed for cardiac output measurements to 
follow minute concentrations of sulphur hexafluoride (SF6). This is an inert marker gas 
that is non-absorbed and has been used for some years in similar tests.  
The LCI is the best reported measure of ventilation heterogeneity. This is calculated by 
dividing the cumulative expired volume required to wash the marker gas to 1/40
th
 of its 
starting concentration by the functional residual capacity (FRC, the volume of air in the 
lungs at the start of the washout). In other words, LCI represents the number of lung 
turnovers required to wash the gas out. Hence an increase in heterogeneity of ventilation 
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Innocor 
Innocor was developed to measure cardiac output using the technique of inert gas 
rebreathing. This involves the patient breathing in a mixture of a blood soluble gas (N2O) 
and an insoluble gas (SF6) for a short period. The disappearance rate of the blood soluble 
gas (relative to the insoluble gas) is proportional to the pulmonary blood flow. This is 
then used to calculate cardiac output (and other derived parameters). This procedure 
requires rebreathing of gas mixture from a bag.  
The intended use is for the patient to carry out an incremental exercise test with Innocor 
continuously measuring oxygen uptake and CO2 production (known as the breath by 
breath function). Periodic measurements of cardiac output are then performed at pre-
programmed intervals/workloads.  
Innocor measures the concentration of the gases SF6, N2O, CO2 and O2 using a novel 
technique known as photoacoustic mass spectroscopy. The gas molecules absorb energy 
from pulsed infrared light. This change in energy generates a sound wave which is 
measured by an extremely sensitive microphone. The microphone signal is then filtered to 
separate the three modulation frequencies that correspond to the different gas 
concentrations. The amplitude of each component of the sound wave is directly 
proportional to the corresponding gas concentration. This method is very sensitive to low 
concentrations of SF6 (0-0.2%), with excellent signal:noise ratio and minimal drift. The 
downside of this is that the rise time of the gas analyser is slower than that of a standard 
mass spectrometer, which may limit use of this apparatus in subjects less than 5 yrs old.  
The use of Innocor to measure lung clearance by inert gas washout is a non-standard 
adaptation of the device, and there are a number of features of Innocor that are either 
redundant or have to be worked around; these are covered in the relevant sections below. 
Innocor does not generate a measure of lung clearance index, the data have to be exported 
to another computer for analysis on custom built software. 
 
Additional background information on Innocor, and the process of validating the device 
for LCI measurement, can be found in Horsley et al., Thorax, 2008. 
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Part 2: Hardware Adaptations 
 
The patient interface that comes with Innocor (known as the rebreathing valve unit, or 
RVU) cannot be easily disassembled. It is designed for exercise testing and hence has 
both low resistance to flow and a large dead space. For the tidal breathing involved in 
inert gas washout, resistance to flow is much less of an issue, but minimal dead space is 
important. For inert gas washout, a smaller filter and pneuomtachograph (flow sensing 
device) are needed, and we do not use the ones supplied with the machine. The 
recommended arrangement and component details are as below. 
 
Description Manufacturer Part Number 
Adult flowmeter Hans Rudolph, 
Missouri, USA 
4700A 
Paediatric flowmeter 4719 
Adult filter DAR,Tyco Healthcare, UK Barrierbac S 
Paediatric Filter Air Safety, UK 9070/01 
Adult mouthpiece 
Ferraris,UK PKM0902051000000 
Hans Rudolph Small bite mouthpiece 





Adult patient-interface for inert  
gas washout, disassembled (top) 












The end of the flowmeter furthest from the patient needs to be drilled so that a 20G needle 
can be placed through the hole with the tip in the middle of the stream of air (figure 3). 
This then needs to be secured and sealed to ensure that there is no leak around the needle 
as it passes through the housing. The site of the hole should be adjacent to the pressure 
transducer lines and sufficiently far back to not interfere with the fitting of the flow-past 
circuit, but otherwise to be as far from the flowmeter membrane as possible. The gas 
sample line on the RVU has a Luer fitting, so this can be unscrewed and attached to the 
needle. 
T-piece Flowmeter Filter Mouthpiece 
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Figure 3: A: Site for sample port indicated by arrow on distal part of flowmeter housing, 
between main chamber and T-piece attachment. B: Flowmeter with needle hole drilled and needle 
in place. C: End-on view showing needle tip in centre of stream of air. 
 
Attaching the pneumotachograph 
Because the RVU cannot easily be dismantled, the most efficient method of connecting 
the flowmeter to the Innocor pressure transducer is to use a new connection entirely. 
Innovision can supply, on request, a connector that plugs into the RVU connection on 
Innocor, but only contains patent ports for the two pressure transducer lines (figure 4).  
These ports can then be connected to the appropriate ports on the flowmeter using equal 
lengths of plastic tubing (Guttasyn, Hamburg, Germany). The gas sample connects 
separately to the Innocor device, and has a Luer fitting which facilitates its connection to 
the alternative gas sample needle described above. 
 
 
Figure 4: Modified pneumotachograph connector  
attached to RVU port on side of Innocor. 
 
Patient Interface 
An acceptable and comfortable method of positioning the mouthpiece for the patient 
needs to be devised. In Edinburgh we have adapted the swing arm from an anglepoise 
lamp, with the mouthpiece, filter and flowmeter clamped at the end of the arm and 
adjustable in 3 dimensions (figure 5).  
When positioning the patient interface, ensure that the gas sample and flowmeter pressure 
transducer lines are not in a downward (6 o’clock) position. There is a theoretical risk that 
A B C 
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moisture could condense around the gas sample needle or flowmeter membrane and run 
down into the lines. Ideally the flowmeter should be rotated so that the lines exit in the 12 




Figure 5: Patient interface for MBW measurements. The flow-meter is  
clamped to the end of a swing arm which is fixed to the side of a table. 
Flow-past circuit 
During the wash-in phase of the test, the patient breathes in from the flow-past circuit. 
This consists of two pieces of long tubing joined to a T-piece connector as shown in 
Figure 6. One limb of the tubing is connected to a cylinder containing 0.2% SF6 in air, 
and the other limb is the exhaust. If the test room is particularly small or poorly 
ventilated, then it would be sensible to place the exhaust limb outside of the room. 
The patient breathes from, and back into, the tubing with expired gas vented out of the 
tubing by the constant flow from the cylinder. The downstream limb of the circuit should 
be around 1m long. The upstream limb should be around 0.5m in length, with a reservoir 
bag placed in-line with the tubing (Figure 7). This allows a lower gas flow in the circuit, 















Figure 6: T-piece (green) with 
tubing attached through which 
SF6/air mix flows 
Figure 7: Reservoir bag attached 
to SF6 source 
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Part 3:  Software Settings 
 
Washout Test 
Innocor has a number of preset protocols for exercise testing, which involve incremental 
increases in workload and intermittent rebreathing manoeuvres to determine cardiac 
output. For inert gas washout, a protocol is needed which allows a prolonged period of 
breath by breath measurements at zero workload and without interruption for rebreathing. 
To set this: 
 
• Select Measurement, and then Test from the right hand menu of the main report 
screen. 
• A window will appear for you to enter details about patient weight, haemoglobin 
etc. You do not need to worry about this and can leave it blank, these data are used 
in cardiac output calculations. Press OK. 




• Enter Washout as the protocol name. 
• The protocol appears on the top line of the yellow box. Ensure this is highlighted. 
• Press RB/NIBP repeatedly until the symbols disappear from the left hand column 
(the number 1 will remain). 
• Set the load to 0.0 watt 
• Set the time to 60 mins. 
• The columns for Bag, Bolus and RB freq. should have been cleared when the 
symbols were cleared from the left hand column. 
• Select OK. 
• You will be returned to the previous menu. Select BBB graphs Setup. 
• You can now select what data to display during the breath by breath manoeuvre. 
Bear in mind that even though you can select three graphs, one of these will be 
obscured by the online data graph anyway. 
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The suggested settings are: 
 Graph 1: Time (x axis) vs Vt. This displays the tidal volume of each breath 
against time. Set Y axis 0-1.5L (adult) to display physiological range clearly. 
 Graph 2: Time (x axis) vs V’CO2 & V’O2.  
 Graph 3: blank. Cover with online data readout during test. 
• OK to return to protocol menu. 
• Press the  symbol near the bottom right corner of the menu until the exercise device 
for your protocol is selected as Manual control. Otherwise Innocor will be looking 
for an exercise machine to synchronise with at the start of each test. 
• To set up the data display on the left hand side of a test, start a dummy run test. Select 
Table Setup from the bottom left corner. 
You do not need all the defunct cardiac output measurment data displayed. Suggested 
data to be displayed are: 
 Vt (tidal volume) 
 Resp Freq. 
 Ve (minute ventilation) 
 V’CO2 (CO2 production) 
 VO2 (Oxygen consumption) 
 R (Respiratory quotient) 
 If using the oxygen saturation monitor, then you should also select SpO2 and 
HR. 
 






If changing a flowmeter, replacing it after cleaning, or changing the type of filter used, 
you must perform the following procedure. This is so that Innocor can interpret the 
pressure changes in the flowmeter in a linear fashion over the full range of flows. It is 
important that this is performed using the appropriate filter. Adding a filter to the circuit 
changes the flow entering the flowmeter and can lead to errors in measurement. This is 
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avoided by performing the linearisation with the filter in place. Both filters selected have 
been tested and shown not to affect the flowmeter over the physiological range, providing 
that the output is first calibrated as described. 
 
• Connect the calibration syringe to the flowmeter using the appropriate sized filter 
(i.e. a paediatric filter when preparing the paediatric flowmeter, and an adult filter 
for the adult flowmeter). 
• Exit to windows (see page 17). 
• Select the directory C:/Innocor/Programme and click on 
Flowmetercalibration.exe. 
• Select Calibrate. 
• Select Prepare Syringe size and ensure that correct syringe size is set. 
• Select Add stroke. A table appears with a flow/volume graph in the left. 
• Following the instructions in the window at top left, complete a number of syringe 
empty and fill manoeuvres, covering a wide range of flow rates. 
• If you make an error, that stroke can be de-selected from the right hand table by 
highlighting that data and pressing Use/skip. 
• Press Accept. 
• Unless the %error throughout is <3%, repeat the process. 
• To finish press Accept and then Cancel. 
• Select the option to save data, and select the file bbblin1.cal as the filename. You 
will be asked if you wish to overwrite the saved file, select Yes. 
• Exit takes you back to Windows. 
 
Flowmeter re-zero 
A feature of the Innocor flowmeter is that it automatically re-zeroes the flowmeter at 
regular intervals to correct for any drift. Whilst doing this the computer generates a non-
physiological flow signal of 100L/sec for 1 second. This helps to maintain the accuracy of 
the flowmeter but if it occurs during expiration in the washout it will effectively wipe out 
that 1 second of data, as well as requiring manual adjustment of the washout analysis. In 
order to avoid this, we try to set the interval between re-zeroes such that the re-zero 
occurs at the end of wash-in (and therefore will not be repeated before washout is 
complete). This takes a degree of judgement and guesswork, since normal volunteers 
wash-in in far less time than a subject with moderately severe CF. We have found that, for 
adults, 5 minutes represents a reasonable compromise between an excessive wash-in time 
for subjects who are well, and too frequent re-zeroes affecting washout analysis. For 
children, 4 minutes is usually sufficient.  
 
In order to set the time interval between flowmeter re-zero: 
• Exit to Windows (see page 17) 
• Unless you have a keyboard connected through the Innocor USB port, select On-
Screen Keyboard.exe from the Startup menu. 
• Select directory C:/Innocor/setup and select the Text file Hardware.ini 
• Scroll down until you come to the line reading: 
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   [BBB] 
   Installed=1 
   FlowzeroAfterRB=0 
   FlowzeroInterval=300 
 
• The number after FlowzeroInterval is the time in seconds between re-zero 
manoeuvres. Using the On-Screen Keyboard (or a keyboard connected through the 
USB port) set this to the desired time interval between re-zeroes (e.g. 300 for an 
interval of 5 mins). 
• Close the text box, and confirm that you want the changes saved when prompted. 




Part 4 - Daily Checks 
 
You do not need to unscrew the small cylinder at the back of the Innocor machine after 
use, and when prompted about this simply confirm that you have done it. This procedure 
is necessary with the standard RVU to prevent gas leak. Since the modified connector we 
use has all the gas cylinder ports occluded it is not necessary for us to do this. 
Ensure that all connections are tight and leak free. Attention should also be paid to the 
flowmeter pressure lines and gas sample line. These should be tightly fitted to the 
flowmeter and gas sample needle, and should not be kinked, twisted or occluded at any 
point throughout their length. 
 
Warm up 
The machine should be left for 20minutes after switching on to ensure that the 
photoacoustic gas analyser is fully warmed up. 
 
Calibration of pneumotachograph 
This should be performed daily. 
If a new flowmeter is being used, this should first be linearised, see page 9. 
 
• Select Setup from the menu on the opening screen. 
• Select Calibration.  
• From the pop-up menu select Adjust Flowmeter.  
• Connect a 1 or 3L calibration syringe to the flowmeter 
using the appropriate filter and set the syringe size on the screen  
accordingly. 
• Empty the syringe. 
• Press Calibrate. 
• When instructed, fill the syringe slowly, at a low flow rate, without bumping the 
end. 
• Continue to follow the instructions on the screen. A total 5 fill and empty 
procedures are performed (2 slow, 2 medium and 1 fast). After each stroke the 


















• At the end of the calibration, the new gain is displayed. This should be between 
0.9 and 1.1. If acceptable, press OK and Exit. 
• The measured syringe volume should also differ by less than +/- 3%. In other 
words, once the correct gain is applied the measured volume should be between 
2.91 and 3.09 litres. It is preferable for the accuracy to be greater than this, and we 
aim to achieve an error of +/-2% (i.e. measured volume between 2.94 and 3.06 L 
once correct gain applied). 
• If the gain, or the accuracy, are outwith this range, press Calibrate and repeat the 
process. If the gain remains unacceptable then: 
o Ensure the correct flowmeter and correct syringe are being used. 
o Ensure that the correct filter is being used. Adding a filter changes the flow 
and hence pressure/flow characteristics of the flowmeter, so all calibrations 
and linearisation procedures must be performed with the appropriate filter 
connected. 
o Ensure all connections between flowmeter and tubing and tubing and RVU 
cable are secure and leak free. 
o Ensure the syringe is securely connected to the flowmeter. 
• If the problem remains then the flowmeter linearity may need to be adjusted (see 
page 8). 
• Always record the gain in the log book, so that any trends in errors can be 
identified. 
 
Flow-gas delay calibration 
This should be performed daily and recorded in the log book.  
It is vital that this is known before lung clearance data are calculated as accurate 
alignment of the signals is vital. The delay is calculated by generating rapid changes in 
flow on inspiration, which also causes a rapid change in CO2 concentration. This 
manoeuvre should be performed by the operator, not the patient. 
 
• From the opening menu select Setup and then select Calibration. 
• From the pop-up menu select Calculate gas delay. 
• Wait for the device to warm up. 
• When warmed up the operator breathes through the flowmeter. The delay is 
specific to the equipment set-up so a filter and mouthpiece must be used exactly as 
if you were a patient undergoing a test, and the sample line must be connected. 
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• When ready press calibrate and 
perform 11 slow expirations 
followed by 11 very fast 
inspirations. The inspirations have 
to be as fast as possible to get an 
accurate determination of gas 
delay. 
• The delay calculated can be shown 
by pressing the      icon. The 
software filters out breaths that 
fail. 
• Overall gas delay should not vary 
by more than 20-40msecs on 
different days. If the new delay is 
excessive, check all connections and repeat the calibration. 
• It is the CO2 delay that matches the SF6 delay, this should be recorded in the log 
book. 




The Innocor machine generates raw data signals which, after analysis, need to be adjusted 
to standardised BTPS conditions (convert volumes to those they would occupy at Body 
Temperature, standard barometric Pressure, and water Saturated). To do this, the ambient 
conditions need to be known. These will also affect the flowmeter output and possibly the 
flow-gas delay too, though these are calibrated daily so no other adjustment is needed.  
In Edinburgh, we maintain the constancy of ambient conditions by using air conditioning 
in the test room. This maintains the room at a reasonably constant 23
o
C (which we check 
daily) and relative humidity. Fluctuations in barometric pressure are generally small and 
we do not measure these but assume a constant 760mmHg.  
If using the apparatus in a room without air conditioning, it is important to measure 
temperature and relative humidity and record these daily. In addition, if there are 
substantial changes in ambient conditions over the course of a day, the machine should be 
recalibrated before use (in other words do not calibrate during a cool morning and use on 
a hot afternoon). The Innocor usage log allows for these factors to be recorded. 
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Part 5 - Performing a Test 
 
Equipment required 
• Innocor device, modified and set up as described in previous sections. 
• Supply of 0.2% SF6 in air 
• Sterile filter 
• Clean mouthpiece and noseclips 
• Calibration syringe 
• Fan 
• Visual feedback system – computer screen visible to patient 
• Television 
• Innocor log to record settings 
 
 
1. Before starting 
• Switch machine on. Ignore onscreen instructions about Innocor gas cylinder, press 
OK to continue. 
• Ensure that daily checks and calibrations have been completed (page 10). 
• Ensure that knob on top of 0.2% SF6 cylinder is switched to on. 
• Check that all equipment is correctly arranged and that gas sample and pressure 
transducer lines from Innocor are tightly connected to gas sample port and 
flowmeter respectively. 
• Check that the pneumotach for breath volume feedback is switched on, zeroed, 
and correctly connected to the laptop. Ensure that the visual feedback software 
loads correctly, and that the screen can be seen by the subject. 
 
2. Entering patient data & patient codes 
• From the Measurement screen select New Patient. 




• Use the keyboard to enter the relevant data and then select OK. 
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• ID is the patient code, and will be used in the filename of the data generated for 
that patient (along with the date and time).  
• See separate sheet for recommended patient codes for the different CFGT studies. 
 
3. Instructions to Patient 
Before starting 
• Ensure patient is comfortably seated and suitably distracted. 
• Attach noseclip (again ensure this is comfortable) and ensure that a good 
mouthpiece seal can be achieved. 
• Demonstrate the procedure for detaching the T-piece before starting the first wash-
in and instruct patient not to alter their breathing pattern whilst you are doing this 
during the test. 
 
Instructions 
• Instruct patient to breathe normally. 
• They should breathe in and out regularly, without long pauses between inspiration 
and expiration. 
• Warn them that you may need to give instruction to breathe more or less deeply if 
their tidal volume is inadequate or excessive. 
• Show them the visual feedback display and indicate that you will place a target on 
the display once they have settled into a stable pattern. The target may require 
slightly deeper or shallower breaths than they have been completing 
spontaneously. 
• If they need to cough, they can do this through the device. 
• It is important that a good seal around the mouthpiece is maintained at all times. 
 
Important points 
It is important that regular breathing is maintained throughout the test. To achieve this, 
the patient needs to be comfortable, both with the position of the apparatus and with the 
fit of the mouthpiece. They also need to be adequately distracted, preferably by watching 
a television. Attention should be paid to the breathing pattern to ensure that it is both 
regular and stable with a reasonable tidal volume (0.5-1.0L for an adult). 
It is also important that long expiratory pauses are avoided. The sample port has a flow 
rate of 120ml/min and during a long pause can sample all the expired gas in the end of the 
flowmeter, so that room air is then sampled. The fall in SF6 concentration can look like 
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Figure 8: Patient testing. Subject is comfortably seated, with noseclip  
applied, and achieving an effective mouthpiece seal. 
 
4. Starting the test 
• From the opening screen of Innocor select Measurement. 
• Select New Pt. to enter data for a new patient (as above) or select the patient from 
the list displayed. The patient details can also be retrieved from the database using 
the Search facility. 
• After entering or choosing a patient press Select.  
• Press Test to prepare a new measurement.  
• Select “Washout test” from the list of possible protocols (see page 7 for details on 
how to set this). 
• For a new patient, you will be required to confirm the height & weight data before 
starting. You will then be required to confirm that the load is set to zero: this is for 
exercise testing and the instruction can be ignored but you must select OK before 
recording can start. 
5. Wash-in Phase 
• Ensure that the T-piece connects the patient to the flow past circuit and turn on the 
gas. The gas in the flow-past should be set at a sufficient rate to ensure that no 
expired air is re-inspired. For an adult this should be at least 10 L/min, but will 
need to be increased if the patient breathes faster or deeper than average. 
• Instruct the patient to breathe normally through the system, with a target 
inspiratory volume of between 0.5 and 1.0L. They should then expire to a relaxed 
FRC. It is important that long pauses between inspiration and expiration are 
avoided.  
• As the patient breathes in, the bar on the visual feedback display should rise. For 
the first 1-2minutes, allow the subject to achieve a comfortable tidal volume 
without targeting the inspiration.  




• Once a steady breath volume is achieved, place target arrow on the screen at 
approximately the middle of the breath volume range. If this is outwith the desired 
breath volume range of 0.5-1L, then place the arrow within the target range and 
alert the patient to this.  
• In order to display the real-time SF6 concentration, select Show 
results from the right hand menu and then select Show online 
data from the pop-up menu. 
• This pulls up a graph that shows real-time flow and gas 
concentrations. To enlarge the scale and so view the SF6 
concentration, press      




• If the SF6 concentration suddenly falls on an inspiration it is likely that the gas 
flow in the flow-past is insufficient. Check for leaks and increase the flow rate to 
cope with the patient’s minute ventilation and peak inspiratory flow.  
Note that when observing the real-time data that the gas signals are approximately 
1.5 seconds (or half a breath) behind the flow signals. 
6. Wash Out Phase 
• Continue the wash-in phase until the inspiratory and expiratory SF6 concentrations 
are equal (i.e. differ by less than 2% relative, or are within 0.004% absolute of the 
starting SF6 concentration). After this, continue for a further 30 seconds before 
starting the washout.  
• Turn on fan so that a stream of air is directed over the end of the flowmeter. 
• Once the SF6 has been fully washed in, rapidly disconnect the T-piece during 
expiration. It is usually possible to identify expiration by watching the patient’s 
chest movement and/or the breath volume feedback. If this is difficult, instruct the 
patient to continue breathing normally, but to raise a hand during expiration.  
• When disconnected plug the open arm of the T-piece so that SF6 does not escape 
into the test room, and then quickly switch off the gas supply. 
• The patient now breathes room air until the peak expiratory SF6 concentration has 
fallen to less than 0.005%. Continue for a few breaths beyond this point. 
• At the end of the test close the online data window and stop the test by pressing 
Stop protocol from the right hand menu.  
o If you have paused the test by pressing Hold protocol, do not press Stop 
protocol but restart before terminating. 
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Part 6: Special considerations in subjects under 16 yrs 
Standard Procedure for Older Children (5 yrs and over) 
The equipment used and procedure for adult patients is suitable for paediatric patients in 
this age-group. There are, however, some differences in approach that ensure the best 
quality data. Previous experience in communicating with children and explaining 
procedures is useful. 
Prior explanation of procedure: 
• It is important that the procedure is fully explained to the child in language that 
they will understand. Explain the purpose of the test as a whole, the gas, the 
mouthpiece and the tubing. Children, especially older ones, are able to understand 
difficult concepts if clear language is used. Allow questions and encourage them 
that they can come off if they feel unwell or find it difficult to breathe. 
• The must have confidence in the person conducting the test or they may be 
unwilling to continue.  
• A calm, relaxed approach means that the child will feel happy taking part and they 
will trust the researcher. 
Equipment 
• General testing environment 
The room should be friendly and inviting without being too full of distractions.  
Make sure the chair the child sits in is comfortable for them. A cushioned chair is not 
necessarily the most comfortable option as it is harder to stay still in. A swivel chair or 
one on wheels is very hard to sit still in. One that encourages children to sit straight 
and not to move around is best. The recommended chair is “q-learn chair senior” 
distributed by Morleys (01869320320, product code CS60281). 
• Flowmeter  
Generally a different flowmeter is used to try to minimize deadspace. The 
recommended pneumotach for 10-16 yrs is manufactured by Hans Rudolph (model 
4719).  An adult sized pneumotach is probably suitable for older children (≥5 yrs). 
• Mouthpiece 
Most children down to 5 yrs can fit the whole mouthpiece in as it is designed. This 
may require some encouragement. If this is impossible, then keeping their lips on the 
inner rim of the mouthpiece is adequate. This method is more difficult as they require 
a more deliberate seal with their lips and the edges of the mouthpiece often hurt the 
corners of the mouth after a few minutes. Some practice before starting is a good idea 
to familiarise them with the procedure. Explain that the mouthpiece is like a diver’s 
mouthpiece and all their breath has to go through the machine, not out the edges. Most 
children are interested by, and understand, this explanation. 
• Breath volume feedback software 
Some children will be able to use this to regulate tidal volume if the concept is 
explained. Other children may find this confusing if they are not able to change breath 
volume easily. The breaths may become more erratic. Also, other children may “play” 
with it and make huge or very fast breaths just to make the display move. If this 
happens it is probably advisable simply to turn the display away. 
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The issues that can make multiple breath washout difficult in children are: 
• Not understanding the procedure – make sure they know to keep a good seal round 
the mouthpiece with their lips. They may need to be reminded. 
• Playing with the equipment. Make sure hands are kept away from the pneumotach, 
especially the open port. 
• Becoming easily distracted with other things going on in the room - keep 
conversation and movement to a minimum. 
• The feeling that they don’t know what’s going on – make sure there is a member 
of staff visible to the child all the time. If this is not possible tell the child where 
you are going, even if it is just behind them. 
• Talking or moving during the test – it is important that they don’t talk during the 
test as this obviously upsets the natural breathing pattern and introduces leaks. 
Make sure any verbal instructions are phrased to discourage a reply. Children can 
forget they are not to talk. Generally keep verbal communication to a minimum. It 
is frustrating to be talked to and not be able to reply. 
• When explaining the test make sure the change-over from washin to washout is 
explained before the test starts. It is better not to say anything before removing the 
T-piece during the test as this often interrupts the breathing pattern or the child 
may think the test is over and detach themselves from the mouthpiece. 
• Suitable distraction is vital. Children are generally easily distracted and often 
forget instructions they have been given. Therefore a cartoon that keeps their 
attention will ensure they don’t start talking or moving around too much. Try to 
avoid videos that have singing or too much excitement as the child may join in. 
Make sure the screen is easily visible (i.e. straight ahead of them) and the lights 
are dimmed if possible. Make sure the sound is loud enough so that the child is 
unlikely to be distracted by other noise or movement. 
Innocor in young children (<5 yrs) 
The concern about using Innocor in this age group is the speed of the gas analyser. To be 
able to integrate a gas concentration signal with a flow signal and calculate volume of gas 
expired the signal rise has to reflect the true rise in gas concentration with each breath. 
This is conventionally documented as the time taken for the gas concentration to rise from 
10% to 90% of the concentration after a step-change. On analysis of artificial step-
changes in gas concentration, a mass spectrometer has a documented10-90% rise time of 
80milliseconds. This is when measuring both the rise in expired gas concentration and fall 
in inspired concentration. Innocor has a documented rise time of 120ms but was found to 
be 150ms in practice. This is considerably slower and may introduce inaccuracies in the 
integrated gas volumes at faster respiratory rates (e.g. in younger children). For this 
reason, ATS/ERS guidelines on performing multiple breath washout tests in those less 
than 5 yrs old have recommended a gas analyser response time of <100ms. For adults and 
children >5 yrs, the resting respiratory rates are slower, and any error caused by the 
slower rise time is minimal.  
However, we cannot recommend using the current set-up in children under 5 yrs old. We 
are however actively looking at methods to enhance the gas analyser response in Innocor. 
More details on this research can be obtained from the authors. 
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Part 7 - Data Export 
USB stick 
• This is the recommended method of data export. 
• First exit to Windows by touching in rapid sequence the right upper followed by 
the left upper corner of the screen. 
 













• When given the option to exit to Windows select OK. 




• Insert the USB stick into the free port at the back of the Innocor machine and wait 
until this is recognised by the computer and displayed as an option in the left hand 
column. 
• To locate the data, use the mouse to select the file C:/Innocor/RawDataBBB, this 
is the file into which all the breath by breath data are saved.  
It is advisable not to try using the touch screen for this, as it is hard to accurately 
select and copy the files of interest.  
• Files are saved according to the formula:  
BBB[Patient ID]-[Date]-[Time].ino. 
To find the most recent files, first click on  and select the Details format. Then 
click on Date Modified to arrange data in date-generated order. You may need to 
click twice to get the most recent data displayed at the top of the column. 
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• Select the files for that day by clicking on or highlighting them, and click and drag 
them to the USB drive in the left hand menu. The files should then be copied to 
the USB stick. 
• Once the files are saved, you can remove the USB stick without having to 
deactivate it first. 
• It is recommended that data are copied from Innocor’s hard drive at least daily 
(when it is in use) as this prevents data loss if anything were to happen to the 
machine.  
• Use a dedicated memory stick, and only download to a single computer with up-
to-date virus checking software. 
 
Return to Innocor 
• Select Shortcut from the list of files in the C:/Innocor/ directory. 




 Do not alter any other settings within Innocor unless explicitly instructed. 
 If wanting to shut the computer down, you must first return to Innocor and 
select Exit from the opening menu. Do not simply press ⌧ in the top right 
hand corner. This will default to a screen showing the Innovision label, which 




This is a surprisingly slow method of data transfer, and for most purposes the memory 
stick will be sufficient. 
• Plug the LAN cable into the port at the back of the Innocor machine and into the 
second computer. 
 
In order for the two computers to link, the first part of their IP addresses need to be the 
same. The simplest way to do this is to set the IP address of your computer to be similar 
to that of the Innocor machine. 
 
To find the Innocor IP address:  
• In the main shortcut window, right click and select NewShortcut. 
• Enter cmd in the window that appears. Windows will find and direct you to the 
command window. Open this and type ipconfig./all 
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Setting your IP address: 
• On your computer, select Control PanelNetwork & Internet 
ConnectionsNetwork ConnectionsLAN connection. 
• Select TCP/IP Internet protocol and then select Properties. The default setting 
is an automatically configured IP address. Select User Configured and enter the 
address 10.0.0.xx , where “xx” are two digits that are different from those at the 
end of the Innocor IP address. 
 
• To check that the two computers can link up, enter the command window of your 
computer (Start menuRunType cmd). Type ping followed by Innocor’s IP 
address. You should get a message back that Innocor has been successfully 
pinged. 
• To access Innocor’s files, type “\\” followed by Innocor’s IP address in the 
Address window of your computer’s control panel. This should pull up all the 
files on Innocor, though may take some time to load. You can also access Innocor 
from Control PanelNetwork ConnectionsMy Network PlacesEntire 
NetworkMicrosoft Windows NetworkInno_wrkgrp. 
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Part 8 - Infection Control      
 
To ensure safety of patients during studies we need to adhere to infection control 
guidelines that ensure minimal risk of contamination of re-usable parts that can infect 
other patients. 
All CF patients are colonised with infectious organisms which can be passed to other 
susceptible patients via aerosol spread. In particular MRSA and B.cepacia colonised 
patients require special attention, but all patients should be treated as possible carriers of 
these organisms. Guidelines apply to all patients at all visits. 
 
After discussion with infection control team at the Royal Hospital for Sick Children 
(RHSC) in Edinburgh, it was agreed that it is reasonable to have more than one patient in 
one day if local policy can be adhered to regarding separation of patients and adequate 
cleaning of equipment between patients. Two patients will not be tested or be in the test 
room at the same time.  
Special attention has to be paid to cleaning and disinfecting parts in direct contact with 
exhaled breath or mucous membranes. It may be necessary to obtain similar approval 
from your own site. 
 
Standard procedures recommended for cleaning and disinfecting equipment are:  
 (may be adapted according to local hospital policy) 
• Hard surface wipes – Soap-based cleaning cloths (not alcohol-based). 
• Disinfection tablets – Disifin or locally agreed alternative (e.g. Tristal). 
Adherance to protocol is required. 
• Disposal – clinical waste. 
• Hand washing – soap/ alcohol gel. 
 
 
Non-disposable equipment in contact with patients during run-in studies: 
• Multiple breath washout apparatus 
• Other equipment: furniture etc. 
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Not in contact with patient. Can be wiped with hard surface 
wipes (not touchscreen). 
Flow-meter  
 
Protected from patient by bacterial/viral filter. Requires 
periodical cleaning by dismantling and disinfection –           
every 10-15 patients. 
Pressure lines Protected from patient by in-line filter. Should be wiped 
thoroughly after each patient (hard surface wipes). 
Flow-meter stand (if 
applicable)  
Should be wiped (hard surface wipes) after each patient 
Bias flow elephant tubing 




Protected from patient contamination by filter but attention 
should be made to any evidence of condensation inside 
tubing. Given that patient’s breath is exhaled through 
exhaust end, tubing should be changed periodically – every 
10-15 patients.  
T-piece should be disinfected 
Rebreathe bag and gas 
tubing    
?? possible special recommendations during normal 
clinical practice (awaiting further discussion with infection 
control nurses) 
Gas tank and flow tap 
 
Not in contact with patient. 
Mouthpiece  Disinfected after every patient. Strict separation of clean 
and used. 
Noseclip  Disinfected after every patient. Strict separation of clean 
and used. 
In-line filter  
 
Single use. Disposed of after testing. New filter for each 





Chairs, trolleys, other hard surfaces should be wiped after 
every patient. This should include all surfaces in contact 
with patient e.g. door handles etc. 
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Summary of recommendations 
• Use a new disposable filter for each patient. 
• Wash hands between patients. Either use gloves to handle filters, mouthpieces and 
noseclips or wash hands after doing so. 
• After each patient use, wipe the machine, swing arm and seat with detergent 
wipes. 
• Mouthpieces and noseclips should be sterilised as below. 
• Although there is no evidence that any potentially harmful organisms will be 
missed by these procedures, it is advisable to change the flowpast circuit 
periodically (i.e. dispose of and replace the tubing, the T-pieces can be sterilised as 
per mouthpieces). This should be done every ten patients, and the date of this 
recorded in the logbook (under Notes) 
Sterilisation of Mouthpieces, Masks, Noseclips & T-pieces 
These items can be reused and should be sterilised as below. 
• Dissolve 1 tablets of Disifin (RMP UK Ltd, London) in 0.5L of hot water. 
• Clean mouthpieces or masks in warm soapy water to remove any deposits. 
• Soak in Disfin solution for a minimum of 30minutes. Can be left overnight. 
• Rinse in cold running water for a minimum of 60minutes. 
• Allow to dry. 
• Disfin solution should be discarded after 24hrs. 
 
Cleaning of Flowmeter 
Because we are using a filter, this is not necessary after every use but should be 
performed if there is reason to expect that the flowmeter has become contaminated. It is 
also good practice to routinely inspect the flowmeter and clean it if there appears to be 
debris on the mesh. 
Cleaning is according to the manufacturer’s instructions. We recommend the following 
steps: 
Carefully disassemble the flowmeter. 
Wash in Disfin solution for 30 minutes. 
Rinse in cold running water for 60 minutes. 
Allow to dry, preferably overnight. 
Visual inspection to confirm apparatus is clean and dry and reassembly. 
You will need to repeat the flowmeter linearisation after cleaning (see page 8) 
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Part 9 - Innocor Usage Log 
 
The Innocor log is intended to be a daily record of the machine use and outputs. By 
recording flow gas delay and flowmeter gain daily, any large or sudden variations in these 
variables can be detected early. Similarly a log of cylinder pressure allows the operator to 
identify when replacements are required. Ambient conditions and flow-gas delay are 
necessary for the correct interpretation of the raw data, and even if stored on the patient 
data sheet the presence of a copy of these data on the daily log is a useful back-up. 
 
Date Operator Usage 
Flowmeter Cal. Gain Gas Delay Innocor Cylinder 
pressure at start 
 
bar 
Remember to unscrew cylinder at end. 




Remember to close cylinder at end. 
 
Fill  O2 
                                 
msecs 
Empty  CO2 
                                 
msecs 
Notes Temp oC RH% 
 
Date Operator Usage 
Flowmeter Cal. Gain Gas Delay Innocor Cylinder 
pressure at start 
 
bar 
Remember to unscrew cylinder at end. 




Remember to close cylinder at end. 
 
Fill  O2 
                                 
msecs 
Empty  CO2 
                                 
msecs 
Notes Temp oC RH% 
 
Date Operator Usage 
Flowmeter Cal. Gain Gas Delay Innocor Cylinder 
pressure at start 
 
bar 
Remember to unscrew cylinder at end. 




Remember to close cylinder at end. 
 
Fill  O2 
                                 
msecs 
Empty  CO2 
                                 
msecs 
Notes Temp oC RH% 
 
Date Operator Usage 
Flowmeter Cal. Gain Gas Delay Innocor Cylinder 
pressure at start 
 
bar 
Remember to unscrew cylinder at end. 




Remember to close cylinder at end. 
 
Fill  O2 
                                 
msecs 
Empty  CO2 
                           
msecs 
Notes Temp oC RH% 
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Appendix B – Standard operating procedure for data 
analysis of multiple breath washouts using Innocor 
 
Version 1.2, devised in Edinburgh on 2/2/07 by:  







In the majority of cases analysis should be a semi-automated process. The software 
automatically identifies when a change from inspiration to expiration has taken place, and 
moves to the next phase of respiration. It does this by identifying when the flow changes 
from negative (inspiration) to positive (expiration), though the software is not infallible as 
will be discussed below. Irregular respiration, coughing, swallowing, respiratory pauses, 
and a host of other features, cause irregular changes in flow that can fool the automatic 
analysis. In most cases, little input is required from the operator, but a small number of 
washouts can be quite complex to analyse.  
 
There are a number of scenarios that can lead to discrepancies between the data analysis 
by different operators. Following lengthy discussions, the guidelines below aim to cover 
the major potential discrepancies, and how to approach them. It is not possible to be 
exhaustive however. When encountering a scenario that is not adequately covered by the 
guidelines, the important principle to apply is what makes most physiological sense. For 
example, there may be confusion over whether the breath in question represent a true 
breath, is a continuation of an interrupted expiration or just a blip in flow that is not truly 
part of respiration (eg a swallow). If the tracing is expanded it is usually possible to work 
out what is going on, and adjust the analysis accordingly. If there is still doubt as to the 
correct approach, then consensus should be sought from the other operators. 
 




Close inspection of a washout trace 
 
The “inspect” function of the analysis software is not a very useful function. If you are 
unsure what is happening, the most effective method of examining the trace more closely 
is to adjust the x axis. To do this: 
• Double click on the main tracing window 
• A new window opens, select the Axis Settings button on the far right. 
• In the Axis Settings window, 
you can alter the start and end of 
the x axis by changing the 
numbers in the From and To 
boxes in the top left corner 
(circled in red). You will 
typically need numbers in the 
thousands. To get an idea of the 
range, inspect the x axis of the 
main window and select the 
upper and lower limits of the 
region you wish to expand. 
• Unclick the Auto box to set your range (circled in red). 
• Select OK to return to the analysis. 




Basic software settings 
 
1. The Delay should be the CO2 delay, which is calculated as part of the daily calibration 
procedure, plus 50ms. The reason for the additional time delay is to realign the signal, and 
thereby artificially improve the analyser response time. The rationale behind this is given 
elsewhere. 
 
2. The re-insp box should be left unchecked. This is used if the volume of re-inspired SF6 
is to be calculated and taken into account. Again, the reasons why this is not used in the 
analysis of data from Innocor are covered elsewhere. 
 
3. The Cet%Pos box represents the means of identification of the end tidal SF6 
concentration (Cet). Because of the signal realignment, selecting the final gas 
concentration value before the flow change often selects an SF6 concentration that is from 
the falling part of the gas signal during early inspiration. To overcome this, click on 
Cet%Pos and select 10 for #samples from the end (-) and select 10 for Window of avg 
cet. This means that the Cet is the average of 10 gas samples (100ms), taken 10 samples 
back from the change in flow. This is also shown as a yellow bar in the Slope SF6 
window, so you can check that this is accurate. 
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4. Changes can be made to the automatically identified start and end of a breath using the 
toggles and windows at the bottom left. We are not overly concerned with the inspired 
gas, though as a general principle it is important to try to be accurate with inspiration too. 
However, it is very important that expiration is correctly identified. 
Start and End points can be moved using the toggles, which move in increments of 100 
samples. Alternatively, click on the window below the toggle, and move the value using 
the cursor keys, or shift and cursor key which moves in increments of 10 samples. 
As the start and end points are moved the corresponding flow value is shown in the lowest 
box in blue. Thus you can identify the start of a breath by moving the Exp-Start bar 
along using the cursor and watch for a change in flow from negative to positive. 
 
5. These guidelines do not cover phase III slope analysis (also shown as the red line on 























Data Analysis: standardisation of procedure 
 
1. The starting SF6 concentration (Cinit) 
• This should be the alveolar gas concentration at the start of the washout. In other 
words, the end tidal gas concentration (the same as is measured during washout) - not 
the inspiratory gas concentration which may be marginally greater, especially if wash-
in is imperfect. 
• Because of the additional time delay offset, it is essential that you correct the 
Cinit. This is done by clicking on the box beneath the Insp-start bar. Then reduce the 
number in the box by 5 by pressing the down arrow on your keyboard 5 times. This 
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• You should ensure, by visual inspection of the Insp-start bar, that the software has 
picked the correct start point of the first breath. This is crucial, because Cinit is taken 
from the gas concentration at this point, and is used both to calculate FRC and to 
define the end target Cet. If the start point is incorrect, then inspect and adjust by 
altering the position of the bar, as described above in point 4. 
• Cinit% is given in a box on the right hand side of the screen. End%, in the box 
below, is defined as 1/40
th
 of Cinit, and is the target Cet cut off for the end of the 
washout.  
 
Cinit% will vary marginally from washout to washout. This is because the end-tidal 
(alveolar) gas concentration at the start will not be precisely the same every time. 
 
2. Efficiency of wash-in 
We are aiming for a steady state in SF6 concentration in wash-in. In reality, there will be 
some variability, though this should be minimal. The wash-in inspiratory and expiratory 
gas concentrations can be inspected by clincking Next through the final few wash-in 
breaths. The inspiratory and expiratory gas concentrations can be read off from the Slope 
SF6 window (the graph is an in inversion of a washout curve, with concentration falling, 
rather than rising, to an alveolar plateau). 
We should aim for a difference between inspiration and expiration of less than 2% (+/- 
0.004% SF6). If the difference is more than this, record in the washout notes that wash-in 
may be inadequate, but continue with the analysis. 
 
3. End of washout 
The end of the washout occurs when the end tidal SF6 concentration (Cet) falls to 1/40
th
 of 
the starting concentration (Cinit). In normal subjects, Cet falls with each breath and this 
end point is usually unequivocal. In CF patients, particularly the more severe subjects, 
abnormal gas mixing means that there is a steeply sloping alveolar plateau. Hence the Cet 
can vary with alterations in expiratory volume. The question then arises: at which point do 
you terminate the analysis? 
To achieve consistency, we have agreed that the washout end when there are two 
consecutive breaths with Cet at or below the target cut off. This means that single breath 
variations in Cet should not affect the analysis. In addition, very small breaths can lead to 
inappropriately low Cet. To avoid this, we set a minimum breath volume for identification 
of Cet of 400ml. In adults and children less than 50kg, this minimum volume is 8ml/kg. 
The breath volume of 400ml is based upon observations that this is sufficient to obtain an 
alveolar gas sample in adults. 
 
To determine washout end: 
• Inspect Cet%. Check that it has been correctly identified on the Slope SF6 graph. If it 
is above End% then continue washout, regardless of the volume of the breath. 
• If Cet is the same or less than End%, check ExpVol[L]. If the volume is less than 
0.4L in adults (or 8ml/kg in children and adults less than 50kg), then this Cet does not 
count, and you should continue the analysis. 
• If volume of breath is >0.4L, then continue on to next breath. If this is also of 
sufficient volume and Cet is below End%, end the washout here, without saving this 
last breath. 
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• If Cet is greater than End% (regardless of volume), save this breath and continue the 
analysis. The search for two consecutive breaths with Cet below End% is reset to 
zero (i.e. you are still looking for 2 breaths, not just another single one). 
• If Cet is below End%, but the second breath volume is <0.4L, then this breath does 
not count, save it and continue the analysis. However, the first breath still counts, and 
you are still only looking for one more breath that is of sufficient volume and with 
Cet<End%. When you find the 2
nd
 breath that fulfils these criteria, end the washout 
without saving. 
 
Ne xt B re ath :
C e t% <En d%





N ext B r eath :
Ce t% < End%
Exp V ol> 0.4 L
NO
YES
En d  W a sh o u t.
Do  n o t s ave  th is
las t  b re ath .
NO
Y E S
En d o f washo ut ana lys is  a lgor ithm
 
Notes:  
The target of 0.4L is for adults. For children (and adults<50kg) a target of 8ml/kg is used. 
To count as reaching the target End%, Cet must be the same or less than End%. 
 
This algorithm is not perfect, and there may still occasions when the end of the washout is 
upset by smaller than average breaths (>0.4L) or by much larger breaths. However it 
represents a compromise that allows analysis of both complex and straightforward 
washouts, without overly complicating the latter. 




Interruptions to flow 
 
1. Flow zero 
Peculiar to Innocor washout data, every 5mins the flowmeter re-zeros. At this time, it 
generates a flow signal of -100 for 1 second. 
This is a problem if it occurs during expiration, particularly in the first few breaths. 
 
The following algorithm to deal with flow re-zeros has been devised: 
1. If the re-zero occurs up to (and including) breath 10, then it must be removed from the 
washout data. See below. 
2. If re-zero occurs in inspiration it can be ignored, but ensure that that the -100 signal is 
not included in the inspiratory volume calculation. 
3. If re-zero occurs during expiration, then analyse up to (but not including) the first -
100. Save this breath. The next breath is the second part of that same expiration, from 
the end of re-zero onwards. 
 
Although this loses 1 second of data, it again represents a reasonable compromise. The 
effect of losing these data is greater in the early part of the washout, hence the need to 
remove the re-zero signal if it occurs at this time. 
 
Flattening the re-zero signal 
This is done by first opening the washout file in a text box. Delete down to 
time=300000ms (5min). Save and reopen in Excel. Locate the re-zero that you wish to 
remove. Flatten by copying the flow signal immediately preceding it into the re-zero 
period.  Save as a text file. 
If this causes a flat flow signal during the change from expiration to inspiration, you may 
need to adjust the end expiration bar during analysis so that the end of expiration 
coincides with the peak SF6 concentration. 
 
2. Patient interruptions to flow. 
There are often small changes in flow, or respiratory pauses, that cause confusion during 
analysis. The basic principle is one of physiological common sense. The following 
guidelines have been devised to aid this. The points are illustrated on the washout graph 
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1. During expiration, ignore small inspiratory flows (<20ml). 
E.g. subject may pause during expiration, and flow may even become negative 
(inspiratory). The magnitude of this inspiration can be assessed by following the change 
in ExpVol[L] as you move the End-Exp bar along. If this inspiration is of minimal 
volume (and certainly if <20ml), then it is insufficient to count as a proper inspiration and 
can be ignored. Continue to move the End-Exp bar along until inspiration starts properly. 
Another important feature is to look at the SF6 signal. If this continues to rise after a 
pause, or a tiny inspiration, then you are looking at a pause in expiration rather than a new 
breath, and this should be analysed as a single breath. 
To complicate things further, the software does not recognise the sign of the flow signal. 
So it will integrate negative (inspiratory) flow as expiratory if it is included between the 
Exp-Start and Exp-End markers. Thus, inspiratory volumes greater than 20ml should 
trigger a new breath. 
 
 
This counts as a single breath. 
The expiration is interrupted by a brief 
pause, and a very small inspiration (7ml, 
shown as flow dipping below the central grey 
line). The SF6 signal continues to rise, 
confirming that this is a single expiration that 








2. Expiratory pauses 
If the subject pauses at the end of expiration, end the breath once flow has returned to 
zero. However, if the subject pauses, then breathes out again before inspiration, include 
the pause and second expiratory peak, as part of the same breath.  
The same rule of 20ml applies. So if there is inspiratory flow that equates to a 
volume>20ml during the pause, analyse the later part as a second breath. Once again, if 




3. Small expirations 
Occasionally there are small blips in flow which occur during inspiration, or even during 
respiratory pauses, which the software identifies as a new breath. If these are less than 
50ml in volume they can be ignored, and should not be saved. If they are greater than 
50ml then they should be saved and counted as a separate breath. 
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4. Mis-identification of the start of expiration 
Occasionally the software will identify 
a very small blip in flow at the start of 
inspiration as being the start of 
expiration, and will include the whole 
of inspiration as part of the breath. 
This can be spotted in the Slope-SF6 
window as the long flat part of the 
graph before the SF6 signal rises on 
expiration (or looking like an 
anatomical deadspace of several 
hundred ml) (see figure on right). You 
must re-adjust the Exp-Start bar until it crosses zero (i.e. becomes positive) again.  
A similar picture is seen with very small breaths. This is because the Slope-SF6 graph 
autoscales. In this case, the volume of deadspace is only 100ml or so (read off from the x 
axis), and the total volume only 200ml or so. Because the deadspace represents a large 
portion of the total breath volume, when it is autoscaled it looks similar to the mis-
identified breaths. In this case, moving the Exp-Start bar along, you will not see any 
negative flow. Save this breath as per normal. 
 
 
Interruption to SF6 signal 
There have been occasional interruptions to the SF6 signal noted. These probably occurred 
as a result of physical or electrical interference with the machine, but the effect is a non-
physiological sine wave in the SF6 signal. This should be treated like a flow re-zero. 
In other words, integrate up to the start of the erroneous signal and again after the end of 
it, splitting a single breath into two. The exception to this is if the error signal occurs 
entirely in the first or last quarter of the breath, in which case it is reasonable not to 
integrate the part of the breath occurring before or after the error signal respectively. 
Doing so would result in a very small breath, which would affect average Vt and have 







In accordance with published recommendations, the final FRC and LCI that we quote is 
the mean of at least two reproducible washouts. 
In order to achieve this, we perform three washouts, so that if one is excluded we can still 
have two reproducible measurements. 
A washout is excluded if: 
 
1. The FRC differs by more than 10% from both the other two repeats. This is in 
accordance with published guidelines in children, and allows for leak or significant 
differences in starting point. 
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2. The LCI differs by more than 20% from both the other two repeats. This is an 
adjustment that we have included in order to allow for washouts where there is significant 
change in breathing pattern at the end of a washout that alters the end point to such an 
extent that a clearly erroneous value for LCI is obtained.  
 
3. The washout ends prematurely, i.e. before target Cet is achieved. 
 
4. The wash-in is inadequate (i.e. difference between inspiratory and expiratory SF6 
concentrations of more than 2% of the inspiratory [SF6]). 
 
5. Any other procedural irregularities. 
 
In all cases the reason for exclusion must be recorded, and the number of repeats affected 
should be minimal. 
If two reproducible washouts cannot be obtained, it may be reasonable to use the average 






The above represents a summary of the main problems identified during discussion, and it 
is likely that further issues will arise with time. Also, the volumes suggested for what 
qualifies as a significant inspiratory or expiratory volumes are based on a combination of 
common sense, experience and consensus – but are not proscriptive. Each difficulty 
during analysis must be considered in its own right, and difficult analyses should be 
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Appendix C –Published manuscripts from this thesis 
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